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e150Preamble
The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the beneﬁts and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to
a thorough review of evidence has resulted in the production
of clinical practice guidelines that assist clinicians in selecting
the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a founda-
tion for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
produced guidelines in the area of cardiovascular disease
since 1980. The ACCF/AHA Task Force on Practice Guide-
lines (Task Force), charged with developing, updating, and
revising practice guidelines for cardiovascular diseases and
procedures, directs and oversees this effort. Writing commit-
tees are charged with regularly reviewing and evaluating
all available evidence to develop balanced, patient-centric
recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-speciﬁc data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a literature review; weigh the
strength of evidence for or against particular tests, treatments,
or procedures; and include estimates of expected outcomes
where such data exist. Patient-speciﬁc modiﬁers, comorbid-
ities, and issues of patient preference that may inﬂuence the
choice of tests or therapies are considered. When available,
information from studies on cost is considered, but data on
efﬁcacy and outcomes constitute the primary basis for the
recommendations contained herein.
In analyzing the data and developing recommendations and
supporting text, the writing committee uses evidence-based
methodologies developed by the Task Force (1). The Class
of Recommendation (COR) is an estimate of the size of the
treatment effect considering risks versus beneﬁts in addition
to evidence and/or agreement that a given treatment or
procedure is or is not useful/effective or in some situations
may cause harm. The Level of Evidence (LOE) is an estimate
of the certainty or precision of the treatment effect. The
writing committee reviews and ranks evidence supporting
each recommendation with the weight of evidence ranked as
LOE A, B, or C according to speciﬁc deﬁnitions that are
included in Table 1. Studies are identiﬁed as observational,
retrospective, prospective, or randomized where appropriate.
For certain conditions for which inadequate data are available,recommendations are based on expert consensus and clinical
experience and are ranked as LOE C. When recommendations
at LOE C are supported by historical clinical data, appropriate
references (including clinical reviews) are cited if available.
For issues for which sparse data are available, a survey of
current practice among the clinicians on the writing committee
is the basis for LOE C recommendations and no references are
cited. The schema for COR and LOE are summarized in
Table 1, which also provides suggested phrases for writing
recommendations within each COR. A new addition to this
methodology is separation of the Class III recommendations to
delineate whether the recommendation is determined to be of
“no beneﬁt” or is associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested phrases
for writing recommendations for the comparative effectiveness
of one treatment or strategy versus another have been added
for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as deﬁned by
ACCF/AHA guideline–recommended therapies (primarily
Class I). This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address
patient populations (and clinicians) residing in North America,
drugs that are not currently available in North America are
discussed in the text without a speciﬁc COR. For studies
performed in large numbers of subjects outside North America,
each writing committee reviews the potential inﬂuence of
different practice patterns and patient populations on the
treatment effect and relevance to the ACCF/AHA target pop-
ulation to determine whether the ﬁndings should inform
a speciﬁc recommendation.
The ACCF/AHA practice guidelines are intended to assist
clinicians in clinical decision making by describing a range of
generally acceptable approaches to the diagnosis, manage-
ment, and prevention of speciﬁc diseases or conditions. The
guidelines attempt to deﬁne practices that meet the needs of
most patients in most circumstances. The ultimate judgment
regarding care of a particular patient must be made by the
clinician and patient in light of all the circumstances presented
by that patient. As a result, situations may arise for which
deviations from these guidelines may be appropriate. Clinical
decision making should involve consideration of the quality
and availability of expertise in the area where care is
provided. When these guidelines are used as the basis for
regulatory or payer decisions, the goal should be improve-
ment in quality of care. The Task Force recognizes that
situations arise in which additional data are needed to inform
patient care more effectively; these areas will be identiﬁed
within each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
of patient understanding and adherence may adversely affect
Table 1. Applying Classification of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do
not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful
or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use.
yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve
direct comparisons of the treatments or strategies being evaluated.
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e151outcomes, clinicians should make every effort to engage the
patient’s active participation in prescribed medical regimens
and lifestyles. In addition, patients should be informed of the
risks, beneﬁts, and alternatives to a particular treatment and be
involved in shared decision making whenever feasible,
particularly for COR IIa and IIb, for which the beneﬁt-to-risk
ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conﬂicts of interest that may arise as
a result of industry relationships or personal interests amongthe members of the writing committee. All writing committee
members and peer reviewers of the guideline are required to
disclose all current healthcare-related relationships, including
those existing 12 months before initiation of the writing effort.
In December 2009, the ACCF and AHA implemented a new
policy for relationship with industry and other entities (RWI)
that requires the writing committee chair plus a minimum of
50% of the writing committee to have no relevant RWI
(Appendix 1 includes the ACCF/AHA deﬁnition of rele-
vance). These statements are reviewed by the Task Force and
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e152all members during each conference call and/or meeting of the
writing committee and are updated as changes occur. All
guideline recommendations require a conﬁdential vote by the
writing committee and must be approved by a consensus of
the voting members. Members are not permitted to draft or
vote on any text or recommendations pertaining to their RWI.
Members who recused themselves from voting are indicated
in the list of writing committee members, and speciﬁc section
recusals are noted in Appendix 1. Authors’ and peer
reviewers’ RWI pertinent to this guideline are disclosed in
Appendixes 1 and 2, respectively. Additionally, to ensure
complete transparency, writing committee members’ com-
prehensive disclosure informationdincluding RWI not
pertinent to this documentdis available as an online supple-
ment. Comprehensive disclosure information for the Task
Force is also available online at http://www.cardiosource.org/
en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-
and-Documents-Task-Forces.aspx. The work of writing
committees is supported exclusively by the ACCF and AHA
without commercial support. Writing committee members
volunteered their time for this activity.
In an effort to maintain relevance at the point of care for
practicing clinicians, the Task Force continues to oversee an
ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to these guidelines
will be apparent, including limited narrative text, a focus on
summary and evidence tables (with references linked to
abstracts in PubMed), and more liberal use of summary
recommendation tables (with references that support LOE) to
serve as a quick reference.
In April 2011, the Institute of Medicine released 2 reports:
Clinical Practice Guidelines We Can Trust and Finding What
Works in Health Care: Standards for Systematic Reviews
(2,3). It is noteworthy that the ACCF/AHA practice guide-
lines are cited as being compliant with many of the proposed
standards. A thorough review of these reports and of our
current methodology is under way, with further enhancements
anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update or the
full-text guideline is revised. Guidelines are ofﬁcial policy of
both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are, whenever
possible, evidence based. An extensive evidence review was
conducted through October 2011 and includes selected other
references through April 2013. Searches were extended to
studies, reviews, and other evidence conducted in human
subjects and that were published in English from PubMed,
EMBASE, Cochrane, Agency for Healthcare Research andQuality Reports, and other selected databases relevant to this
guideline. Key search words included but were not limited to
the following: heart failure, cardiomyopathy, quality of life,
mortality, hospitalizations, prevention, biomarkers, hyper-
tension, dyslipidemia, imaging, cardiac catheterization,
endomyocardial biopsy, angiotensin-converting enzyme
inhibitors, angiotensin-receptor antagonists/blockers, beta
blockers, cardiac, cardiac resynchronization therapy, deﬁ-
brillator, device-based therapy, implantable cardioverter-
deﬁbrillator, device implantation, medical therapy, acute
decompensated heart failure, preserved ejection fraction,
terminal care and transplantation, quality measures, and
performance measures. Additionally, the committee reviewed
documents related to the subject matter previously published
by the ACCF and AHA. References selected and published in
this document are representative and not all-inclusive.
To provide clinicians with a representative evidence base,
whenever deemed appropriate or when published, the abso-
lute risk difference and number needed to treat or harm are
provided in the guideline (within tables), along with conﬁ-
dence intervals and data related to the relative treatment
effects such as odds ratio, relative risk, hazard ratio, and
incidence rate ratio.
1.2. Organization of the Writing Committee
The committee was composed of physicians and a nurse with
broad expertise in the evaluation, care, and management of
patients with heart failure (HF). The authors included general
cardiologists, HF and transplant specialists, electrophysiolo-
gists, general internists, and physicians with methodological
expertise. The committee included representatives from the
ACCF, AHA, American Academy of Family Physicians,
American College of Chest Physicians, American College of
Physicians, Heart Rhythm Society, and International Society
for Heart and Lung Transplantation.
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by both the ACCF and the AHA, as well as 1 to 2
reviewers each from the American Academy of Family
Physicians, American College of Chest Physicians, Heart
Rhythm Society, and International Society for Heart and Lung
Transplantation, as well as 32 individual content reviewers
(including members of the ACCF Adult Congenital and
Pediatric Cardiology Council, ACCF Cardiovascular Team
Council, ACCF Council on Cardiovascular Care for Older
Adults, ACCF Electrophysiology Committee, ACCF Heart
Failure and Transplant Council, ACCF Imaging Council,
ACCF Prevention Committee, ACCF Surgeons’ Scientiﬁc
Council, and ACCF Task Force on Appropriate Use Criteria).
All information on reviewers’ RWI was distributed to the
writing committee and is published in this document
(Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF and AHA and endorsed by the
American Association of Cardiovascular and Pulmonary
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Rhythm Society, and International Society for Heart and Lung
Transplantation.1.4. Scope of This Guideline With Reference
to Other Relevant Guidelines or Statements
This guideline covers multiple management issues for the
adult patient with HF. Although there is an abundance of
evidence addressing HF, for many important clinical consid-
erations, this writing committee was unable to identify sufﬁ-
cient data to properly inform a recommendation. The writing
committee actively worked to reduce the number of LOE “C”
recommendations, especially for Class Irecommended
therapies. Despite these limitations, it is apparent that much
can be done for HF. Adherence to the clinical practice
guidelines herein reproduced should lead to improved patient
outcomes.
Although of increasing importance, HF in children and
congenital heart lesions in adults are not speciﬁcally
addressed in this guideline. The reader is referred to publically
available resources to address questions in these areas.
However, this guideline does address HF with preserved
ejection fraction (EF) in more detail and similarly revisits
hospitalized HF. Additional areas of renewed interest are in
stage D HF, palliative care, transition of care, and quality of
care for HF. Certain management strategies appropriate for
the patient at risk for HF or already affected by HF are also
reviewed in numerous relevant clinical practice guidelines and
scientiﬁc statements published by the ACCF/AHA Task Force
on Practice Guidelines, AHA, ACCF Task Force on Appro-
priate Use Criteria, European Society of Cardiology, Heart
Failure Society of America, and the National Heart, Lung, and
Blood Institute. The writing committee saw no need to reit-
erate the recommendations contained in those guidelines and
chose to harmonize recommendations when appropriate and
eliminate discrepancies. This is especially the case for device-
based therapeutics, where complete alignment between the
HF guideline and the device-based therapy guideline was
deemed imperative (4). Some recommendations from earlier
guidelines have been updated as warranted by new evidence
or a better understanding of earlier evidence, whereas others
that were no longer accurate or relevant or which were
overlapping were modiﬁed; recommendations from previous
guidelines that were similar or redundant were eliminated or
consolidated when possible.
The present document recommends a combination of life-
style modiﬁcations and medications that constitute GDMT.
GDMT is speciﬁcally referenced in the recommendations for
the treatment of HF (Section 7.3.2). Both for GDMT and
other recommended drug treatment regimens, the reader is
advised to conﬁrm dosages with product insert material and to
evaluate carefully for contraindications and drug-drug inter-
actions. Table 2 is a list of documents deemed pertinent to this
effort and is intended for use as a resource; it obviates the
need to repeat already extant guideline recommendations.Additional other HF guideline statements are highlighted as
well for the purpose of comparison and completeness.
2. Deﬁnition of HF
HF is a complex clinical syndrome that results from any
structural or functional impairment of ventricular ﬁlling or
ejection of blood. The cardinal manifestations of HF are
dyspnea and fatigue, which may limit exercise tolerance, and
ﬂuid retention, which may lead to pulmonary and/or
splanchnic congestion and/or peripheral edema. Some patients
have exercise intolerance but little evidence of ﬂuid retention,
whereas others complain primarily of edema, dyspnea, or
fatigue. Because some patients present without signs or
symptoms of volume overload, the term “heart failure” is
preferred over “congestive heart failure.” There is no single
diagnostic test for HF because it is largely a clinical diagnosis
based on a careful history and physical examination.
The clinical syndrome of HF may result from disorders of
the pericardium, myocardium, endocardium, heart valves, or
great vessels or from certain metabolic abnormalities, but
most patients with HF have symptoms due to impaired left
ventricular (LV) myocardial function. It should be empha-
sized that HF is not synonymous with either cardiomyopathy
or LV dysfunction; these latter terms describe possible
structural or functional reasons for the development of HF.
HF may be associated with a wide spectrum of LV functional
abnormalities, which may range from patients with normal
LV size and preserved EF to those with severe dilatation and/
or markedly reduced EF. In most patients, abnormalities of
systolic and diastolic dysfunction coexist, irrespective of EF.
EF is considered important in classiﬁcation of patients with
HF because of differing patient demographics, comorbid
conditions, prognosis, and response to therapies (35) and
because most clinical trials selected patients based on EF. EF
values are dependent on the imaging technique used, method
of analysis, and operator. Because other techniques may
indicate abnormalities in systolic function among patients
with a preserved EF, it is preferable to use the terms preserved
or reduced EF over preserved or reduced systolic function.
For the remainder of this guideline, we will consistently refer
to HF with preserved EF and HF with reduced EF as HFpEF
and HFrEF, respectively (Table 3).
2.1. HF With Reduced EF (HFrEF)
In approximately half of patients with HFrEF, variable
degrees of LV enlargement may accompany HFrEF (36,37).
The deﬁnition of HFrEF has varied, with guidelines of
left ventricular ejection fraction (LVEF) 35%, <40%,
and 40% (18,19,38). Randomized controlled trials (RCTs)
in patients with HF have mainly enrolled patients with HFrEF
with an EF 35% or 40%, and it is only in these patients
that efﬁcacious therapies have been demonstrated to date.
For the present guideline, HFrEF is deﬁned as the clinical
diagnosis of HF and EF 40%. Those with LV systolic
Table 2. Associated Guidelines and Statements
Title Organization
Publication Year
(Reference)
Guidelines
Guidelines for the Management of Adults With Congenital Heart Disease ACCF/AHA 2008 (5)
Guidelines for the Management of Patients With Atrial Fibrillation ACCF/AHA/HRS 2011 (6–8)
Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults ACCF/AHA 2010 (9)
Guideline for Coronary Artery Bypass Graft Surgery ACCF/AHA 2011 (10)
Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities ACCF/AHA/HRS 2013 (4)
Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy ACCF/AHA 2011 (11)
Guideline for Percutaneous Coronary Intervention ACCF/AHA/SCAI 2011 (12)
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and
Other Atherosclerotic Vascular Disease: 2011 Update
AHA/ACCF 2011 (13)
Guideline for the Diagnosis and Management of Patients With Stable Ischemic
Heart Disease
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 2012 (14)
Guideline for the Management of ST-Elevation Myocardial Infarction ACCF/AHA 2013 (15)
Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation
Myocardial Infarction
ACCF/AHA 2013 (16)
Guidelines for the Management of Patients With Valvular Heart Disease ACCF/AHA 2008 (17)
Comprehensive Heart Failure Practice Guideline HFSA 2010 (18)
Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure ESC 2012 (19)
Chronic Heart Failure: Management of Chronic Heart Failure in Adults in Primary and
Secondary Care
NICE 2010 (20)
Antithrombotic Therapy and Prevention of Thrombosis ACCP 2012 (21)
Guidelines for the Care of Heart Transplant Recipients ISHLT 2010 (22)
Statements
Contemporary Definitions and Classification of the Cardiomyopathies AHA 2006 (23)
Genetics and Cardiovascular Disease AHA 2012 (24)
Appropriate Utilization of Cardiovascular Imaging in Heart Failure ACCF 2013 (25)
Appropriate Use Criteria for Coronary Revascularization Focused Update ACCF 2012 (26)
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure
NHLBI 2003 (27)
Implications of Recent Clinical Trials for the National Cholesterol Education Program
Adult Treatment Panel III Guidelines
NHLBI 2002 (28)
Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention
Programs at Clinical Centers and Beyond
AHA/AACVPR 2011 (29)
Decision Making in Advanced Heart Failure AHA 2012 (30)
Recommendations for the Use of Mechanical Circulatory Support: Device Strategies
and Patient Selection
AHA 2012 (31)
Advanced Chronic Heart Failure ESC 2007 (32)
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial
Fibrillation
AHA/ASA 2012 (33)
Third Universal Definition of Myocardial Infarction ESC/ACCF/AHA/WHF 2012 (34)
AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AATS, American Association for Thoracic Surgery; ACCF, American College
of Cardiology Foundation; ACCP, American College of Chest Physicians; ACP, American College of Physicians; AHA, American Heart Association; ASA, American Stroke
Association; ESC, European Society of Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm Society; ISHLT, International Society for Heart and Lung
Transplantation; NHLBI, National Heart, Lung, and Blood Institute; NICE, National Institute for Health and Clinical Excellence; PCNA, Preventive Cardiovascular Nurses
Association; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; and WHF, World Heart Federation.
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as well (39). Although coronary artery disease (CAD) with
antecedent myocardial infarction (MI) is a major cause of
HFrEF, many other risk factors (Section 4.6) may lead to LV
enlargement and HFrEF.2.2. HF With Preserved EF (HFpEF)
In patients with clinical HF, studies estimate that the preva-
lence of HFpEF is approximately 50% (range 40% to 71%)
(40). These estimates vary largely because of the differing
EF cut-off criteria and challenges in diagnostic criteria for
Table 3. Definitions of HFrEF and HFpEF
Classification EF (%) Description
I. Heart failure with reduced
ejection fraction (HFrEF)
40 Also referred to as systolic HF. Randomized controlled trials have mainly enrolled patients with HFrEF, and it
is only in these patients that efficacious therapies have been demonstrated to date.
II. Heart failure with preserved
ejection fraction (HFpEF)
50 Also referred to as diastolic HF. Several different criteria have been used to further define HFpEF. The
diagnosis of HFpEF is challenging because it is largely one of excluding other potential noncardiac
causes of symptoms suggestive of HF. To date, efficacious therapies have not been identified.
a. HFpEF, borderline 41 to 49 These patients fall into a borderline or intermediate group. Their characteristics, treatment patterns, and
outcomes appear similar to those of patients with HFpEF.
b. HFpEF, improved >40 It has been recognized that a subset of patients with HFpEF previously had HFrEF. These patients with
improvement or recovery in EF may be clinically distinct from those with persistently preserved or
reduced EF. Further research is needed to better characterize these patients.
EF indicates ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction.
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>45%, >50%, and 55%. Because some of these patients do
not have entirely normal EF but also do not have major
reduction in systolic function, the term preserved EF has
been used. Patients with an EF in the range of 40% to 50%
represent an intermediate group. These patients are often
treated for underlying risk factors and comorbidities and with
GDMT similar to that used in patients with HFrEF. Several
criteria have been proposed to deﬁne the syndrome of HFpEF.
These include a) clinical signs or symptoms of HF; b)
evidence of preserved or normal LVEF; and c) evidence of
abnormal LV diastolic dysfunction that can be determined by
Doppler echocardiography or cardiac catheterization (41).
The diagnosis of HFpEF is more challenging than the diag-
nosis of HFrEF because it is largely one of excluding other
potential noncardiac causes of symptoms suggestive of HF.
Studies have suggested that the incidence of HFpEF is
increasing and that a greater portion of patients hospitalized
with HF have HFpEF (42). In the general population, patients
with HFpEF are usually older women with a history of
hypertension. Obesity, CAD, diabetes mellitus, atrial ﬁbril-
lation (AF), and hyperlipidemia are also highly prevalent in
HFpEF in population-based studies and registries (40,43).
Despite these associated cardiovascular risk factors, hyper-
tension remains the most important cause of HFpEF, withTable 4. Comparison of ACCF/AHA Stages of HF and NYHA Functional
ACCF/AHA Stages of HF (38)
A At high risk for HF but without structural heart
disease or symptoms of HF
None
B Structural heart disease but without signs or
symptoms of HF
I No limitation o
C Structural heart disease with prior or current
symptoms of HF
I No limitation o
II Slight limitation
symptoms o
III Marked limitat
causes sym
IV Unable to carry
D Refractory HF requiring specialized interventions IV Unable to carry
ACCF indicates American College of Cardiology Foundation; AHA, American Hearta prevalence of 60% to 89% from large controlled trials,
epidemiological studies, and HF registries (44). It has been
recognized that a subset of patients with HFpEF previously
had HFrEF (45). These patients with improvement or
recovery in EF may be clinically distinct from those with
persistently preserved or reduced EF. Further research is
needed to better characterize these patients.
See Online Data Supplement 1 for additional data on
HFpEF.3. HF Classiﬁcations
Both the ACCF/AHA stages of HF (38) and the New York
Heart Association (NYHA) functional classiﬁcation (38,46)
provide useful and complementary information about the
presence and severity of HF. The ACCF/AHA stages of HF
emphasize the development and progression of disease and
can be used to describe individuals and populations, whereas
the NYHA classes focus on exercise capacity and the symp-
tomatic status of the disease (Table 4).
The ACCF/AHA stages of HF recognize that both risk
factors and abnormalities of cardiac structure are associated
with HF. The stages are progressive and inviolate; once
a patient moves to a higher stage, regression to an earlier stageClassifications
NYHA Functional Classification (46)
f physical activity. Ordinary physical activity does not cause symptoms of HF.
f physical activity. Ordinary physical activity does not cause symptoms of HF.
of physical activity. Comfortable at rest, but ordinary physical activity results in
f HF.
ion of physical activity. Comfortable at rest, but less than ordinary activity
ptoms of HF.
on any physical activity without symptoms of HF, or symptoms of HF at rest.
on any physical activity without symptoms of HF, or symptoms of HF at rest.
Association; HF, heart failure; and NYHA, New York Heart Association.
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with reduced 5-year survival and increased plasma natriuretic
peptide concentrations (47). Therapeutic interventions in each
stage aimed at modifying risk factors (stage A), treating
structural heart disease (stage B), and reducing morbidity and
mortality (stages C and D) (covered in detail in Section 7) are
reviewed in this document. The NYHA functional classiﬁ-
cation gauges the severity of symptoms in those with struc-
tural heart disease, primarily stages C and D. It is a subjective
assessment by a clinician and can change frequently over
short periods of time. Although reproducibility and validity
may be problematic (48), the NYHA functional classiﬁcation
is an independent predictor of mortality (49). It is widely used
in clinical practice and research and for determining the
eligibility of patients for certain healthcare services.
See Online Data Supplement 2 for additional data on
ACCF/AHA stages of HF and NYHA functional
classiﬁcations.
4. Epidemiology
The lifetime risk of developing HF is 20% for Americans 40
years of age (50). In the United States, HF incidence has
largely remained stable over the past several decades, with
>650,000 new HF cases diagnosed annually (51–53). HF
incidence increases with age, rising from approximately 20
per 1,000 individuals 65 to 69 years of age to >80 per 1,000
individuals among those 85 years of age (52). Approxi-
mately 5.1 million persons in the United States have clinically
manifest HF, and the prevalence continues to rise (51). In the
Medicare-eligible population, HF prevalence increased from
90 to 121 per 1,000 beneﬁciaries from 1994 to 2003 (52).
HFrEF and HFpEF each make up about half of the overall HF
burden (54). One in 5 Americans will be >65 years of age by
2050 (55). Because HF prevalence is highest in this group, the
number of Americans with HF is expected to signiﬁcantly
worsen in the future. Disparities in the epidemiology of HF
have been identiﬁed. Blacks have the highest risk for HF (56).
In the ARIC (Atherosclerosis Risk in Communities) study,
incidence rate per 1,000 person-years was lowest among
white women (52,53) and highest among black men (57), with
blacks having a greater 5-year mortality rate than whites (58).
HF in non-Hispanic black males and females has a prevalence
of 4.5% and 3.8%, respectively, versus 2.7% and 1.8% in
non-Hispanic white males and females, respectively (51).
4.1. Mortality
Although survival has improved, the absolute mortality rates
for HF remain approximately 50% within 5 years of diagnosis
(53,59). In the ARIC study, the 30-day, 1-year, and 5-year
case fatality rates after hospitalization for HF were 10.4%,
22%, and 42.3%, respectively (58). In another population
cohort study with 5-year mortality data, survival for stage A,
B, C, and D HF was 97%, 96%, 75%, and 20%, respectively
(47). Thirty-day postadmission mortality rates decreased from12.6% to 10.8% from 1993 to 2005; however, this was due to
lower in-hospital death rates. Postdischarge mortality actually
increased from 4.3% to 6.4% during the same time frame (60).
These observed temporal trends in HF survival are primarily
restricted to patients with reduced EF and are not seen in those
with preserved EF (40).
See Online Data Supplement 3 for additional data on
mortality.
4.2. Hospitalizations
HF is the primary diagnosis in >1 million hospitalizations
annually (51). Patients hospitalized for HF are at high risk for
all-cause rehospitalization, with a 1-month readmission rate of
25% (61). In 2013, physician ofﬁce visits for HF cost $1.8
billion. The total cost of HF care in the United States exceeds
$30 billion annually, with over half of these costs spent on
hospitalizations (51).
4.3. Asymptomatic LV Dysfunction
The prevalence of asymptomatic LV systolic or diastolic
dysfunction ranges from 6% to 21% and increases with age
(62–64). In the Left Ventricular Dysfunction Prevention
study, participants with untreated asymptomatic LV
dysfunction had a 10% risk for developing HF symptoms and
an 8% risk of death or HF hospitalization annually (65). In
a community-based population, asymptomatic mild LV dia-
stolic dysfunction was seen in 21% and moderate or severe
diastolic dysfunction in 7%, and both were associated with an
increased risk of symptomatic HF and mortality (64).
4.4. Health-Related Quality of Life and
Functional Status
HF signiﬁcantly decreases health-related quality of life
(HRQOL), especially in the areas of physical functioning
and vitality (66,67). Lack of improvement in HRQOL after
discharge from the hospital is a powerful predictor of reho-
spitalization and mortality (68,69). Women with HF have
consistently been found to have poorer HRQOL than men
(67,70). Ethnic differences also have been found, with
Mexican Hispanics reporting better HRQOL than other ethnic
groups in the United States (71). Other determinants of poor
HRQOL include depression, younger age, higher body mass
index (BMI), greater symptom burden, lower systolic blood
pressure, sleep apnea, low perceived control, and uncertainty
about prognosis (70,72–76). Memory problems may also
contribute to poor HRQOL (76).
Pharmacological therapy is not a consistent determinant of
HRQOL; therapies such as angiotensin-converting enzyme
(ACE) inhibitors and angiotensin-receptor blockers (ARBs)
improve HRQOL only modestly or delay the progressive
worsening of HRQOL in HF (77). At present, the only ther-
apies shown to improve HRQOL are cardiac resynchroniza-
tion therapy (CRT) (78) and certain disease management and
educational approaches (79–82). Self-care and exercise may
improve HRQOL, but the results of studies evaluating these
interventions are mixed (83–86). Throughout this guideline
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satisfactory to the patient.
See Online Data Supplement 4 for additional data on
HRQOL and functional capacity.4.5. Economic Burden of HF
In 1 in 9 deaths in the United States, HF is mentioned on the
death certiﬁcate. The number of deaths with any mention of
HF was as high in 2006 as it was in 1995 (51). Approximately
7% of all cardiovascular deaths are due to HF.
As previously noted, in 2013, HF costs in the United States
exceeded $30 billion (51). This total includes the cost of
healthcare services, medications, and lost productivity. The
mean cost of HF-related hospitalizations was $23,077 per
patient and was higher when HF was a secondary rather than
the primary diagnosis. Among patients with HF in 1 large
population study, hospitalizations were common after HF
diagnosis, with 83% of patients hospitalized at least once and
43% hospitalized at least 4 times. More than half of the
hospitalizations were related to noncardiovascular causes
(87–89).4.6. Important Risk Factors for HF
(Hypertension, Diabetes Mellitus, Metabolic
Syndrome, and Atherosclerotic Disease)
Many conditions or comorbidities are associated with an
increased propensity for structural heart disease. The expe-
dient identiﬁcation and treatment of these comorbid condi-
tions may forestall the onset of HF (14,27,90). A list of the
important documents that codify treatment for these
concomitant conditions appears in Table 2.
Hypertension
Hypertension may be the single most important modiﬁable
risk factor for HF in the United States. Hypertensive men and
women have a substantially greater risk for developing HF
than normotensive men and women (91). Elevated levels of
diastolic and especially systolic blood pressure are major risk
factors for the development of HF (91,92). The incidence of
HF is greater with higher levels of blood pressure, older age,
and longer duration of hypertension. Long-term treatment of
both systolic and diastolic hypertension reduces the risk of HF
by approximately 50% (93–96). With nearly a quarter of the
American population afﬂicted by hypertension and the life-
time risk of developing hypertension at >75% in the United
States (97), strategies to control hypertension are a vital part
of any public health effort to prevent HF.
Diabetes Mellitus
Obesity and insulin resistance are important risk factors for
the development of HF (98,99). The presence of clinical
diabetes mellitus markedly increases the likelihood of devel-
oping HF in patients without structural heart disease (100) and
adversely affects the outcomes of patients with established HF
(101,102).Metabolic Syndrome
The metabolic syndrome includes any 3 of the following:
abdominal adiposity, hypertriglyceridemia, low high-density
lipoprotein, hypertension, and fasting hyperglycemia. The
prevalence of metabolic syndrome in the United States
exceeds 20% of persons 20 years of age and 40% of those
>40 years of age (103). The appropriate treatment of hyper-
tension, diabetes mellitus, and dyslipidemia (104) can
signiﬁcantly reduce the development of HF.
Atherosclerotic Disease
Patients with known atherosclerotic disease (e.g., of the
coronary, cerebral, or peripheral blood vessels) are likely to
develop HF, and clinicians should seek to control vascular
risk factors in such patients according to guidelines (13).5. Cardiac Structural Abnormalities
and Other Causes of HF
5.1. Dilated Cardiomyopathies
5.1.1. Deﬁnition and Classiﬁcation of
Dilated Cardiomyopathies
Dilated cardiomyopathy (DCM) refers to a large group of
heterogeneous myocardial disorders that are characterized by
ventricular dilation and depressed myocardial contractility in
the absence of abnormal loading conditions such as hyper-
tension or valvular disease. In clinical practice and multicenter
HF trials, the etiology of HF has often been categorized into
ischemic or nonischemic cardiomyopathy, with the term
DCM used interchangeably with nonischemic cardiomyop-
athy. This approach fails to recognize that “nonischemic
cardiomyopathy” may include cardiomyopathies due to
volume or pressure overload, such as hypertension or valvular
heart disease, which are not conventionally accepted as DCM
(105). With the identiﬁcation of genetic defects in several
forms of cardiomyopathies, a new classiﬁcation scheme based
on genomics was proposed in 2006 (23). We recognize that
classiﬁcation of cardiomyopathies is challenging, mixing
anatomic designations (i.e., hypertrophic and dilated) with
functional designations (i.e., restrictive), and is unlikely to
satisfy all users. The aim of the present guideline is to target
appropriate diagnostic and treatment strategies for preventing
the development and progression of HF in patients with
cardiomyopathies; we do not wish to redeﬁne new classiﬁ-
cation strategies for cardiomyopathies.
5.1.2. Epidemiology and Natural History of DCM
The age-adjusted prevalence of DCM in the United States
averages 36 cases per 100,000 population, and DCM accounts
for 10,000 deaths annually (106). In most multicenter
RCTs and registries in HF, approximately 30% to 40% of
enrolled patients have DCM (107–109). Compared with
whites, African Americans have almost a 3-fold increased risk
for developing DCM, irrespective of comorbidities or socio-
economic factors (108–110). Sex-related differences in the
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confounded by differing etiologies (108,109,111). The prog-
nosis in patients with symptomatic HF and DCM is relatively
poor, with 25% mortality at 1 year and 50% mortality at 5
years (112). Approximately 25% of patients with DCM with
recent onset of HF symptoms will improve within a short time
even in the absence of optimal GDMT (113), but patients with
symptoms lasting >3 months who present with severe clinical
decompensation generally have less chance of recovery (113).
Patients with idiopathic DCM have a lower total mortality rate
than patients with other types of DCM (114). However,
GDMT is beneﬁcial in all forms of DCM (78,109,115–117).
5.2. Familial Cardiomyopathies
Increasingly, it is recognized that many (20% to 35%) patients
with an idiopathic DCM have a familial cardiomyopathy
(deﬁned as 2 closely related family members who meet the
criteria for idiopathic DCM) (118,119). Consideration of
familial cardiomyopathies includes the increasingly important
discovery of noncompaction cardiomyopathies. Advances in
technology permitting high-throughput sequencing and gen-
otyping at reduced costs have brought genetic screening to the
clinical arena. For further information on this topic, the reader
is referred to published guidelines, position statements, and
expert consensus statements (118,120–123) (Table 5).
5.3. Endocrine and Metabolic Causes
of Cardiomyopathy
5.3.1. Obesity
Obesity cardiomyopathy is deﬁned as cardiomyopathy due
entirely or predominantly to obesity (Section 7.3.1.5).
Although the precise mechanisms causing obesity-related HF
are not known, excessive adipose accumulation results in an
increase in circulating blood volume. A subsequent, persistent
increase in cardiac output, cardiac work, and systemic blood
pressure (124) along with lipotoxicity-induced cardiac myo-
cyte injury and myocardial lipid accumulation have been
implicated as potential mechanisms (125,126). A study with
participants from the Framingham Heart Study reported that
after adjustment for established risk factors, obesity was
associated with signiﬁcant future risk of development of HF
(99). There are no large-scale studies of the safety or efﬁcacyTable 5. Screening of Family Members and Genetic Testing in Patients
Condition Screening of Family Members
Familial DCM  First-degree relatives not known to be affected should undergo
serial echocardiographic screening with assessment of LV fun
and size.
 Frequency of screening is uncertain, but every 3–5 y is
reasonable (118).
Idiopathic DCM  Patients should inform first-degree relatives of their diagnosis.
 Relatives should update their clinicians and discuss whether the
should undergo screening by echocardiography.
DCM indicates dilated cardiomyopathy; and LV, left ventricular.of weight loss with diet, exercise, or bariatric surgery in obese
patients with HF.
5.3.2. Diabetic Cardiomyopathy
Diabetes mellitus is now well recognized as a risk factor for
the development of HF independent of age, hypertension,
obesity, hypercholesterolemia, or CAD. The association
between mortality and hemoglobin A1c (HbA1c) in patients
with diabetes mellitus and HF appears U-shaped, with the
lowest risk of death in those patients with modest glucose
control (7.1%<HbA1c7.8%) and with increased risk with
extremely high or low HbA1c levels (127). The optimal
treatment strategy in patients with diabetes mellitus and HF is
controversial; some studies have suggested potential harm
with several glucose-lowering medications (127,128). The
safety and efﬁcacy of diabetes mellitus therapies in HF,
including metformin, sulfonylureas, insulin, and glucagon-
like peptide analogues, await further data from prospective
clinical trials (129–131). Treatment with thiazolidinediones
(e.g., rosiglitazone) is associated with ﬂuid retention in
patients with HF (129,132) and should be avoided in patients
with NYHA class II through IV HF.
5.3.3. Thyroid Disease
Hyperthyroidism has been implicated in causing DCM but
most commonly occurs with persistent sinus tachycardia or
AF and may be related to tachycardia (133). Abnormalities in
cardiac systolic and diastolic performance have been reported
in hypothyroidism. However, the classic ﬁndings of
myxedema do not usually indicate cardiomyopathy. The low
cardiac output results from bradycardia, decreased ventricular
ﬁlling, reduced cardiac contractility, and diminished
myocardial work (133,134).
5.3.4. Acromegaly and Growth Hormone Deﬁciency
Impaired cardiovascular function has been associated with
reduced life expectancy in patients with growth hormone
deﬁciency and excess. Experimental and clinical studies
implicate growth hormone and insulin-like growth factor I in
cardiac development (135). Cardiomyopathy associated with
acromegaly is characterized by myocardial hypertrophy with
interstitial ﬁbrosis, lympho-mononuclear inﬁltration, myocyte
necrosis, and biventricular concentric hypertrophy (135).With Idiopathic or Familial DCM
Genetic Testing
periodic,
ction
 Genetic testing may be considered in conjunction with genetic
counseling (118,121–123).
y
 The utility of genetic testing in this setting remains uncertain.
 Yield of genetic testing may be higher in patients with
significant cardiac conduction disease and/or a family history
of premature sudden cardiac death (118,121–123).
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5.4.1. Alcoholic Cardiomyopathy
Chronic alcoholism is one of the most important causes of
DCM (136). The clinical diagnosis is suspected when
biventricular dysfunction and dilatation are persistently
observed in a heavy drinker in the absence of other known
causes for myocardial disease. Alcoholic cardiomyopathy
most commonly occurs in men 30 to 55 years of age who
have been heavy consumers of alcohol for >10 years (137).
Women represent approximately 14% of the alcoholic
cardiomyopathy cases but may be more vulnerable with less
lifetime alcohol consumption (136,138). The risk of asymp-
tomatic alcoholic cardiomyopathy is increased in those
consuming >90 g of alcohol per day (approximately 7 to 8
standard drinks per day) for >5 years (137). Interestingly, in
the general population, mild to moderate alcohol consumption
has been reported to be protective against development of HF
(139,140). These paradoxical ﬁndings suggest that duration of
exposure and individual genetic susceptibility play an
important role in pathogenesis. Recovery of LV function after
cessation of drinking has been reported (141). Even if LV
dysfunction persists, the symptoms and signs of HF improve
after abstinence (141).
5.4.2. Cocaine Cardiomyopathy
Long-term abuse of cocaine may result in DCM even without
CAD, vasculitis, or MI. Depressed LV function has been
reported in 4% to 18% of asymptomatic cocaine abusers
(142–144). The safety and efﬁcacy of beta blockers for
chronic HF due to cocaine use are unknown (145).
5.4.3. Cardiotoxicity Related to Cancer Therapies
Several cytotoxic antineoplastic drugs, especially the anthra-
cyclines, are cardiotoxic and can lead to long-term cardiac
morbidity. Iron-chelating agents that prevent generation of
oxygen free radicals, such as dexrazoxane, are car-
dioprotective (146,147), and reduce the occurrence and
severity of anthracycline-induced cardiotoxicity and devel-
opment of HF.
Other antineoplastic chemotherapies with cardiac toxicity
are the monoclonal antibody trastuzumab (Herceptin), high-
dose cyclophosphamide, taxoids, mitomycin-C, 5-ﬂuorouracil,
and the interferons (148). In contrast to anthracycline-
induced cardiac toxicity, trastuzumab-related cardiac dys-
function does not appear to increase with cumulative dose,
nor is it associated with ultrastructural changes in the
myocardium. However, concomitant anthracycline therapy
signiﬁcantly increases the risk for cardiotoxicity during
trastuzumab treatment. The cardiac dysfunction associated
with trastuzumab is most often reversible on discontinuation
of treatment and initiation of standard medical therapy for HF
(149). The true incidence and reversibility of chemotherapy-
related cardiotoxicity are not well documented, and mean-
ingful interventions to prevent injury have not yet been
elucidated.5.4.4. Other Myocardial Toxins and
Nutritional Causes of Cardiomyopathy
In addition to the classic toxins described above, a number of
other toxic agents may lead to LV dysfunction and HF,
including ephedra, cobalt, anabolic steroids, chloroquine,
clozapine, amphetamine, methylphenidate, and catechol-
amines (150). Ephedra, which has been used for athletic
performance enhancement and weight loss, was ultimately
banned by the U.S. Food and Drug Administration for its high
rate of adverse cardiovascular outcomes, including LV
systolic dysfunction, development of HF, and sudden cardiac
death (SCD) (151).
Primary and secondary nutritional deﬁciencies may lead to
cardiomyopathy. Chronic alcoholism, anorexia nervosa,
AIDS, and pregnancy can account for other rare causes of
thiamine deﬁciency–related cardiomyopathy in the western
world (152). Deﬁciency in L-carnitine, a necessary cofactor
for fatty acid oxidation, may be associated with a syndrome of
progressive skeletal myopathy and cardiomyopathy (153).
5.5. Tachycardia-Induced Cardiomyopathy
Tachycardia-induced cardiomyopathy is a reversible cause of
HF characterized by LV myocardial dysfunction caused by
increased ventricular rate. The degree of dysfunction corre-
lates with the duration and rate of the tachyarrhythmia.
Virtually any supraventricular tachycardia with a rapid
ventricular response may induce cardiomyopathy. Ventricular
arrhythmias, including frequent premature ventricular com-
plexes, may also induce cardiomyopathy. Maintenance of
sinus rhythm or control of ventricular rate is critical to treating
patients with tachycardia-induced cardiomyopathy (154).
Reversibility of the cardiomyopathy with treatment of the
arrhythmia is the rule, although this may not be complete in
all cases. The underlying mechanisms for this are not well
understood.
Ventricular pacing at high rates may cause cardiomyop-
athy. Additionally, right ventricular pacing alone may exac-
erbate HF symptoms, increase hospitalization for HF, and
increase mortality (155,156). Use of CRT in patients with
a conduction delay due to pacing may result in improved LV
function and functional capacity.
5.6. Myocarditis and Cardiomyopathies
Due to Inﬂammation
5.6.1. Myocarditis
Inﬂammation of the heart may cause HF in about 10% of
cases of initially unexplained cardiomyopathy (105,157). A
variety of infectious organisms, as well as toxins and medi-
cations, most often postviral in origin, may cause myocarditis.
In addition, myocarditis is also seen as part of other systemic
diseases such as systemic lupus erythematosus and other
myocardial muscle diseases such as HIV cardiomyopathy and
possibly peripartum cardiomyopathy. Presentation may be
acute, with a distinct onset, severe hemodynamic compro-
mise, and severe LV dysfunction as seen in acute fulminant
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and better-tolerated LV dysfunction (158). Prognosis varies,
with spontaneous complete resolution (paradoxically most
often seen with acute fulminant myocarditis) (158) to the
development of DCM despite immunosuppressive therapy
(159). The role of immunosuppressive therapy is controversial
(159). Targeting such therapy to speciﬁc individuals based on
the presence or absence of viral genome in myocardial biopsy
samples may improve response to immunosuppressive
therapy (160).
Giant cell myocarditis is a rare form of myocardial
inﬂammation characterized by fulminant HF, often associated
with refractory ventricular arrhythmias and a poor prognosis
(161,162). Histologic ﬁndings include diffuse myocardial
necrosis with numerous multinucleated giant cells without
granuloma formation. Consideration for advanced HF thera-
pies, including immunosuppression, mechanical circulatory
support (MCS), and transplantation, is warranted.
5.6.2. Acquired Immunodeﬁciency Syndrome
The extent of immunodeﬁciency inﬂuences the incidence of
HIV-associated DCM (163–165). In long-term echocardio-
graphic follow-up (166), 8% of initially asymptomatic HIV-
positive patients were diagnosed with DCM during the
5-year follow-up. Whether early treatment with ACE inhibi-
tors and/or beta blockers will prevent or delay disease
progression in these patients is unknown at this time.
5.6.3. Chagas Disease
Although Chagas disease is a relatively uncommon cause of
DCM in North America, it remains an important cause of
death in Central and South America (167). Symptomatic
chronic Chagas disease develops in an estimated 10% to 30%
of infected persons, years or even decades after the Trypa-
nosoma cruzi infection. Cardiac changes may include biven-
tricular enlargement, thinning or thickening of ventricular
walls, apical aneurysms, and mural thrombi. The conduction
system is often affected, typically resulting in right bundle-
branch block, left anterior fascicular block, or complete
atrioventricular block.5.7. Inﬂammation-Induced Cardiomyopathy:
Noninfectious Causes
5.7.1. Hypersensitivity Myocarditis
Hypersensitivity to a variety of agents may result in allergic
reactions that involve the myocardium, characterized by
peripheral eosinophilia and a perivascular inﬁltration of the
myocardium by eosinophils, lymphocytes, and histiocytes. A
variety of drugs, most commonly the sulfonamides, penicil-
lins, methyldopa, and other agents such as amphotericin B,
streptomycin, phenytoin, isoniazid, tetanus toxoid, hydro-
chlorothiazide, dobutamine, and chlorthalidone, have been
reported to cause allergic hypersensitivity myocarditis (168).
Most patients are not clinically ill but may die suddenly,
presumably secondary to an arrhythmia.5.7.2. Rheumatological/Connective Tissue Disorders
Along with a number of cardiac abnormalities (e.g., pericar-
ditis, pericardial effusion, conduction system abnormalities,
including complete atrioventricular heart block), DCM can be
a rare manifestation of systemic lupus erythematosus and
usually correlates with disease activity (169). Studies suggest
that echocardiographic evidence of abnormal LV ﬁlling may
reﬂect the presence of myocardial ﬁbrosis and could be
a marker of subclinical myocardial involvement in systemic
lupus erythematosus patients (170).
Scleroderma is a rare cause of DCM. One echocardio-
graphic study showed that despite normal LV dimensions or
fractional shortening, subclinical systolic impairment was
present in the majority of patients with scleroderma (171).
Cardiac involvement in rheumatoid arthritis generally is
in the form of myocarditis and/or pericarditis, and develop-
ment of DCM is rare (172). Myocardial involvement in
rheumatoid arthritis is thought to be secondary to micro-
vasculitis and subsequent microcirculatory disturbances.
Myocardial disease in rheumatoid arthritis can occur in the
absence of clinical symptoms or abnormalities of the elec-
trocardiogram (ECG) (173).
5.8. Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a disease of unknown cause in
which LV dysfunction occurs during the last trimester of
pregnancy or the early puerperium. It is reported in 1:1300 to
1:4000 live births (174). Risk factors for peripartum cardio-
myopathy include advanced maternal age, multiparity,
African descent, and long-term tocolysis. Although its
etiology remains unknown, most theories have focused on
hemodynamic and immunologic causes (174). The prognosis
of peripartum cardiomyopathy is related to the recovery of
ventricular function. Signiﬁcant improvement in myocardial
function is seen in 30% to 50% of patients in the ﬁrst 6
months after presentation (174). However, for those patients
who do not recover to normal or near-normal function, the
prognosis is similar to other forms of DCM (175). Car-
diomegaly that persists for >4 to 6 months after diagnosis
indicates a poor prognosis, with a 50% mortality rate at 6
years. Subsequent pregnancy in women with a history of
peripartum cardiomyopathy may be associated with a further
decrease in LV function and can result in clinical deteriora-
tion, including death. However, if ventricular function has
normalized in women with a history of peripartum cardio-
myopathy, the risk may be less (174). There is an increased
risk of venous thromboembolism, and anticoagulation is
recommended, especially if ventricular dysfunction is
persistent.
5.9. Cardiomyopathy Caused by
Iron Overload
Iron overload cardiomyopathy manifests itself as systolic or
diastolic dysfunction secondary to increased deposition of
iron in the heart and occurs with common genetic disorders
such as primary hemochromatosis or with lifetime transfusion
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Hereditary hemochromatosis, an autosomal recessive dis-
order, is the most common hereditary disease of Northern
Europeans, with a prevalence of approximately 5 per 1,000.
The actuarial survival rates of persons who are homozygous
for the mutation of the hemochromatosis gene C282Y have
been reported to be 95%, 93%, and 66%, at 5, 10, and 20
years, respectively (177). Similarly, in patients with thalas-
semia major, cardiac failure is one of the most frequent causes
of death. Chelation therapy, including newer forms of oral
chelators, such as deferoxamine, and phlebotomy, have
dramatically improved the outcome of hemochromatosis, and
the roles of gene therapy, hepcidin, and calcium channel
blockers are being actively investigated (178).
5.10. Amyloidosis
Cardiac amyloidosis involves the deposition of insoluble
proteins as ﬁbrils in the heart, resulting in HF. Primary or AL
amyloidosis (monoclonal kappa or lambda light chains),
secondary amyloidosis (protein A), familial TTR amyloidosis
(mutant transthyretin), dialysis-associated amyloidosis (beta-
2-microglobulin), or senile TTR amyloidosis (wild-type
transthyretin) can affect the heart, but cardiac involvement is
primarily encountered in AL and TTR amyloidosis (179). The
disease can be rapidly progressive, and in patients with
ventricular septum thickness >15 mm, LVEF <40%, and
symptoms of HF, median survival may be <6 months (180).
Cardiac biomarkers (e.g., B-type natriuretic peptide [BNP],
cardiac troponin) have been reported to predict response and
progression of disease and survival (181). Three percent to
4% of African Americans carry an amyloidogenic allele of the
human serum protein transthyretin (TTR V122I), which
appears to increase risk for cardiac amyloid deposition after
65 years of age (182).
5.11. Cardiac Sarcoidosis
Cardiac sarcoidosis is an underdiagnosed disease that may
affect as many as 25% of patients with systemic sarcoidosis.
Although most commonly recognized in patients with other
manifestations of sarcoidosis, cardiac involvement may occur
in isolation and go undetected. Cardiac sarcoidosis may
present as asymptomatic LV dysfunction, HF, atrioventricular
block, atrial or ventricular arrhythmia, and SCD (183).
Although untested in clinical trials, early use of high-dose
steroid therapy may halt or reverse cardiac damage (184).
Cardiac magnetic resonance and cardiac positron emission
tomographic scanning can identify cardiac involvement with
patchy areas of myocardial inﬂammation and ﬁbrosis. In the
setting of ventricular tachyarrhythmia, patients may require
placement of an implantable cardioverter-deﬁbrillator (ICD)
for primary prevention of SCD (185).
5.12. Stress (Takotsubo) Cardiomyopathy
Stress cardiomyopathy is characterized by acute reversible
LV dysfunction in the absence of signiﬁcant CAD, triggered
by acute emotional or physical stress (23). This phenomenonis identiﬁed by a distinctive pattern of “apical ballooning,”
ﬁrst described in Japan as takotsubo, and often affects post-
menopausal women (186). A majority of patients have a clini-
cal presentation similar to that of acute coronary syndrome
(ACS) and may have transiently elevated cardiac enzymes.
6. Initial and Serial Evaluation
of the HF Patient
6.1. Clinical Evaluation
6.1.1. History and Physical Examination:
Recommendations
CLASS I
1. A thorough history and physical examination should be ob-
tained/performed in patients presenting with HF to identify
cardiac and noncardiac disorders or behaviors that might
cause or accelerate the development or progression of HF.
(Level of Evidence: C)
2. In patients with idiopathic DCM, a 3-generational family
history should be obtained to aid in establishing the diag-
nosis of familial DCM. (Level of Evidence: C)
3. Volume status and vital signs should be assessed at each
patient encounter. This includes serial assessment of
weight, as well as estimates of jugular venous pressure and
the presence of peripheral edema or orthopnea (187–190).
(Level of Evidence: B)
Despite advances in imaging technology and increasing
availability of diagnostic laboratory testing, a careful history
and physical examination remain the cornerstones in the
assessment of patients with HF. The components of a focused
history and physical examination for the patient with HF are
listed in Table 6. The history provides clues to the etiology of
the cardiomyopathy, including the diagnosis of familial
cardiomyopathy (deﬁned as 2 relatives with idiopathic
DCM). Familial syndromes are now recognized to occur in 20%
to 35% of patients with apparent idiopathic DCM (118); thus,
a 3-generation family history should be obtained. The history
also provides information about the severity of the disease and
the patient’s prognosis and identiﬁes opportunities for thera-
peutic interventions. The physical examination provides
information about the severity of illness and allows assessment
of volume status and adequacy of perfusion. In advanced
HFrEF, orthopnea and jugular venous pressure are useful
ﬁndings to detect elevated LV ﬁlling pressures (187,189,190).
See Online Data Supplements 5, 6, and 7 for additional
data on stress testing and clinical evaluation.
6.1.2. Risk Scoring: Recommendation
CLASS IIa
1. Validated multivariable risk scores can be useful to estimate
subsequent risk of mortality in ambulatory or hospitalized
patients with HF (199–207). (Level of Evidence: B)
In the course of standard evaluation, clinicians should
routinely assess the patient’s potential for adverse outcome,
because accurate risk stratiﬁcation may help guide therapeutic
decision making, including a more rapid transition to advanced
Table 6. History and Physical Examination in HF
Comments
History
Potential clues suggesting etiology of HF A careful family history may identify an underlying familial cardiomyopathy in
patients with idiopathic DCM (118). Other etiologies outlined in Section 5
should be considered as well.
Duration of illness A patient with recent-onset systolic HF may recover over time (113).
Severity and triggers of dyspnea and fatigue, presence of chest pain,
exercise capacity, physical activity, sexual activity
To determine NYHA class; identify potential symptoms of coronary ischemia.
Anorexia and early satiety, weight loss Gastrointestinal symptoms are common in patients with HF. Cardiac cachexia is
associated with adverse prognosis (191).
Weight gain Rapid weight gain suggests volume overload.
Palpitations, (pre)syncope, ICD shocks Palpitations may be indications of paroxysmal AF or ventricular tachycardia. ICD
shocks are associated with adverse prognosis (192).
Symptoms suggesting transient ischemic attack or thromboembolism Affects consideration of the need for anticoagulation.
Development of peripheral edema or ascites Suggests volume overload.
Disordered breathing at night, sleep problems Treatment for sleep apnea may improve cardiac function and decrease
pulmonary hypertension (193).
Recent or frequent prior hospitalizations for HF Associated with adverse prognosis (194).
History of discontinuation of medications for HF Determine whether lack of GDMT in patients with HFrEF reflects intolerance, an
adverse event, or perceived contraindication to use. Withdrawal of these
medications has been associated with adverse prognosis (195,196).
Medications that may exacerbate HF Removal of such medications may represent a therapeutic opportunity.
Diet Awareness and restriction of sodium and fluid intake should be assessed.
Adherence to medical regimen Access to medications; family support; access to follow-up; cultural sensitivity
Physical Examination
BMI and evidence of weight loss Obesity may be a contributing cause of HF; cachexia may correspond with poor
prognosis.
Blood pressure (supine and upright) Assess for hypertension or hypotension. Width of pulse pressure may reflect
adequacy of cardiac output. Response of blood pressure to Valsalva
maneuver may reflect LV filling pressures (197).
Pulse Manual palpation will reveal strength and regularity of pulse rate.
Examination for orthostatic changes in blood pressure and heart rate Consistent with volume depletion or excess vasodilation from medications.
Jugular venous pressure at rest and following abdominal compression
(http://wn.com/jugular_venous_distension_example)
Most useful finding on physical examination to identify congestion
(187–190,198).
Presence of extra heart sounds and murmurs S3 is associated with adverse prognosis in HFrEF (188). Murmurs may be
suggestive of valvular heart disease.
Size and location of point of maximal impulse Enlarged and displaced point of maximal impulse suggests ventricular
enlargement.
Presence of right ventricular heave Suggests significant right ventricular dysfunction and/or pulmonary hypertension.
Pulmonary status: respiratory rate, rales, pleural effusion In advanced chronic HF, rales are often absent despite major pulmonary
congestion.
Hepatomegaly and/or ascites Usually markers of volume overload.
Peripheral edema Many patients, particularly those who are young, may be not edematous despite
intravascular volume overload. In obese patients and elderly patients, edema
may reflect peripheral rather than cardiac causes.
Temperature of lower extremities Cool lower extremities may reflect inadequate cardiac output.
AF indicates atrial fibrillation; BMI, body mass index; DCM, dilated cardiomyopathy; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure
with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LV, left ventricular; and NYHA, New York Heart Association.
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including biomarker testing (Section 6.3), as well as a variety of
multivariable clinical risk scores ( Table 7); these risk scores are
for use in ambulatory (199,203,205,206,208) and hospitalized
patients (200,202,204,205,209). Risk models speciﬁcally for
patients with HFpEF have also been described (201).One well-validated risk score, the Seattle Heart Failure
Model, is available in an interactive application on the
Internet (210) and provides robust information about risk of
mortality in ambulatory patients with HF. For patients
hospitalized with acutely decompensated HF, the model
developed by ADHERE (Acute Decompensated Heart Failure
Table 7. Selected Multivariable Risk Scores to Predict Outcome in HF
Risk Score Reference/Link
Chronic HF
All patients with chronic HF
Seattle Heart Failure Model (203) http://SeattleHeartFailureModel.org
Heart Failure Survival Score (199) http://handheld.softpedia.com/get/Health/Calculator/HFSS-Calc-37354.shtml
CHARM Risk Score (206)
CORONA Risk Score (207)
Specific to chronic HFpEF
I-PRESERVE Score (201)
Acutely decompensated HF
ADHERE Classification and Regression Tree (CART) Model (200)
American Heart Association Get With The Guidelines Score (205) http://www.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/
GetWithTheGuidelinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home-
%20Page_UCM_306087_SubHomePage.jsp
EFFECT Risk Score (202) http://www.ccort.ca/Research/CHFRiskModel.aspx
ESCAPE Risk Model and Discharge Score (214)
OPTIMIZE HF Risk-Prediction Nomogram (215)
ADHERE indicates Acute Decompensated Heart Failure National Registry; CHARM, Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity;
CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; EFFECT, Enhanced Feedback for Effective Cardiac Treatment; ESCAPE, Evaluation Study of
Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; I-PRESERVE,
Irbesartan in Heart Failure with Preserved Ejection Fraction Study; and OPTIMIZE, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart
Failure.
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on hospital admission (i.e., systolic blood pressure, blood urea
nitrogen, and serum creatinine) and stratiﬁes subjects into
categories with a 10-fold range of crude in-hospital mortality
(from 2.1% to 21.9%) (200). Notably, clinical risk scores have
not performed as well in estimating risk of hospital read-
mission (211). For this purpose, biomarkers such as natriuretic
peptides hold considerable promise (212,213) (Section 6.3).
See Online Data Supplement 8 for additional data on
clinical evaluation risk scoring.
6.2. Diagnostic Tests: Recommendations
CLASS I
1. Initial laboratory evaluation of patients presenting with HF
should include complete blood count, urinalysis, serum
electrolytes (including calcium and magnesium), blood urea
nitrogen, serum creatinine, glucose, fasting lipid proﬁle,
liver function tests, and thyroid-stimulating hormone. (Level
of Evidence: C)
2. Serial monitoring, when indicated, should include serum
electrolytes and renal function. (Level of Evidence: C)
3. A 12-lead ECG should be performed initially on all patients
presenting with HF. (Level of Evidence: C)
CLASS IIa
1. Screening for hemochromatosis or HIV is reasonable in
selected patients who present with HF (216). (Level of
Evidence: C)
2. Diagnostic tests for rheumatologic diseases, amyloidosis, or
pheochromocytoma are reasonable in patients presenting
with HF in whom there is a clinical suspicion of these
diseases. (Level of Evidence: C)6.3. Biomarkers: Recommendations
A. Ambulatory/Outpatient
CLASS I
1. In ambulatory patients with dyspnea, measurement of BNP
or N-terminal pro-B-type natriuretic peptide (NT-proBNP) is
useful to support clinical decision making regarding the
diagnosis of HF, especially in the setting of clinical uncer-
tainty (217–223). (Level of Evidence: A)
2. Measurement of BNP or NT-proBNP is useful for establishing
prognosis or disease severity in chronic HF (222,224–229).
(Level of Evidence: A)
CLASS IIa
1. BNP- or NT-proBNP–guided HF therapy can be useful to
achieve optimal dosing of GDMT in select clinically euvole-
mic patients followed in a well-structured HF disease
management program (230–237). (Level of Evidence: B)
CLASS IIb
1. The usefulness of serial measurement of BNP or NT-proBNP
to reduce hospitalization or mortality in patients with HF is
not well established (230–237). (Level of Evidence: B)
2. Measurement of other clinically available tests such as
biomarkers of myocardial injury or ﬁbrosis may be consid-
ered for additive risk stratiﬁcation in patients with chronic
HF (238–244). (Level of Evidence: B)
B. Hospitalized/Acute
CLASS I
1. Measurement of BNP or NT-proBNP is useful to support clin-
ical judgment for the diagnosis of acutely decompensated
HF, especially in the setting of uncertainty for the diagnosis
(212,245–250). (Level of Evidence: A)
Table 8. Selected Causes of Elevated Natriuretic Peptide
Concentrations
Cardiac
 Heart failure, including RV syndromes
 Acute coronary syndrome
 Heart muscle disease, including LVH
 Valvular heart disease
 Pericardial disease
 Atrial fibrillation
 Myocarditis
 Cardiac surgery
 Cardioversion
Noncardiac
 Advancing age
 Anemia
 Renal failure
 Pulmonary: obstructive sleep apnea, severe pneumonia, pulmonary
hypertension
 Critical illness
 Bacterial sepsis
 Severe burns
 Toxic-metabolic insults, including cancer chemotherapy and envenomation
LVH indicates left ventricular hypertrophy; and RV, right ventricular.
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is useful for establishing prognosis or disease severity
in acutely decompensated HF (248,251–258). (Level of
Evidence: A)
CLASS IIb
1. The usefulness of BNP- or NT-proBNP–guided therapy for
acutely decompensated HF is not well established
(259,260). (Level of Evidence: C)
2. Measurement of other clinically available tests such as
biomarkers of myocardial injury or ﬁbrosis may be consid-
ered for additive risk stratiﬁcation in patients with acutely
decompensated HF (248,253,256,257,261–267). (Level of
Evidence: A)
In addition to routine clinical laboratory tests, other
biomarkers are gaining greater attention for their utility in
HF management. These biomarkers may reﬂect various
pathophysiological aspects of HF, including myocardial wall
stress, hemodynamic abnormalities, inﬂammation, myocyte
injury, neurohormonal upregulation, and myocardial remod-
eling, as well as extracellular matrix turnover. Thus, these
biomarkers are potentially powerful adjuncts to current stan-
dards for the diagnosis, prognosis, and treatment of acute and
chronic HF.
6.3.1. Natriuretic Peptides: BNP or NT-proBNP
BNP or its amino-terminal cleavage equivalent (NT-proBNP)
is derived from a common 108-amino acid precursor peptide
(proBNP108) that is generated by cardiomyocytes in the
context of numerous triggers, most notably myocardial
stretch. Following several steps of processing, BNP and NT-
proBNP are released from the cardiomyocyte, along with
variable amounts of proBNP108, the latter of which is
detected by all assays that measure either “BNP” or “NT-
proBNP.”
Assays for BNP and NT-proBNP have been increasingly
used to establish the presence and severity of HF. In general,
BNP and NT-proBNP values are reasonably correlated, and
either can be used in patient care settings as long as their
respective absolute values and cut points are not used inter-
changeably. BNP and NT-proBNP are useful to support
clinical judgment for the diagnosis or exclusion of HF, in the
setting of chronic ambulatory HF (217–223) or acute
decompensated HF (245–250); the value of natriuretic peptide
testing is particularly signiﬁcant when the etiology of dyspnea
is unclear.
Although lower values of BNP or NT-proBNP exclude the
presence of HF and higher values have reasonably high
positive predictive value to diagnose HF, clinicians should be
aware that elevated plasma levels for both natriuretic peptides
have been associated with a wide variety of cardiac and
noncardiac causes (Table 8) (268–271).
BNP and NT-proBNP levels improve with treatment of
chronic HF (225,272–274), with lowering of levels over time
in general, correlating with improved clinical outcomes
(248,251,254,260). Thus, BNP or NT-proBNP “guided”
therapy has been studied against standard care without natri-
uretic peptide measurement to determine whether guidedtherapy renders superior achievement of GDMT in patients
with HF. However, RCTs have yielded inconsistent results.
The positive and negative natriuretic peptide–guided
therapy trials differ primarily in their study populations, with
successful trials enrolling younger patients and only those
with HFrEF. In addition, a lower natriuretic peptide goal and/
or a substantial reduction in natriuretic peptides during treat-
ment are consistently present in the positive “guided” therapy
trials (275). Although most trials examining the strategy of
biomarker “guided” HF management were small and under-
powered, 2 comprehensive meta-analyses concluded that
BNP-guided therapy reduces all-cause mortality in patients
with chronic HF compared with usual clinical care (231,232),
especially in patients <75 years of age. This survival beneﬁt
may be attributed to increased achievement of GDMT. In
some cases, BNP or NT-proBNP levels may not be easily
modiﬁable. If the BNP or NT-proBNP value does not fall
after aggressive HF care, risk for death or hospitalization for
HF is signiﬁcant. On the other hand, some patients with
advanced HF have normal BNP or NT-proBNP levels or have
falsely low BNP levels because of obesity and HFpEF. All of
these patients should still receive appropriate GDMT.
6.3.2. Biomarkers of Myocardial Injury:
Cardiac Troponin T or I
Abnormal concentrations of circulating cardiac troponin are
found in patients with HF, often without obvious myocardial
ischemia and frequently in those without underlying CAD.
This suggests ongoing myocyte injury or necrosis in these
patients (238–241,276). In chronic HF, elaboration of cardiac
troponins is associated with impaired hemodynamics (238),
progressive LV dysfunction (239), and increased mortality
rates (238–241,276). Similarly, in patients with acute
decompensated HF, elevated cardiac troponin levels are
Table 9. Recommendations for Biomarkers in HF
Biomarker, Application Setting COR LOE References
Natriuretic peptides
Diagnosis or exclusion of HF Ambulatory, Acute I A 212,217–223,245–250
Prognosis of HF Ambulatory, Acute I A 222,224–229,248,251–258
Achieve GDMT Ambulatory IIa B 230–237
Guidance for acutely
decompensated HF therapy
Acute IIb C 259,260
Biomarkers of myocardial injury
Additive risk stratification Acute, Ambulatory I A 238–241,248,253,256–267
Biomarkers of myocardial fibrosis
Additive risk stratification Ambulatory IIb B 242–244
Acute IIb A 248,253,256,258–260,262,264–267
COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; and LOE, Level of Evidence.
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(253,257,263); decrease in troponin levels over time with
treatment is associated with a better prognosis than persistent
elevation in patients with chronic (239) or acute HF (277).
Given the tight association with ACS and troponin elevation as
well as the link between MI and the development of acute HF
(278), the measurement of troponin I or T should be routine in
patients presentingwith acutely decompensatedHF syndromes.
6.3.3. Other Emerging Biomarkers
Besides natriuretic peptides or troponins, multiple other
biomarkers, including those reﬂecting inﬂammation, oxidative
stress, neurohormonal disarray, and myocardial and matrix
remodeling, have been widely examined for their prognostic
value in HF. Biomarkers of myocardial ﬁbrosis, soluble ST2
and galectin-3 are not only predictive of hospitalization and
death in patients with HF but also additive to natriuretic
peptide levels in their prognostic value. Markers of renal
injury may also offer additional prognostic value because
renal function or injury may be involved in the pathogenesis,
progression, decompensation, or complications in chronic or
acute decompensated HF (242–244,264,265,279). StrategiesTable 10. Recommendations for Noninvasive Cardiac Imaging
Recommendations
Patients with suspected, acute, or new-onset HF should undergo a chest x
A 2-dimensional echocardiogram with Doppler should be performed for ini
Repeat measurement of EF is useful in patients with HF who have had a s
clinical status or received treatment that might affect cardiac function o
of device therapy
Noninvasive imaging to detect myocardial ischemia and viability is reasona
Viability assessment is reasonable before revascularization in HF patients w
Radionuclide ventriculography or MRI can be useful to assess LVEF and vo
MRI is reasonable when assessing myocardial infiltration or scar
Routine repeat measurement of LV function assessment should not be per
CAD indicates coronary artery disease; COR, Class of Recommendation; E
ventricular; LVEF, left ventricular ejection fraction; and MRI, magnetic resothat combine multiple biomarkers may ultimately prove
beneﬁcial in guiding HF therapy in the future.
See Table 9 for a summary of recommendations from this
section.
6.4. Noninvasive Cardiac Imaging:
Recommendations
See Table 10 for a summary of recommendations from this
section.
CLASS I
1. Patients with suspected or new-onset HF, or those pre-
senting with acute decompensated HF, should undergo
a chest x-ray to assess heart size and pulmonary congestion
and to detect alternative cardiac, pulmonary, and other
diseases that may cause or contribute to the patient’s
symptoms. (Level of Evidence: C)
2. A 2-dimensional echocardiogram with Doppler should be
performed during initial evaluation of patients presenting
with HF to assess ventricular function, size, wall thickness,
wall motion, and valve function. (Level of Evidence: C)
3. Repeat measurement of EF and measurement of the severity
of structural remodeling are useful to provide information in
patients with HF who have had a signiﬁcant change inCOR LOE
-ray I C
tial evaluation of HF I C
ignificant change in
r for consideration
I C
ble in HF and CAD IIa C
ith CAD IIa B (281–285)
lume IIa C
IIa B (286–288)
formed III: No Benefit B (289,290)
F, ejection fraction; HF, heart failure; LOE, Level of Evidence; LV, left
nance imaging.
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a clinical event; or who have received treatment, including
GDMT, that might have had a signiﬁcant effect on cardiac
function; or who may be candidates for device therapy.
(Level of Evidence: C)
CLASS IIa
1. Noninvasive imaging to detect myocardial ischemia and
viability is reasonable in patients presenting with de novo
HF, who have known CAD and no angina, unless the patient
is not eligible for revascularization of any kind. (Level of
Evidence: C)
2. Viability assessment is reasonable in select situations
when planning revascularization in HF patients with CAD
(281–285). (Level of Evidence: B)
3. Radionuclide ventriculography or magnetic resonance
imaging can be useful to assess LVEF and volume when
echocardiography is inadequate. (Level of Evidence: C)
4. Magnetic resonance imaging is reasonable when assessing
myocardial inﬁltrative processes or scar burden (286–288).
(Level of Evidence: B)
CLASS III: No Beneﬁt
1. Routine repeat measurement of LV function assessment in
the absence of clinical status change or treatment inter-
ventions should not be performed (289,290). (Level of
Evidence: B)
The chest x-ray is important for the evaluation of patients
presenting with signs and symptoms of HF because it assesses
cardiomegaly and pulmonary congestion and may reveal
alternative causes, cardiopulmonary or otherwise, of the
patient’s symptoms. Apart from congestion, however, other
ﬁndings on chest x-ray are associated with HF only in the
context of clinical presentation. Cardiomegaly may be absent
in HF. A chest x-ray may also show other cardiac chamber
enlargement, increased pulmonary venous pressure, interstitial
or alveolar edema, valvular or pericardial calciﬁcation, or
coexisting thoracic diseases. Considering its low sensitivity
and speciﬁcity, the chest x-ray should not be the sole deter-
minant of the speciﬁc cause of HF. Moreover, a supine chest
x-ray has limited value in acute decompensated HF.
Although a complete history and physical examination are
important ﬁrst steps, the most useful diagnostic test in the
evaluation of patients with or at risk for HF (e.g., postacute MI)
is a comprehensive 2-dimensional echocardiogram; coupled
with Doppler ﬂow studies, the transthoracic echocardiogram
can identify abnormalities of myocardium, heart valves, and
pericardium. Echocardiography can reveal subclinical HF and
predict risk of subsequent events (291–295). Use of echocar-
diograms in patients with suspected HF improves disease
identiﬁcation and provision of appropriate medical care (296).
Echocardiographic evaluation should address whether
LVEF is reduced, LV structure is abnormal, and other struc-
tural abnormalities are present that could account for the
clinical presentation. This information should be quantiﬁed,
including numerical estimates of EF measurement, ventricular
dimensions, wall thickness, calculations of ventricular
volumes, and evaluation of chamber geometry and regional
wall motion. Documentation of LVEF is an HF quality-of-care performance measure (297). Right ventricular size
and function as well as atrial size and dimensions should also
be measured. All valves should be evaluated for anatomic
and ﬂow abnormalities. Secondary changes, particularly the
severity of mitral and tricuspid valve insufﬁciency, should be
determined. Noninvasive hemodynamic data constitute
important additional information. Mitral valve inﬂow pattern,
pulmonary venous inﬂow pattern, and mitral annular velocity
provide data about LV ﬁlling and left atrial pressure. The
tricuspid valve regurgitant gradient, coupled with measure-
ment of inferior vena cava diameter and its response during
respiration, provides estimates of systolic pulmonary artery
pressure and central venous pressure. Many of these abnor-
malities are prognostically important and can be present
without manifest HF.
Serial echocardiographic evaluations are useful because
evidence of cardiac reverse remodeling can provide important
information in patients who have had a change in clinical
status or have experienced or recovered from an event or
treatment that affects cardiac function. However, the routine
repeat assessment of ventricular function in the absence of
changing clinical status or a change in treatment intervention
is not indicated.
The preference for echocardiography as an imaging
modality is due to its widespread availability and lack of
ionizing radiation; however, other imaging modalities may be
of use. Magnetic resonance imaging assesses LV volume and
EF measurements at least as accurately as echocardiography.
However, additional information about myocardial perfusion,
viability, and ﬁbrosis from magnetic resonance imaging can
help identify HF etiology and assess prognosis (298).
Magnetic resonance imaging provides high anatomical reso-
lution of all aspects of the heart and surrounding structure,
leading to its recommended use in known or suspected
congenital heart diseases (5). Cardiac computed tomography
can also provide accurate assessment of cardiac structure and
function, including the coronary arteries (299). An advantage
of cardiac computed tomography over echocardiography may
be its ability to characterize the myocardium, but studies have
yet to demonstrate the importance of this factor. Reports of
cardiac computed tomography in patients with suspected HF
are limited. Furthermore, both cardiac computed tomography
and magnetic resonance imaging lose accuracy with high
heart rates. Radionuclide ventriculography may also be used
for evaluation of cardiac function when other tests are
unavailable or inadequate. However, as a planar technique,
radionuclide ventriculography cannot directly assess valvular
structure, function, or ventricular wall thickness; it may be
more useful for assessing LV volumes in patients with
signiﬁcant baseline wall motion abnormalities or distorted
geometry. Ventriculography is highly reproducible (300).
Single photon emission computed tomography or positron
emission tomography scans are not primarily used to deter-
mine LV systolic global and regional function unless these
parameters are quantiﬁed from the resultant images during
myocardial perfusion and/or viability assessment (301,302).
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a high suspicion for obstructive CAD should undergo coro-
nary angiography. Stress nuclear imaging or echocardiog-
raphy may be an acceptable option for assessing ischemia in
patients presenting with HF who have known CAD and no
angina unless they are ineligible for revascularization (303).
Although the results of the STICH (Surgical Treatment for
Ischemic Heart Failure) trial have cast doubt on the role of
myocardial viability assessment to determine the mode of
therapy (304), the data are nevertheless predictive of a posi-
tive outcome. When these data are taken into consideration
with multiple previous studies demonstrating the usefulness
of this approach (281–285), it becomes reasonable to
recommend viability assessment when treating patients with
HFrEF who have known CAD (14).
See Online Data Supplement 9 for additional data on
imagingechocardiography.
6.5. Invasive Evaluation: Recommendations
See Table 11 for a summary of recommendations from this
section.
CLASS I
1. Invasive hemodynamic monitoring with a pulmonary artery
catheter should be performed to guide therapy in patients
who have respiratory distress or clinical evidence of
impaired perfusion in whom the adequacy or excess of
intracardiac ﬁlling pressures cannot be determined from
clinical assessment. (Level of Evidence: C)
CLASS IIa
1. Invasive hemodynamic monitoring can be useful for carefully
selected patients with acute HF who have persistent symp-
toms despite empiric adjustment of standard therapies anda. whose ﬂuid status, perfusion, or systemic or pulmonary
vascular resistance is uncertain;
b. whose systolic pressure remains low, or is associated
with symptoms, despite initial therapy;
c. whose renal function is worsening with therapy;
d. who require parenteral vasoactive agents; or
e. who may need consideration for MCS or transplantation.
(Level of Evidence: C)
2. When ischemia may be contributing to HF, coronary arteri-
ography is reasonable for patients eligible for revasculari-
zation. (Level of Evidence: C)Table 11. Recommendations for Invasive Evaluation
Recommendations
Monitoring with a pulmonary artery catheter should be performed in patien
distress or impaired systemic perfusion when clinical assessment is ina
Invasive hemodynamic monitoring can be useful for carefully selected pati
HF with persistent symptoms and/or when hemodynamics are uncertain
When ischemia may be contributing to HF, coronary arteriography is reaso
Endomyocardial biopsy can be useful in patients with HF when a specific d
suspected that would influence therapy
Routine use of invasive hemodynamic monitoring is not recommended in n
patients with acute HF
Endomyocardial biopsy should not be performed in the routine evaluation o
COR indicates Class of Recommendation; HF, heart failure; and LOE, Le3. Endomyocardial biopsy can be useful in patients presenting
with HF when a speciﬁc diagnosis is suspected that would
inﬂuence therapy. (Level of Evidence: C)
CLASS III: No Beneﬁt
1. Routine use of invasive hemodynamic monitoring is not
recommended in normotensive patients with acute decom-
pensated HF and congestion with symptomatic response to
diuretics and vasodilators (305). (Level of Evidence: B)
CLASS III: Harm
1. Endomyocardial biopsy should not be performed in the
routine evaluation of patients with HF. (Level of Evidence: C)
6.5.1. Right-Heart Catheterization
There has been no established role for routine or periodic
invasive hemodynamic measurements in the management of
HF. Most drugs used for the treatment of HF are prescribed on
the basis of their ability to improve symptoms or survival
rather than their effect on hemodynamic variables. The initial
and target doses of these drugs are generally selected on the
basis of controlled trial experience rather than changes
produced in cardiac output or pulmonary capillary wedge
pressure. Hemodynamic monitoring is indicated in patients
with clinically indeterminate volume status and those refrac-
tory to initial therapy, particularly if intracardiac ﬁlling pres-
sures and cardiac output are unclear. Patients with clinically
signiﬁcant hypotension (systolic blood pressure typically <90
mm Hg or symptomatic low systolic blood pressure) and/or
worsening renal function during initial therapy might also
beneﬁt from invasive hemodynamic measurements (305,306).
Patients being considered for cardiac transplantation or
placement of an MCS device are also candidates for complete
right-heart catheterization, including an assessment of
pulmonary vascular resistance, a necessary part of the initial
transplantation evaluation. Invasive hemodynamic monitoring
should be performed in patients with 1) presumed cardiogenic
shock requiring escalating pressor therapy and consideration
of MCS; 2) severe clinical decompensation in which therapy
is limited by uncertain contributions of elevated ﬁlling
pressures, hypoperfusion, and vascular tone; 3) apparent
dependence on intravenous inotropic infusions after initial
clinical improvement; or 4) persistent severe symptoms
despite adjustment of recommended therapies. On the otherCOR LOE
ts with respiratory
dequate
I C
ents with acute IIa C
nable IIa C
iagnosis is IIa C
ormotensive III: No Benefit B (305)
f HF III: Harm C
vel of Evidence.
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recommended in normotensive patients with acute decom-
pensated HFwho have a symptomatic response to diuretics and
vasodilators. This reinforces the concept that right-heart cath-
eterization is best reserved for those situations where a
speciﬁc clinical or therapeutic question needs to be addressed.
6.5.2. Left-Heart Catheterization
Left-heart catheterization or coronary angiography is indi-
cated for patients with HF and angina and may be useful for
those patients without angina but with LV dysfunction.
Invasive coronary angiography should be used in accordance
with the ACCF/AHA coronary artery bypass graft (CABG)
and percutaneous coronary intervention guidelines (10,12)
and should only be performed in patients who are poten-
tially eligible for revascularization (307–309). In patients with
known CAD and angina or with signiﬁcant ischemia
diagnosed by ECG or noninvasive testing and impaired
ventricular function, coronary angiography is indicated.
Among those without a prior diagnosis, CAD should be
considered as a potential etiology of impaired LV function
and should be excluded wherever possible. Coronary angi-
ography may be considered in these circumstances to detect
and localize large-vessel coronary obstructions. In patients in
whomCAD has been excluded as the cause of LV dysfunction,
coronary angiography is generally not indicated unless a
change in clinical status suggests interim development of
ischemic disease.
6.5.3. Endomyocardial Biopsy
Endomyocardial biopsy can be useful when seeking a speciﬁc
diagnosis that would inﬂuence therapy, and biopsy should
thus be considered in patients with rapidly progressive clinical
HF or worsening ventricular dysfunction that persists despite
appropriate medical therapy. Endomyocardial biopsy should
also be considered in patients suspected of having acute
cardiac rejection status after heart transplantation or having
myocardial inﬁltrative processes. A speciﬁc example is to
determine chemotherapy for primary cardiac amyloidosis.
Additional other indications for endomyocardial biopsy
include in patients with rapidly progressive and unexplained
cardiomyopathy, those in whom active myocarditis, espe-
cially giant cell myocarditis, is being considered (310).
Routine endomyocardial biopsy is not recommended in all
cases of HF, given limited diagnostic yield and the risk of
procedure-related complications.
See Online Data Supplement 10 for additional data on
biopsy.7. Treatment of Stages A to D
7.1. Stage A: Recommendations
CLASS I
1. Hypertension and lipid disorders should be controlled in
accordance with contemporary guidelines to lower the risk
of HF (27,94,311–314). (Level of Evidence: A)2. Other conditions that may lead to or contribute to HF, such
as obesity, diabetes mellitus, tobacco use, and known car-
diotoxic agents, should be controlled or avoided. (Level of
Evidence: C)
7.1.1. Recognition and Treatment of
Elevated Blood Pressure
The lifetime risk for development of hypertension is consid-
erable and represents a major public health issue (97).
Elevated blood pressure is a major risk factor for the devel-
opment of both HFpEF and HFrEF (91,92), a risk that extends
across all age ranges. Long-term treatment of both systolic
and diastolic hypertension has been shown to reduce the risk
of incident HF by approximately 50% (94,311–314). Treat-
ment of hypertension is particularly beneﬁcial in older
patients (311). One trial of a diuretic-based program demon-
strated a number needed to treat of 52 to prevent 1 HF event
in 2 years (311). In another study, elderly patients with
a history or ECG evidence of prior MI had a >80% risk
reduction for incident HF with aggressive blood pressure
control (94). Given the robust outcomes with blood pressure
reduction, clinicians should lower both systolic and diastolic
blood pressure in accordance with published guidelines (27).
Choice of antihypertensive therapy should also follow
guidelines (27), with speciﬁc options tailored to concomitant
medical problems, such as diabetes mellitus or CAD.
Diuretic-based antihypertensive therapy has repeatedly been
shown to prevent HF in a wide range of patients; ACE
inhibitors, ARBs, and beta blockers are also effective. Data
are less clear for calcium antagonists and alpha blockers in
reducing the risk for incident HF.
7.1.2. Treatment of Dyslipidemia and Vascular Risk
Patients with known atherosclerotic disease are likely to
develop HF. Clinicians should seek to control vascular risk
factors in such patients according to guidelines (28).
Aggressive treatment of hyperlipidemia with statins reduces
the likelihood of HF in at-risk patients (315,316). Long-term
treatment with ACE inhibitors in similar patients may also
decrease the risk of HF (314,317).
7.1.3. Obesity and Diabetes Mellitus
Obesity and overweight have been repeatedly linked to an
increased risk for HF (99,318,319). Presumably, the link
between obesity and risk for HF is explained by the clustering
of risk factors for heart disease in those with elevated BMI
(i.e., the metabolic syndrome). Similarly, insulin resistance,
with or without diabetes mellitus, is also an important risk
factor for the development of HF (92,320–323). Diabetes
mellitus is an especially important risk factor for women and
may, in fact, triple the risk for developing HF (91,324).
Dysglycemia appears to be directly linked to risk, with
HbA1c concentrations powerfully predicting incident HF.
Those with HbA1c >10.5% had a nearly 4-fold increase in
the risk for HF compared with those with a value of <6.5%
(322). Current consensus advocates that clinicians should
make every effort to control hyperglycemia, although such
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of HF. Additionally, standard therapies for diabetes mellitus,
such as use of ACE inhibitors or ARBs, can prevent the
development of other risk factors for HF, such as renal
dysfunction (325,326), and may themselves directly lower the
likelihood of HF (327–329). Although risk models for the
development of incident HF in patients with diabetes mellitus
have been developed (323), their prospective use to reduce
risk has not been validated. Despite the lack of supportive,
prospective, randomized data, consensus exists that risk factor
recognition and modiﬁcation are vital for the prevention of
HF among at-risk patients (e.g., obese patients or patients with
diabetes mellitus).
7.1.4. Recognition and Control of Other Conditions
That May Lead to HF
A substantial genetic risk exists in some patients for the
development of HF. As noted in Section 6.1, obtaining a
3-generation family history of HF is recommended. Adequate
therapy of AF is advisable, given a clear association between
uncontrolled heart rate and development of HF. Many thera-
peutic agents can exert important cardiotoxic effects, with
consequent risk for HF, and clinicians should be aware of
such risk. For example, cardiotoxic chemotherapy regimens
(particularly anthracycline based) and trastuzumab may
increase the risk for HF in certain patients (330–332); it may
be reasonable to evaluate those who are receiving (or who
have received) such agents for LV dysfunction. The use of
advanced echocardiographic techniques or biomarkers to
identify increased HF risk in those receiving chemotherapy
may be useful but remain unvalidated as yet (333).
Tobacco use is strongly associated with risk for incident HF
(92,320,334), and patients should be strongly advised about the
hazards of smoking, with attendant efforts at quitting. Cocaine
and amphetamines are anecdotally but strongly associated with
HF, and their avoidance is mandatory. Although it is recognized
that alcohol consumption is associated with subsequent devel-
opment of HF (92,139,140), there is some uncertainty about theTable 12. Recommendations for Treatment of Stage B HF
Recommendations
In patients with a history of MI and reduced EF, ACE inhibitors or ARBs
should be used to prevent HF
In patients with MI and reduced EF, evidence-based beta blockers
should be used to prevent HF
In patients with MI, statins should be used to prevent HF
Blood pressure should be controlled to prevent symptomatic HF
ACE inhibitors should be used in all patients with a reduced EF to prevent HF
Beta blockers should be used in all patients with a reduced EF to prevent HF
An ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy
who are at least 40 d post-MI, have an LVEF 30%, and on GDMT
Nondihydropyridine calcium channel blockers may be harmful in patients with low LVE
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; C
medical therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LOE, Lev
and N/A, not available.amount of alcohol ingested and the likelihood of developing
HF, and there may be sex differences as well. Nevertheless, the
heavy use of alcohol has repeatedly been associated with
heightened risk for development of HF. Therefore, patients
should be counseled about their alcohol intake.
Although several epidemiological studies have revealed an
independent link between risk for incident HF and biomarkers
such as natriuretic peptides (335,336), highly sensitive
troponin (337), and measures of renal function such as creat-
inine, phosphorus, urinary albumin, or albumin-creatinine
ratio (320,323,334,336,338–340), it remains unclear whether
the risk for HF reﬂected by any of these biomarkers is modi-
ﬁable. Although routine screening with BNP before echocar-
diography may be a cost-effective strategy to identify high-risk
patients (341), routine measurement of biomarkers in stage A
patients is not yet justiﬁed.
See Online Data Supplement 11 for additional data on
stage A HF.
7.2. Stage B: Recommendations
See Table 12 for a summary of recommendations from this
section.
CLASS I
1. In all patients with a recent or remote history of MI or ACS
and reduced EF, ACE inhibitors should be used to prevent
symptomatic HF and reduce mortality (342–344). In
patients intolerant of ACE inhibitors, ARBs are appropriate
unless contraindicated (314,345). (Level of Evidence: A)
2. In all patients with a recent or remote history of MI or ACS
and reduced EF, evidence-based beta blockers should be
used to reduce mortality (346–348). (Level of Evidence: B)
3. In all patients with a recent or remote history of MI or ACS,
statins should be used to prevent symptomatic HF and
cardiovascular events (104,349–354). (Level of Evidence: A)
4. In patients with structural cardiac abnormalities, including
LV hypertrophy, in the absence of a history of MI or ACS,
blood pressure should be controlled in accordance with
clinical practice guidelines for hypertension to prevent
symptomatic HF (27,94,311–313). (Level of Evidence: A)COR LOE References
I A 314,342–345
I B 346–348
I A 104,349–354
I A 27,94,311–313
I A 65,344
I C N/A
IIa B 355
F III: Harm C N/A
OR, Class of Recommendation; EF, ejection fraction; GDMT, guideline-directed
el of Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
Yancy et al. JACC Vol. 62, No. 16, 2013
2013 ACCF/AHA Heart Failure Guideline: Full Text October 15, 2013:e147–239
e1705. ACE inhibitors should be used in all patients with a reduced
EF to prevent symptomatic HF, even if they do not have
a history of MI (65,344). (Level of Evidence: A)
6. Beta blockers should be used in all patients with a reduced
EF to prevent symptomatic HF, even if they do not have
a history of MI. (Level of Evidence: C)
CLASS IIa
1. To prevent sudden death, placement of an ICD is reasonable
in patients with asymptomatic ischemic cardiomyopathy
who are at least 40 days post-MI, have an LVEF of 30% or
less, are on appropriate medical therapy, and have reason-
able expectation of survival with a good functional status for
more than 1 year (355). (Level of Evidence: B)
CLASS III: Harm
1. Nondihydropyridine calcium channel blockers with negative
inotropic effects may be harmful in asymptomatic patients
with low LVEF and no symptoms of HF after MI. (Level of
Evidence: C)
Patients with reduced LVEF may not have HF symptoms
and are most often identiﬁed during an evaluation for another
disorder (e.g., abnormal heart sounds, abnormal ECG,
abnormal chest x-ray, hypertension or hypotension, an
arrhythmia, acute MI, or pulmonary or systemic thrombo-
embolic event). However, the cost-effectiveness of routine
periodic population screening for asymptomatic reduced
LVEF is not recommended at this time. Echocardiographic
evaluation should be performed in selected patients who are at
high risk of reduced LVEF (e.g., those with a strong family
history of cardiomyopathy, long-standing hypertension,
previous MI, or those receiving cardiotoxic therapies). In
addition, it should be acknowledged that many adults may
have asymptomatic valvular abnormalities or congenital heart
lesions that if unrecognized could lead to the development of
clinical HF. Although these asymptomatic patients are in
stage B as well, the management of valvular and congenital
heart disease is beyond the scope of this guideline.
7.2.1. Management Strategies for Stage B
In general, all recommendations for patients with stage A HF
also apply to those with stage B HF, particularly with respect to
control of blood pressure in the patient with LV hypertrophy
(27,94,311,312) and the optimization of lipids with statins
(349,356). CAD is a major risk factor for the development of
HF and a key target for prevention of HF. The 5-year risk
of developing HF after acute MI is 7% and 12% for men and
women, respectively; for men and women between the ages of
40 and 69 and those>70 years of age, the risk is 22% and 25%,
respectively (51). Current evidence supports the use of ACE
inhibitors and (to a lower level of evidence) beta-blocker
therapy to impede maladaptive LV remodeling in patients
with stage B HF and low LVEF to improve mortality and
morbidity (344). At 3-year follow-up, those patients treated
with ACE inhibitors demonstrated combined endpoints of
reduced hospitalization or death, a beneﬁt that extended up to
a 12-year follow-up (65). ARBs are reasonable alternatives
to ACE inhibitors. In 1 study, losartan reduced adverse
outcomes in a population with hypertension (357), and inanother study of patients post-MI with low LVEF, valsartan
was equivalent to captopril (345). Data with beta blockers are
less convincing in a population with known CAD, although in
1 trial (346) carvedilol therapy in patients with stage B and low
LVEF was associated with a 31% relative risk reduction in
adverse long-term outcomes. In patients with previously
established structural heart disease, the administration of agents
known to have negative inotropic properties such as non-
dihydropyridine calcium channel blockers and certain antiar-
rhythmics should be avoided.
Elevations in both systolic and diastolic blood pressure are
major risk factors for developing LV hypertrophy, another
form of stage B (91,92). Although the magnitude of beneﬁt
varies with the trial selection criteria, target blood pressure
reduction, and HF criteria, effective hypertension treatment
invariably reduces HF events. Consequently, long-term
treatment of both systolic and diastolic hypertension reduces
the risk of moving from stage A or B to stage C HF
(93,94,311,329). Several large controlled studies have
uniformly demonstrated that optimal blood pressure control
decreases the risk of new HF by approximately 50% (96). It is
imperative that strategies to control hypertension be part of
any effort to prevent HF.
Clinicians should lower both systolic and diastolic blood
pressure in accordance with published guidelines (27). Target
levels of blood pressure lowering depend on major cardio-
vascular risk factors, (e.g., CAD, diabetes mellitus, or renal
disease) (358). Thus, when an antihypertensive regimen is
devised, optimal control of blood pressure should remain the
primary goal, with the choice of drugs determined by the
concomitant medical problems.
Diuretic-based antihypertensive therapy has been shown to
prevent HF in a wide range of target populations (359,360).
In refractory hypertensive patients, spironolactone (25 mg)
should be considered as an additional agent (27). Eplerenone,
in synergy with enalapril, has also demonstrated reduction in
LV mass (361).
ACE inhibitors and beta blockers are also effective in the
prevention of HF (27). Nevertheless, neither ACE inhibitors
nor beta blockers as single therapies are superior to other
antihypertensive drug classes, including calcium channel
blockers, in the reduction of all cardiovascular outcomes.
However, in patients with type 2 diabetes mellitus, ACE
inhibitors and ARBs signiﬁcantly reduced the incidence of HF
in patients (327–329). In contrast, calcium channel blockers
and alpha blockers were less effective in preventing the HF
syndrome, particularly in HFrEF (359).
The Framingham studies have shown a 60% increased risk
of death in patients with asymptomatic low LVEF compared
with those with normal LVEF; almost half of these patients
remained free of HF before their death (62–65). MADIT-II
(Multicenter Automatic Deﬁbrillator Implantation Trial II)
(362) demonstrated a 31% relative risk reduction in all-cause
mortality in patients with post-MI with LVEF 30%
receiving a prophylactic ICD compared with standard of
care (355). These ﬁndings provided justiﬁcation for broad
Table 13. Other ACCF/AHA Guidelines Addressing Patients
With Stage B HF
Consideration Reference
Patients with an acute MI who have not
developed HF symptoms treated
according to GDMT
2013 UA/NSTEMI Guideline (16)
2013 STEMI Guideline (15)
Coronary revascularization for patients
without symptoms of HF in
accordance with GDMT
2011 PCI Guideline (12)
2011 CABG Guideline (10)
2012 SIHD Guideline (14)
Valve replacement or repair for patients
with hemodynamically significant
valvular stenosis or regurgitation and
no symptoms of HF in accordance
with GDMT
2008 Focused Update
incorporated into the
2006 VHD Guideline (17)
ACCF indicates American College of Cardiology Foundation; AHA, American
Heart Association; CABG, coronary artery bypass graft; GDMT, guideline-
directed medical therapy; HF, heart failure; MI, myocardial infarction; PCI,
percutaneous coronary intervention; SIHD, stable ischemic heart disease;
STEMI, ST-elevation myocardial infarction; UA/NSTEMI, unstable angina/non–
ST-elevation myocardial infarction; and VHD, valvular heart disease.
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MI setting with reduced LVEF, even in the absence of HF
symptoms, that is, patients in stage B HF.
Several other ACCF/AHA guidelines addressing the
appropriate management of patients with stage Bdthose with
cardiac structural abnormalities but no symptoms of HFdare
listed in Table 13.
See Online Data Supplement 12 for additional data on
stage B HF.
7.3. Stage C
See Online Data Supplement 13 for additional data on
stage C HF.
7.3.1. Nonpharmacological Interventions
7.3.1.1. EDUCATION: RECOMMENDATION
CLASS I
1. Patients with HF should receive speciﬁc education to facil-
itate HF self-care (363–368). (Level of Evidence: B)
The self-care regimen for patients with HF is complex and
multifaceted (363). Patients need to understand how to
monitor their symptoms and weight ﬂuctuations, restrict their
sodium intake, take their medications as prescribed, and stay
physically active. Education regarding these recommenda-
tions is necessary, albeit not always sufﬁcient, to signiﬁcantly
improve outcomes. After discharge, many patients with HF
need disease management programs, which are reviewed in
Section 11.
A systematic review of 35 educational intervention studies
for patients with HF demonstrated that education improved
knowledge, self-monitoring, medication adherence, time to
hospitalization, and days in the hospital (363). Patients who
receive in-hospital education have higher knowledge scores at
discharge and 1 year later when compared with those who
did not receive in-hospital education (364). Data have calledinto question the survival beneﬁt of discharge education
(369,370). However, prior data have suggested that discharge
education may result in fewer days of hospitalization, lower
costs, and lower mortality rates within a 6-month follow-up
(365). Patients educated in all 6 categories of the HF core
measures from The Joint Commission were signiﬁcantly less
likely to be readmitted for any cause, including HF (366).
Even a single home-based educational intervention for
patients and families has been shown to decrease emergency
visits and unplanned hospitalizations in adults with HF (367).
See Online Data Supplement 14 for additional data on
patient nonadherence.
7.3.1.2. SOCIAL SUPPORT
Social support is thought to buffer stress and promote treat-
ment adherence and a healthy lifestyle (371). Most studies
examining the relationship between social support and
hospitalization in adults with HF have found that a lack of
social support is associated with higher hospitalization rates
(372,373) and mortality risk (374,375).
7.3.1.3. SODIUM RESTRICTION: RECOMMENDATION
CLASS IIa
1. Sodium restriction is reasonable for patients with symp-
tomatic HF to reduce congestive symptoms. (Level of
Evidence: C)
Dietary sodium restriction is commonly recommended to
patients with HF and is endorsed by many guidelines
(18,376,377). The data on which this recommendation is
drawn upon, however, are modest, and variances in protocols,
ﬂuid intake, measurement of sodium intake and compliance,
and other clinical and therapeutic characteristics among these
studies make it challenging to compare data and draw deﬁn-
itive conclusions. Observational data suggest an association
between dietary sodium intake with ﬂuid retention and risk for
hospitalization (378,379). Other studies, however, have
signaled a worsening neurohormonal proﬁle with sodium
restriction in HF (380–390). Sodium homeostasis is altered in
patients with HF as opposed to healthy individuals, which
may partially explain these trends. In most of these studies,
patients were not receiving GDMT; no study to date has
evaluated the effects of sodium restriction on neurohor-
monal activation and outcomes in optimally treated patients
with HF. With the exception of 1 observational study that
evaluated patients with HFpEF (383), all other studies have
focused on patients with HFrEF. These data are mostly from
white patients; when the differences in cardiovascular and
renal pathophysiology among races are considered, the
effects of sodium restriction in nonwhite patients with HF
cannot be ascertained from these studies. To make this
more complicated, the 3 RCTs that assessed outcomes with
sodium restriction have all shown that lower sodium intake is
associated with worse outcomes in patients with HFrEF
(384–386).
These limitations make it difﬁcult to give precise recom-
mendations about daily sodium intake and whether it should
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HFpEF), disease severity (e.g., NYHA class), HF-related
comorbidities (e.g., renal dysfunction), or other characteris-
tics (e.g., age or race). Because of the association between
sodium intake and hypertension, LV hypertrophy, and
cardiovascular disease, the AHA recommendation for restric-
tion of sodium to 1500 mg/d appears to be appropriate for most
patients with stage A and B HF (387–392). However, for
patients with stage C and D HF, currently there are insufﬁcient
data to endorse any speciﬁc level of sodium intake. Because
sodium intake is typically high (>4 g/d) in the general pop-
ulation, clinicians should consider some degree (e.g., <3 g/d)
of sodium restriction in patients with stage C and D HF for
symptom improvement.
7.3.1.4. TREATMENT OF SLEEP DISORDERS:
RECOMMENDATION
CLASS IIa
1. Continuous positive airway pressure can be beneﬁcial to
increase LVEF and improve functional status in patients with
HF and sleep apnea (393–396). (Level of Evidence: B)
Sleep disorders are common in patients with HF. A study
of adults with chronic HF treated with evidence-based ther-
apies found that 61% had either central or obstructive sleep
apnea (397). Despite having less sleep time and sleep efﬁ-
ciency compared with those without HF, patients with HF,
including those with documented sleep disorders, rarely report
excessive daytime sleepiness (398). Thus, a high degree of
suspicion for sleep disorders should be maintained for these
patients. The decision to refer a patient to a sleep study should
be based on clinical judgment.
The primary treatment for obstructive sleep apnea is
nocturnal continuous positive airway pressure. In a major
trial, continuous positive airway pressure for obstructive sleep
apnea was effective in decreasing the apnea–hypopnea index,
improving nocturnal oxygenation, increasing LVEF, lowering
norepinephrine levels, and increasing the distance walked in
6 minutes; these beneﬁts were sustained for up to 2 years
(394). Smaller studies suggest that continuous positive airway
pressure can improve cardiac function, sympathetic activity,
and HRQOL in patients with HF and obstructive sleep apnea
(395,396).
See Online Data Supplement 15 for additional data on the
treatment of sleep disorders.
7.3.1.5. WEIGHT LOSS
Obesity is deﬁned as a BMI 30 kg/m2. Patients with HF
who have a BMI between 30 and 35 kg/m2 have lower
mortality and hospitalization rates than those with a BMI in
the normal range (99). Weight loss may reﬂect cachexia
caused by the higher total energy expenditure associated with
HF compared with that of healthy sedentary subjects (399).
The diagnosis of cardiac cachexia independently predicts
a worse prognosis (191). At the other end of the continuum,
morbidly obese patients may have worse outcomes compared
with patients within the normal weight range and those whoare obese. A U-shaped distribution curve has been suggested
in which mortality is greatest in cachectic patients; lower in
normal, overweight, and mildly obese patients; and higher
again in more severely obese patients (400).
Although there are anecdotal reports about symptomatic
improvement after weight reduction in obese patients with HF
(401,402), large-scale clinical trials on the role of weight loss
in patients with HF with obesity have not been performed.
Because of reports of development of cardiomyopathy,
sibutramine is contraindicated in HF (403).
7.3.1.6. ACTIVITY, EXERCISE PRESCRIPTION, AND
CARDIAC REHABILITATION: RECOMMENDATIONS
CLASS I
1. Exercise training (or regular physical activity) is recom-
mended as safe and effective for patients with HF who are
able to participate to improve functional status (404–407).
(Level of Evidence: A)
CLASS IIa
1.Cardiac rehabilitation can be useful in clinically stable
patients with HF to improve functional capacity, exercise
duration, HRQOL, and mortality (404,406–411). (Level of
Evidence: B)
Exercise training in patients with HF is safe and has
numerous beneﬁts. Meta-analyses show that cardiac rehabili-
tation reduces mortality; improves functional capacity, exer-
cise duration, and HRQOL; and reduces hospitalizations (409).
Other beneﬁts include improved endothelial function, blunted
catecholamine spillover, increased peripheral oxygen extrac-
tion, and reduced hospital admission (405,407,410,411).
Many RCTs of exercise training in HF have been con-
ducted, but the statistical power of most was low (408). A
major trial of exercise and HF randomly assigned 2331
patients (mean EF, 25%; ischemic etiology, 52%) to either
exercise training for 3 months or usual care (406). In unad-
justed analyses, there was no signiﬁcant difference at the end
of the study in either total mortality or hospitalizations. When
adjusted for coronary heart disease risk factors, there was an
11% reduction in all-cause mortality, cardiovascular disease
mortality, or hospitalizations (P<0.03) in the exercise training
group (406). A meta-analysis demonstrated improved peak
oxygen consumption and decreased all-cause mortality with
exercise (409).
See Online Data Supplement 16 for additional data on
cardiac exercise.
7.3.2. Pharmacological Treatment for Stage C HFrEF:
Recommendations
CLASS I
1. Measures listed as Class I recommendations for patients in
stages A and B are recommended where appropriate for
patients in stage C. (Levels of Evidence: A, B, and C as
appropriate)
2. GDMT as depicted in Figure 1 should be the mainstay of
pharmacological therapy for HFrEF (108,343,345,346,
412–426). (Level of Evidence: A)
HFrEF Stage C
NYHA Class I – IV
Treatment:
For NYHA class II-IV patients.
Provided estimated creatinine
>30 mL/min and K+ <5.0 mEq/dL
For persistently symptomatic
African Americans,
NYHA class III-IV
Class I, LOE A
ACEI or ARB AND
Beta Blocker
Class I, LOE C
Loop Diuretics
Class I, LOE A
Hydral-Nitrates
Class I, LOE A
Aldosterone
Antagonist
AddAdd Add
For all volume overload,
NYHA class II-IV patients
Figure 1. Stage C HFrEF: evidence-based, guideline-directed medical therapy. ACEI indicates angiotensin-converting enzyme inhibitor;
ARB, angiotensin-receptor blocker; HFrEF, heart failure with reduced ejection fraction; Hydral-Nitrates, hydralazine and isosorbide dinitrate;
LOE, Level of Evidence; and NYHA, New York Heart Association.
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CLASS I
1. Diuretics are recommended in patients with HFrEF who have
evidence of ﬂuid retention, unless contraindicated, to
improve symptoms. (Level of Evidence: C)
Diuretics inhibit the reabsorption of sodium or chloride at
speciﬁc sites in the renal tubules. Bumetanide, furosemide,
and torsemide act at the loop of Henle (thus, the term loop
diuretics), whereas thiazides, metolazone, and potassium-
sparing agents (e.g., spironolactone) act in the distal portion
of the tubule (427,428). Loop diuretics have emerged as the
preferred diuretic agents for use in most patients with HF.
Thiazide diuretics may be considered in hypertensive patients
with HF and mild ﬂuid retention because they confer more
persistent antihypertensive effects.
Controlled trials have demonstrated the ability of diuretic
drugs to increase urinary sodium excretion and decrease
physical signs of ﬂuid retention in patients with HF (429,430).
In intermediate-term studies, diuretics have been shown to
improve symptoms and exercise tolerance in patients with HF
(431–433); however, diuretic effects on morbidity and
mortality are not known. Diuretics are the only drugs used for
the treatment of HF that can adequately control the ﬂuid
retention of HF. Appropriate use of diuretics is a key element
in the success of other drugs used for the treatment of HF. The
use of inappropriately low doses of diuretics will result inﬂuid retention. Conversely, the use of inappropriately high
doses of diuretics will lead to volume contraction, which can
increase the risk of hypotension and renal insufﬁciency.
7.3.2.1.1. Diuretics: Selection of Patients. Diuretics
should be prescribed to all patients who have evidence of, and
to most patients with a prior history of, ﬂuid retention.
Diuretics should generally be combined with an ACE inhib-
itor, beta blocker, and aldosterone antagonist. Few patients
with HF will be able to maintain target weight without the use
of diuretics.
7.3.2.1.2. Diuretics: Initiation and Maintenance. The
most commonly used loop diuretic for the treatment of HF is
furosemide, but some patients respond more favorably to
other agents in this category (e.g., bumetanide, torsemide)
because of their increased oral bioavailability (434,435).
Table 14 lists oral diuretics recommended for use in the
treatment of chronic HF. In outpatients with HF, diuretic
therapy is commonly initiated with low doses, and the dose is
increased until urine output increases and weight decreases,
generally by 0.5 to 1.0 kg daily. Further increases in the dose
or frequency (i.e., twice-daily dosing) of diuretic administra-
tion may be required to maintain an active diuresis and sustain
weight loss. The ultimate goal of diuretic treatment is to
eliminate clinical evidence of ﬂuid retention. Diuretics are
generally combined with moderate dietary sodium restriction.
Table 14. Oral Diuretics Recommended for Use in the
Treatment of Chronic HF
Drug Initial Daily Dose(s)
Maximum
Total
Daily Dose
Duration
of Action
Loop diuretics
Bumetanide 0.5 to 1.0 mg once
or twice
10 mg 4 to 6 h
Furosemide 20 to 40 mg once or
twice
600 mg 6 to 8 h
Torsemide 10 to 20 mg once 200 mg 12 to 16 h
Thiazide diuretics
Chlorothiazide 250 to 500 mg once
or twice
1,000 mg 6 to 12 h
Chlorthalidone 12.5 to 25.0 mg once 100 mg 24 to 72 h
Hydrochlorothiazide 25 mg once or twice 200 mg 6 to 12 h
Indapamide 2.5 mg once 5 mg 36 h
Metolazone 2.5 mg once 20 mg 12 to 24 h
Potassium-sparing diuretics*
Amiloride 5 mg once 20 mg 24 h
Spironolactone 12.5 to 25.0 mg once 50 mgy 1 to 3 h
Triamterene 50 to 75 mg twice 200 mg 7 to 9 h
Sequential nephron blockade
Metolazonez 2.5 to 10.0 mg once
plus loop diuretic
N/A N/A
Hydrochlorothiazide 25 to 100 mg once
or twice plus loop
diuretic
N/A N/A
Chlorothiazide (IV) 500 to 1,000 mg once
plus loop diuretic
N/A N/A
*Eplerenone, although also a diuretic, is primarily used in chronic HF.
yHigher doses may occasionally be used with close monitoring.
zSee Section 8.4.
HF indicates heart failure; IV, intravenous; and N/A, not applicable.
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should bemaintained in some patients to prevent the recurrence
of volume overload. Patients are commonly prescribed a ﬁxed
dose of diuretic, but the dose of these drugs frequentlymay need
adjustment. In many cases, this adjustment can be accom-
plished by having patients record their weight each day and
adjusting the diuretic dosage if weight increases or decreases
beyond a speciﬁed range. Patients may become unresponsive to
high doses of diuretic drugs if they consume large amounts
of dietary sodium, are taking agents that can block the effects
of diuretics (e.g., nonsteroidal anti-inﬂammatory drugs
[NSAIDs], including cyclooxygenase-2 inhibitors) (436–438)
or have a signiﬁcant impairment of renal function or perfu-
sion (434).Diuretic resistance can generally be overcomeby the
intravenous administration of diuretics (including the use of
continuous infusions) (439) or combination of different diuretic
classes (e.g., metolazone with a loop diuretic) (440–443).
7.3.2.1.3. Diuretics: Risks of Treatment. The principal
adverse effects of diuretics include electrolyte and ﬂuiddepletion, as well as hypotension and azotemia. Diuretics can
cause the depletion of potassium and magnesium, which can
predispose patients to serious cardiac arrhythmias (444). The
risk of electrolyte depletion is markedly enhanced when 2
diuretics are used in combination.
See Online Data Supplement 17 for additional data on
diuretics.
7.3.2.2. ACE INHIBITORS: RECOMMENDATION
CLASS I
1. ACE inhibitors are recommended in patients with HFrEF and
current or prior symptoms, unless contraindicated, to
reduce morbidity and mortality (343,412–414). (Level of
Evidence: A)
7.3.2.2.1. ACE Inhibitors: Selection of Patients. ACE
inhibitors can reduce the risk of death and reduce hospitali-
zation in HFrEF. The beneﬁts of ACE inhibition were seen in
patients with mild, moderate, or severe symptoms of HF and in
patients with or without CAD. ACE inhibitors should be
prescribed to all patients with HFrEF. Unless there is
a contraindication, ACE inhibitors are used together with a beta
blocker. Patients should not be given an ACE inhibitor if they
have experienced life-threatening adverse reactions (i.e.,
angioedema) during previous medication exposure or if they
are pregnant or plan to become pregnant. Clinicians should
prescribe an ACE inhibitor with caution if the patient has
very low systemic blood pressures (systolic blood pressure
<80 mm Hg), markedly increased serum levels of creatinine
(>3 mg/dL), bilateral renal artery stenosis, or elevated levels of
serum potassium (>5.0 mEq/L).
7.3.2.2.2. ACE Inhibitors: Initiation and Maintenance.
The available data suggest that there are no differences among
available ACE inhibitors in their effects on symptoms or
survival (414). Treatment with an ACE inhibitor should be
initiated at low doses (Table 15), followed by gradual dose
increments if lower doses have been well tolerated. Renal
function and serum potassium should be assessed within 1 to
2 weeks of initiation of therapy and periodically thereafter,
especially in patients with preexisting hypotension, hypona-
tremia, diabetes mellitus, azotemia, or in those taking potas-
sium supplements. In controlled clinical trials that were
designed to evaluate survival, the dose of the ACE inhibitor
was not determined by a patient’s therapeutic response but
was increased until the predetermined target dose was reached
(343,413,414). Clinicians should attempt to use doses that
have been shown to reduce the risk of cardiovascular events in
clinical trials. If these target doses of an ACE inhibitor cannot
be used or are poorly tolerated, intermediate doses should be
used with the expectation that there are likely to be only small
differences in efﬁcacy between low and high doses. Abrupt
withdrawal of treatment with an ACE inhibitor can lead to
clinical deterioration and should be avoided.
7.3.2.2.3. ACE Inhibitors: Risks of Treatment. The
majority of the adverse reactions of ACE inhibitors can be
Table 15. Drugs Commonly Used for Stage C HFrEF
Drug Initial Daily Dose(s) Maximum Dose(s)
Mean Doses Achieved in
Clinical Trials
ACE inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times 122.7 mg/d (422)
Enalapril 2.5 mg twice 10 to 20 mg twice 16.6 mg/d (413)
Fosinopril 5 to 10 mg once 40 mg once N/A
Lisinopril 2.5 to 5 mg once 20 to 40 mg once 32.5 to 35.0 mg/d (445)
Perindopril 2 mg once 8 to 16 mg once N/A
Quinapril 5 mg twice 20 mg twice N/A
Ramipril 1.25 to 2.5 mg once 10 mg once N/A
Trandolapril 1 mg once 4 mg once N/A
ARBs
Candesartan 4 to 8 mg once 32 mg once 24 mg/d (420)
Losartan 25 to 50 mg once 50 to 150 mg once 129 mg/d (421)
Valsartan 20 to 40 mg twice 160 mg twice 254 mg/d (108)
Aldosterone antagonists
Spironolactone 12.5 to 25.0 mg once 25 mg once or twice 26 mg/d (425)
Eplerenone 25 mg once 50 mg once 42.6 mg/d (446)
Beta blockers
Bisoprolol 1.25 mg once 10 mg once 8.6 mg/d (117)
Carvedilol 3.125 mg twice 50 mg twice 37 mg/d (447)
Carvedilol CR 10 mg once 80 mg once N/A
Metoprolol succinate extended release
(metoprolol CR/XL)
12.5 to 25 mg once 200 mg once 159 mg/d (448)
Hydralazine and isosorbide dinitrate
Fixed-dose combination (424) 37.5 mg hydralazine/20 mg
isosorbide dinitrate
3 times daily
75 mg hydralazine/40 mg isosorbide
dinitrate 3 times daily
w175 mg hydralazine/90 mg
isosorbide dinitrate daily
Hydralazine and isosorbide dinitrate (449) Hydralazine: 25 to 50 mg,
3 or 4 times daily and
isosorbide dinitrate: 20 to 30 mg
3 or 4 times daily
Hydralazine: 300 mg daily in divided
doses and isosorbide dinitrate:
120 mg daily in divided doses
N/A
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CR, controlled release; CR/XL, controlled release/extended release; HFrEF, heart
failure with reduced ejection fraction; and N/A, not applicable.
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drugs: those related to angiotensin suppression and those
related to kinin potentiation. Other types of adverse effects
may also occur (e.g., rash and taste disturbances). Up to 20% of
patients will experience an ACE inhibitor–induced cough.
With the use of ACE inhibitors, particular care should be given
to the patient’s volume status, renal function, and concomitant
medications (Sections 7.3.2.1 and 7.3.2.9). However, most HF
patients (85% to 90%) can tolerate these drugs.
See Online Data Supplement 18 for additional data on
ACE inhibitors.
7.3.2.3. ARBS: RECOMMENDATIONS
CLASS I
1. ARBs are recommended in patients with HFrEF with current
or prior symptoms who are ACE inhibitor intolerant, unless
contraindicated, to reduce morbidity and mortality
(108,345,415,450). (Level of Evidence: A)CLASS IIa
1. ARBs are reasonable to reduce morbidity and mortality as
alternatives to ACE inhibitors as ﬁrst-line therapy for
patients with HFrEF, especially for patients already taking
ARBs for other indications, unless contraindicated
(451–456). (Level of Evidence: A)
CLASS IIb
1. Addition of an ARB may be considered in persistently
symptomatic patients with HFrEF who are already being
treated with an ACE inhibitor and a beta blocker in whom an
aldosterone antagonist is not indicated or tolerated
(420,457). (Level of Evidence: A)
CLASS III: Harm
1. Routine combined use of an ACE inhibitor, ARB, and aldo-
sterone antagonist is potentially harmful for patients with
HFrEF. (Level of Evidence: C)
ARBs were developed with the rationale that a) angiotensin
II production continues in the presence of ACE inhibition,
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ence with the renin-angiotensin system without inhibition of
kininase would produce all of the beneﬁts of ACE inhibitors
while minimizing the risk of adverse reactions to them.
However, it is now known that some of the beneﬁts of ACE
inhibitors may be related to the accumulation of kinins rather
than to the suppression of angiotensin II formation, whereas
some of the adverse effects of ACE inhibitors in HF are
related to the suppression of angiotensin II formation.
In several placebo-controlled studies, long-term therapy
with ARBs produced hemodynamic, neurohormonal, and
clinical effects consistent with those expected after interfer-
ence with the renin-angiotensin system. Reduced hospitali-
zation and mortality have been demonstrated. ACE inhibitors
remain the ﬁrst choice for inhibition of the renin-angiotensin
system in systolic HF, but ARBs can now be considered
a reasonable alternative.
7.3.2.3.1. ARBs: Selection of Patients. ARBs are used in
patients with HFrEF who are ACE inhibitor intolerant; an
ACE-inhibition intolerance primarily related to cough is the
most common indication. In addition, an ARB may be used as
an alternative to an ACE inhibitor in patients who are already
taking an ARB for another reason, such as hypertension, and
who subsequently develop HF. Angioedema occurs in <1% of
patients who take an ACE inhibitor, but it occurs more
frequently in blacks. Because its occurrence may be life-
threatening, clinical suspicion of this reaction justiﬁes the
subsequent avoidance of all ACE inhibitors for the lifetime of
the patient. ACE inhibitors should not be initiated in any patient
with a history of angioedema. Although ARBs may be consid-
ered as alternative therapy for patients who have developed
angioedema while taking an ACE inhibitor, there are some
patients who have also developed angioedema with ARBs, and
caution is advised when substituting an ARB in a patient who
has had angioedema associated with use of an ACE inhibitor
(458–461).
7.3.2.3.2. ARBs: Initiation and Maintenance. When
used, ARBs should be initiated with the starting doses shown
in Table 15. Many of the considerations with initiation of an
ARB are similar to those with initiation of an ACE inhibitor,
as discussed previously. Blood pressure (including postural
blood pressure changes), renal function, and potassium should
be reassessed within 1 to 2 weeks after initiation and followed
closely after changes in dose. Patients with systolic blood
pressure <80 mmHg, low serum sodium, diabetes mellitus,
and impaired renal function merit close surveillance during
therapy with inhibitors of the renin angiotensin-aldosterone
system. Titration is generally achieved by doubling doses.
For stable patients, it is reasonable to add therapy with beta-
blocking agents before full target doses of either ACE
inhibitors or ARBs are reached.
7.3.2.3.3. ARBs: Risks of Treatment. The risks of ARBs
are attributed to suppression of angiotensin stimulation. These
risks of hypotension, renal dysfunction, and hyperkalemia
are greater when combined with another inhibitor of thisneurohormonal axis, such as ACE inhibitors or aldosterone
antagonists.
See Online Data Supplement 19 for additional data on
ARBs.
7.3.2.4. BETA BLOCKERS: RECOMMENDATION
CLASS I
1. Use of 1 of the 3 beta blockers proven to reduce mortality
(e.g., bisoprolol, carvedilol, and sustained-release metopro-
lol succinate) is recommended for all patients with current
or prior symptoms of HFrEF, unless contraindicated, to
reduce morbidity and mortality (346,416–419,448). (Level
of Evidence: A)
Long-term treatment with beta blockers can lessen the
symptoms of HF, improve the patient’s clinical status, and
enhance the patient’s overall sense of well-being (462–469).
In addition, like ACE inhibitors, beta blockers can reduce the
risk of death and the combined risk of death or hospitalization
(117,447,448,470,471). These beneﬁts of beta blockers were
seen in patients with or without CAD and in patients with or
without diabetes mellitus, as well as in women and blacks.
The favorable effects of beta blockers were also observed in
patients already taking ACE inhibitors.
Three beta blockers have been shown to be effective in
reducing the risk of death in patients with chronic HFrEF:
bisoprolol and sustained-release metoprolol (succinate), which
selectively block beta-1–receptors; and carvedilol, which
blocks alpha-1–, beta-1–, and beta-2–receptors. Positive ﬁnd-
ings with these 3 agents, however, should not be considered
a beta-blocker class effect. Bucindolol lacked uniform effec-
tiveness across different populations, and short-acting meto-
prolol tartrate was less effective in HF clinical trials. Beta-1
selective blocker nebivolol demonstrated a modest reduction
in the primary endpoint of all-cause mortality or cardiovascular
hospitalization but did not affect mortality alone in an elderly
population that included patients with HFpEF (472).
7.3.2.4.1. Beta Blockers: Selection of Patients. Beta
blockers should be prescribed to all patients with stable
HFrEF unless they have a contraindication to their use or are
intolerant of these drugs. Because of its favorable effects on
survival and disease progression, a clinical trial–proven beta
blocker should be initiated as soon as HFrEF is diagnosed.
Even when symptoms are mild or improve with other
therapies, beta-blocker therapy is important and should not be
delayed until symptoms return or disease progression is
documented. Therefore, even if patients have little disability
and experience seemingly minimal symptomatic beneﬁt, they
should still be treated with a beta blocker to reduce the
risks of disease progression, clinical deterioration, and sudden
death (117,448,469–471).
Patients need not take high doses of ACE inhibitors before
initiation of beta-blocker therapy. In patients taking a low
dose of an ACE inhibitor, the addition of a beta blocker
produces a greater improvement in symptoms and reduction
in the risk of death than does an increase in the dose of
the ACE inhibitor, even to the target doses used in clinical
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ﬂuid retention, beta blockers should not be prescribed without
diuretics, because diuretics are needed to maintain sodium and
ﬂuid balance and prevent the exacerbation of ﬂuid retention
that can accompany the initiation of beta-blocker therapy
(474,475). Beta blockers may be considered in patients who
have reactive airway disease or asymptomatic bradycardia but
should be used cautiously in patients with persistent symp-
toms of either condition.
7.3.2.4.2. Beta Blockers: Initiation and Maintenance.
Treatment with a beta blocker should be initiated at very low
doses (Table 15), followed by gradual increments in dose if
lower doses have been well tolerated. Patients should be
monitored closely for changes in vital signs and symptoms
during this uptitration period. Planned increments in the dose
of a beta blocker should be delayed until any adverse effects
observed with lower doses have disappeared. When such
a cautious approach was used, most patients (approximately
85%) enrolled in clinical trials who received beta blockers
were able to tolerate short- and long-term treatment with these
drugs and achieve the maximum planned trial dose
(117,447,448,470). Data show that beta blockers can be safely
started before discharge even in patients hospitalized for HF,
provided they do not require intravenous inotropic therapy for
HF (476). Clinicians should make every effort to achieve
the target doses of the beta blockers shown to be effective in
major clinical trials. Even if symptoms do not improve, long-
term treatment should be maintained to reduce the risk of
major clinical events. Abrupt withdrawal of treatment with
a beta blocker can lead to clinical deterioration and should be
avoided (477).
7.3.2.4.3. Beta Blockers: Risks of Treatment. Initiation
of treatment with a beta blocker may produce 4 types of
adverse reactions that require attention and management:
ﬂuid retention and worsening HF; fatigue; bradycardia or heart
block; and hypotension. The occurrence of ﬂuid retention or
worsening HF is not generally a reason for the permanent
withdrawal of treatment. Such patients generally respond
favorably to intensiﬁcation of conventional therapy, and once
treated, they remain excellent candidates for long-term treat-
ment with a beta blocker. The slowing of heart rate and cardiac
conduction produced by beta blockers is generally asymp-
tomatic and thus requires no treatment; however, if the
bradycardia is accompanied by dizziness or lightheadedness or
if second- or third-degree heart block occurs, clinicians should
decrease the dose of the beta blocker. Clinicians may mini-
mize the risk of hypotension by administering the beta
blocker and ACE inhibitor at different times during the day.
Hypotensive symptoms may also resolve after a decrease in
the dose of diuretics in patients who are volume depleted. If
hypotension is accompanied by other clinical evidence of
hypoperfusion, beta-blocker therapy should be decreased or
discontinued pending further patient evaluation. The symptom
of fatigue is multifactorial and is perhaps the hardest symptom
to address with conﬁdence. Although fatigue may be relatedto beta blockers, other causes of fatigue should be considered,
including sleep apnea, overdiuresis, or depression.
See Online Data Supplement 20 for additional data on beta
blockers.
7.3.2.5. ALDOSTERONE RECEPTOR ANTAGONISTS:
RECOMMENDATIONS
CLASS I
1. Aldosterone receptor antagonists (or mineralocorticoid
receptor antagonists) are recommended in patients with
NYHA class II–IV HF and who have LVEF of 35% or less,
unless contraindicated, to reduce morbidity and mortality.
Patients with NYHA class II HF should have a history of prior
cardiovascular hospitalization or elevated plasma natriuretic
peptide levels to be considered for aldosterone receptor
antagonists. Creatinine should be 2.5 mg/dL or less in men
or 2.0 mg/dL or less in women (or estimated glomerular
ﬁltration rate >30 mL/min/1.73 m2), and potassium should
be less than 5.0 mEq/L. Careful monitoring of potassium,
renal function, and diuretic dosing should be performed at
initiation and closely followed thereafter to minimize risk of
hyperkalemia and renal insufﬁciency (425,426,478). (Level
of Evidence: A)
2. Aldosterone receptor antagonists are recommended to
reduce morbidity and mortality following an acute MI in
patients who have LVEF of 40% or less who develop symp-
toms of HF or who have a history of diabetes mellitus, unless
contraindicated (446). (Level of Evidence: B)
CLASS III: Harm
1. Inappropriate use of aldosterone receptor antagonists is
potentially harmful because of life-threatening hyperkalemia
or renal insufﬁciency when serum creatinine is greater than
2.5 mg/dL in men or greater than 2.0 mg/dL in women
(or estimated glomerular ﬁltration rate <30mL/min/1.73m2),
and/or potassium greater than 5.0 mEq/L (479,480). (Level
of Evidence: B)
The landmark RALES trial (Randomized Aldactone Evalu-
ation Study) (425) showed a 30% reduction in all-cause
mortality as well as a reduced risk of SCD and HF hospitali-
zations with the use of spironolactone in patients with chronic
HFrEF and LVEF <35%. Eplerenone has been shown to
reduce all-cause deaths, cardiovascular deaths, or HF hospi-
talizations in a wider range of patients with HFrEF (426,446).
7.3.2.5.1. Aldosterone Receptor Antagonists: Selection
of Patients. Clinicians should strongly consider the addition
of the aldosterone receptor antagonists spironolactone or
eplerenone for all patients with HFrEF who are already on
ACE inhibitors (or ARBs) and beta blockers. Although the
entry criteria for the trials of aldosterone receptor antagonists
excluded patients with a creatinine >2.5 mg/dL, the majority
of patients had much lower creatinine (95% of patients had
creatinine 1.7 mg/dL) (425,426,446). In contrast, one third
of patients in EMPHASIS-HF (Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure) had an
estimated glomerular ﬁltration rate of <60 mL/min/1.73 m2
(426). Note also that the entry criteria for the EMPHASIS-HF
trial were age of at least 55 years, NYHA class II symptoms,
Table 16. Drug Dosing for Aldosterone Receptor Antagonists
Eplerenone Spironolactone
eGFR (mL/min/1.73 m2) 50 30 to 49 50 30 to 49
Initial dose (only if Kþ 5 mEq/L) 25 mg once daily 25 mg once every other day 12.5 to 25.0 mg once daily 12.5 mg once daily or every other day
Maintenance dose (after 4 wk for Kþ
5 mEq/L)*
50 mg once daily 25 mg once daily 25 mg once or twice daily 12.5 to 25.0 mg once daily
*After dose initiation for Kþ, increase 6.0 mEq/L or worsening renal function, hold until Kþ<5.0 mEq/L. Consider restarting reduced dose after confirming
resolution of hyperkalemia/renal insufficiency for at least 72 h.
eGFR indicates estimated glomerular filtration rate; and Kþ, potassium.
Adapted from Butler et al. (481).
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duration of >130 ms on ECG). To minimize the risk of life-
threatening hyperkalemia in euvolemic patients with HFrEF,
patients should have initial serum creatinine <2.5 mg/dL (or
an estimated glomerular ﬁltration rate >30 mL/min/1.73 m2)
without recent worsening and serum potassium <5.0 mEq/L
without a history of severe hyperkalemia. Careful patient
selection and risk assessment with availability of close
monitoring is essential in initiating the use of aldosterone
receptor antagonists.
7.3.2.5.2. Aldosterone Receptor Antagonists: Initiation
and Maintenance. Spironolactone should be initiated at
a dose of 12.5 to 25 mg daily, while eplerenone should be
initiated at a dose of 25 mg/d, increasing to 50 mg daily.
For those with concerns of hyperkalemia or marginal renal
function (estimated glomerular ﬁltration rate 30 to 49 mL/min/
1.73 m2), an initial regimen of every-other-day dosing is
advised (Table 16). After initiation of aldosterone receptor
antagonists, potassium supplementation should be discon-
tinued (or reduced and carefully monitored in those with
a history of hypokalemia; Table 17), and patients should be
counseled to avoid foods high in potassium and NSAIDs.
Potassium levels and renal function should be rechecked
within 2 to 3 days and again at 7 days after initiation of an
aldosterone receptor antagonist. Subsequent monitoring should
be dictated by the general clinical stability of renal function
and ﬂuid status but should occur at least monthly for the ﬁrst
3 months and every 3 months thereafter. The addition or an
increase in dosage of ACE inhibitors or ARBs should trigger
a new cycle of monitoring.Table 17. Strategies to Minimize the Risk of Hyperkalemia in Patients
1. Impaired renal function is a risk factor for hyperkalemia during treatment with
when serum creatinine is >1.6 mg/dL.* In elderly patients or others with low m
filtration rate, determination that glomerular filtration rate or creatinine clearan
2. Aldosterone antagonists would not ordinarily be initiated in patients with baseline
3. An initial dose of spironolactone of 12.5 mg or eplerenone 25 mg is typical, after w
appropriate.
4. The risk of hyperkalemia is increased with concomitant use of higher doses of A
5. In most circumstances, potassium supplements are discontinued or reduced whe
6. Close monitoring of serum potassium is required; potassium levels and renal funct
least monthly for the first 3 mo.
*Although the entry criteria for the trials of aldosterone antagonists included creatin
(425), 95% of patients had creatinine 1.7 mg/dL.
ACE indicates angiotensin-converting enzyme.There are limited data to support or refute that spi-
ronolactone and eplerenone are interchangeable. The per-
ceived difference between eplerenone and spironolactone is
the selectivity of aldosterone receptor antagonism and not
the effectiveness of blocking mineralocorticoid activity. In
RALES, there was increased incidence (10%) of gyneco-
mastia or breast pain with use of spironolactone (a nonse-
lective antagonist). The incidence of these adverse events
was <1% in EPHESUS (Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efﬁcacy and Survival Study) and
EMPHASIS-HF without any difference in adverse events
between the eplerenone and placebo (426,446).
7.3.2.5.3. Aldosterone Receptor Antagonists: Risks of
Treatment. The major risk associated with use of aldoste-
rone receptor antagonists is hyperkalemia due to inhibition of
potassium excretion, ranging from 2% to 5% in large clinical
trials (425,426,446) to 24% to 36% in population-based
registries (479,480). Routine triple combination of an ACE
inhibitor, ARB, and aldosterone receptor antagonist should be
avoided.
The development of potassium levels >5.5 mEq/L
(approximately 12% in EMPHASIS-HF [426]) should
generally trigger discontinuation or dose reduction of the
aldosterone receptor antagonist unless other causes are iden-
tiﬁed. The development of worsening renal function should
lead to careful evaluation of the entire medical regimen and
consideration for stopping the aldosterone receptor antagonist.
Patients should be instructed speciﬁcally to stop the aldoste-
rone receptor antagonist during an episode of diarrhea or
dehydration or while loop diuretic therapy is interrupted.Treated With Aldosterone Antagonists
aldosterone antagonists. The risk of hyperkalemia increases progressively
uscle mass in whom serum creatinine does not accurately reflect glomerular
ce is >30 mL/min/1.73 m2 is recommended.
serum potassium >5.0 mEq/L.
hich the dose may be increased to spironolactone 25 mg or eplerenone 50 mg if
CE inhibitors (captopril 75 mg daily; enalapril or lisinopril 10 mg daily).
n initiating aldosterone antagonists.
ion are most typically checked in 3 d and at 1 wk after initiating therapy and at
ine <2.5 mg/dL, the majority of patients had much lower creatinine; in 1 trial
Table 18. Medical Therapy for Stage C HFrEF: Magnitude of
Benefit Demonstrated in RCTs
GDMT
RR Reduction in
Mortality (%)
NNT for Mortality
Reduction
(Standardized
to 36 mo)
RR Reduction
in HF
Hospitalizations
(%)
ACE inhibitor or ARB 17 26 31
Beta blocker 34 9 41
Aldosterone antagonist 30 6 35
Hydralazine/nitrate 43 7 33
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor
blocker; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF,
heart failure with reduced ejection fraction; NNT, number needed to treat;
RCTs, randomized controlled trials; and RR, relative risk.
Adapted with permission from Fonarow et al. (483).
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e1797.3.2.6. HYDRALAZINE AND ISOSORBIDE DINITRATE:
RECOMMENDATIONS
CLASS I
1. The combination of hydralazine and isosorbide dinitrate is
recommended to reduce morbidity and mortality for patients
self-described as African Americans with NYHA class III–IV
HFrEF receiving optimal therapy with ACE inhibitors and
beta blockers, unless contraindicated (423,424). (Level of
Evidence: A)
CLASS IIa
1. A combination of hydralazine and isosorbide dinitrate can be
useful to reduce morbidity or mortality in patients with
current or prior symptomatic HFrEF who cannot be given an
ACE inhibitor or ARB because of drug intolerance, hypoten-
sion, or renal insufﬁciency, unless contraindicated (449).
(Level of Evidence: B)
In a large-scale trial that compared the vasodilator combi-
nation with placebo, the use of hydralazine and isosorbide
dinitrate reduced mortality but not hospitalizations in patients
with HF treated with digoxin and diuretics but not an ACE
inhibitor or beta blocker (449). However, in 2 other trials that
compared the vasodilator combination with an ACE inhibitor,
the ACE inhibitor produced more favorable effects on
survival (412,482). A post hoc retrospective analysis of these
vasodilator trials demonstrated particular efﬁcacy of iso-
sorbide dinitrate and hydralazine in the African American
cohort (423). In a subsequent trial, which was limited to
patients self-described as African American, the addition of
a ﬁxed-dose combination of hydralazine and isosorbide
dinitrate to standard therapy with an ACE inhibitor or ARB,
a beta blocker, and an aldosterone antagonist offered signiﬁ-
cant beneﬁt (424).
7.3.2.6.1. Hydralazine and Isosorbide Dinitrate: Selec-
tion of Patients. The combination of hydralazine and iso-
sorbide dinitrate is recommended for African Americans with
HFrEF who remain symptomatic despite concomitant use of
ACE inhibitors, beta blockers, and aldosterone antagonists.
Whether this beneﬁt is evident in non–African Americans
with HFrEF remains to be investigated. The combination of
hydralazine and isosorbide dinitrate should not be used for the
treatment of HFrEF in patients who have no prior use of
standard neurohumoral antagonist therapy and should not be
substituted for ACE inhibitor or ARB therapy in patients who
are tolerating therapy without difﬁculty. Despite the lack of
data with the vasodilator combination in patients who are
intolerant of ACE inhibitors or ARBs, the combined use of
hydralazine and isosorbide dinitrate may be considered as
a therapeutic option in such patients.
7.3.2.6.2. Hydralazine and Isosorbide Dinitrate: Initia-
tion and Maintenance. If the ﬁxed-dose combination is
available, the initial dose should be 1 tablet containing 37.5
mg of hydralazine hydrochloride and 20 mg of isosorbide
dinitrate 3 times daily. The dose can be increased to 2 tablets
3 times daily for a total daily dose of 225 mg of hydralazine
hydrochloride and 120 mg of isosorbide dinitrate. When the 2drugs are used separately, both pills should be administered at
least 3 times daily. Initial low doses of the drugs given sepa-
rately may be progressively increased to a goal similar to that
achieved in the ﬁxed-dose combination trial (424).
7.3.2.6.3. Hydralazine and Isosorbide Dinitrate: Risks
of Treatment. Adherence to this combination has generally
been poor because of the large number of tablets required,
frequency of administration, and the high incidence of
adverse reactions (412,449). Frequent adverse effects include
headache, dizziness, and gastrointestinal complaints. Never-
theless, the beneﬁt of these drugs can be substantial andwarrant
a slower titration of the drugs to enhance tolerance of the
therapy.
See Table 18 for a summary of the treatment beneﬁt of GDMT
in HFrEF.
7.3.2.7. DIGOXIN: RECOMMENDATION
CLASS IIa
1. Digoxin can be beneﬁcial in patients with HFrEF, unless con-
traindicated, to decrease hospitalizations for HF (484–491).
(Level of Evidence: B)
Several placebo-controlled trials have shown that treatment
with digoxin for 1 to 3 months can improve symptoms,
HRQOL, and exercise tolerance in patients with mild to
moderate HF (485–491). These beneﬁts have been seen
regardless of the underlying rhythm (normal sinus rhythm or
AF), cause of HF (ischemic or nonischemic cardiomyopathy),
or concomitant therapy (with or without ACE inhibitors). In
a long-term trial that primarily enrolled patients with NYHA
class II or III HF, treatment with digoxin for 2 to 5 years had
no effect on mortality but modestly reduced the combined risk
of death and hospitalization (484).
7.3.2.7.1. Digoxin: Selection of Patients. Clinicians may
consider adding digoxin in patients with persistent symptoms
of HFrEF during GDMT. Digoxin may also be added to the
initial regimen in patients with severe symptoms who have
not yet responded symptomatically during GDMT.
Alternatively, treatment with digoxin may be delayed until
the patient’s response to GDMT has been deﬁned and may be
*In the absence of contraindications to anticoagulation.
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with the neurohormonal antagonists. If a patient is taking
digoxin but not an ACE inhibitor or a beta blocker, treatment
with digoxin should not be withdrawn, but appropriate
therapy with the neurohormonal antagonists should be insti-
tuted. Digoxin is prescribed occasionally in patients with HF
and AF, but beta blockers are usually more effective when
added to digoxin in controlling the ventricular response,
particularly during exercise (492–495).
Patients should not be given digoxin if they have signiﬁ-
cant sinus or atrioventricular block unless the block has been
addressed with a permanent pacemaker. The drug should be
used cautiously in patients taking other drugs that can depress
sinus or atrioventricular nodal function or affect digoxin
levels (e.g., amiodarone or a beta blocker), even though such
patients usually tolerate digoxin without difﬁculty.
7.3.2.7.2. Digoxin: Initiation and Maintenance.
Therapy with digoxin is commonly initiated and maintained
at a dose of 0.125 to 0.25 mg daily. Low doses (0.125 mg
daily or every other day) should be used initially if the patient
is >70 years of age, has impaired renal function, or has a low
lean body mass (496). Higher doses (e.g., digoxin 0.375 to
0.50 mg daily) are rarely used or needed in the management
of patients with HF. There is no reason to use loading doses
of digoxin to initiate therapy in patients with HF.
Doses of digoxin that achieve a plasma concentration of
drug in the range of 0.5 to 0.9 ng/mL are suggested, given the
limited evidence currently available. There has been no
prospective, randomized evaluation of the relative efﬁcacy or
safety of different plasma concentrations of digoxin. Retro-
spective analysis of 2 studies of digoxin withdrawal found
that prevention of worsening HF by digoxin at lower
concentrations in plasma (0.5 to 0.9 ng/mL) was as great as
that achieved at higher concentrations (497,498).
7.3.2.7.3. Digoxin: Risks of Treatment. When adminis-
tered with attention to dose and factors that alter its metabo-
lism, digoxin is well tolerated by most patients with HF (499).
The principal adverse reactions occur primarily when digoxin
is administered in large doses, especially in the elderly, but
large doses are not necessary for clinical beneﬁts (500–502).
The major adverse effects include cardiac arrhythmias (e.g.,
ectopic and re-entrant cardiac rhythms and heart block),
gastrointestinal symptoms (e.g., anorexia, nausea, and vom-
iting), and neurological complaints (e.g., visual disturbances,
disorientation, and confusion). Overt digoxin toxicity is
commonly associated with serum digoxin levels >2 ng/mL.
However, toxicity may also occur with lower digoxin
levels, especially if hypokalemia, hypomagnesemia, or
hypothyroidism coexists (503,504). The concomitant use of
clarithromycin, dronedarone, erythromycin, amiodarone, itra-
conazole, cyclosporine, propafenone, verapamil, or quinidine
can increase serum digoxin concentrations and may increase
the likelihood of digoxin toxicity (505–507). The dose of
digoxin should be reduced if treatment with these drugs is
initiated. In addition, a low lean body mass and impaired renalfunction can also elevate serum digoxin levels, which may
explain the increased risk of digoxin toxicity in elderly patients.
7.3.2.8. OTHER DRUG TREATMENT
7.3.2.8.1. Anticoagulation: Recommendations
CLASS I
1. Patients with chronic HF with permanent/persistent/
paroxysmal AF and an additional risk factor for car-
dioembolic stroke (history of hypertension, diabetes melli-
tus, previous stroke or transient ischemic attack, or ‡75
years of age) should receive chronic anticoagulant therapy*
(508–514). (Level of Evidence: A)
2. Theselectionof ananticoagulant agent (warfarin, dabigatran,
apixaban, or rivaroxaban) for permanent/persistent/parox-
ysmal AF should be individualized on the basis of risk factors,
cost, tolerability, patient preference, potential for drug inter-
actions, and other clinical characteristics, including time in
the international normalized ratio therapeutic range if the
patient has been taking warfarin. (Level of Evidence: C)
CLASS IIa
1. Chronic anticoagulation is reasonable for patients with
chronic HF who have permanent/persistent/paroxysmal AF
but are without an additional risk factor for cardioembolic
stroke* (509–511,515–517). (Level of Evidence: B)
CLASS III: No Beneﬁt
1. Anticoagulation is not recommended in patients with
chronic HFrEF without AF, a prior thromboembolic event, or
a cardioembolic source (518–520). (Level of Evidence: B)
Patients with chronic HFrEF are at an increased risk of
thromboembolic events due to stasis of blood in dilated
hypokinetic cardiac chambers and in peripheral blood vessels
(521,522) and perhaps due to increased activity of procoa-
gulant factors (523). However, in large-scale studies, the risk
of thromboembolism in clinically stable patients has been low
(1% to 3% per year), even in those with a very depressed
EF and echocardiographic evidence of intracardiac thrombi
(524–528). These rates are sufﬁciently low to limit the
detectable beneﬁt of anticoagulation in these patients.
In several retrospective analyses, the risk of thromboem-
bolic events was not lower in patients with HF taking warfarin
than in patients not treated with antithrombotic drugs
(524,526,527). The use of warfarin was associated with a
reduction in major cardiovascular events and death in patients
with HF in some studies but not in others (518,529,530). An
RCT that compared the outcome of patients with HFrEF
assigned to aspirin, warfarin, or clopidogrel was completed
(519), but no therapy appeared to be superior. Another trial
compared aspirin with warfarin in patients with reduced LVEF,
sinus rhythm, and no cardioembolic source and demonstrated
no difference in either the primary outcome of death, stroke, or
intracerebral hemorrhage (520). There was also no difference
in the combined outcome of death, ischemic stroke, intrace-
rebral hemorrhage, MI, or HF hospitalization. There was
a signiﬁcant increase in major bleeding with warfarin. Given
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of bleeding, there is no compelling evidence to use warfarin or
aspirin in patients with HFrEF in the absence of a speciﬁc
indication.
The efﬁcacy of long-term warfarin for the prevention of
stroke in patients with AF is well established. However, the
ACCF/AHA guidelines for AF (6) recommend use of the
CHADS2 [Congestive heart failure, Hypertension, Age 75
years, Diabetes mellitus, previous Stroke/transient ischemic
attack (doubled risk weight)] score to assess patient risk for
adverse outcomes before initiating anticoagulation therapy.
More recently, a revised score, CHADS2-VASc, has been
suggested as more applicable to a wider range of patients
(531), but this revised score has not yet been fully studied in
patients with HF. Regardless of whether patients receive
rhythm or rate control, anticoagulation is recommended for
patients with HF and AF for stroke prevention in the presence
of at least 1 additional risk factor. For patients with HF and
AF in the absence of another cardioembolic risk factor, anti-
coagulation is reasonable.
Trials of newer oral anticoagulants have compared efﬁcacy
and safety with warfarin therapy rather than placebo. Several
new oral anticoagulants are now available, including the
factor Xa inhibitors apixaban and rivaroxaban and the direct
thrombin inhibitor dabigatran (508,512–514). These drugs
have few food and drug interactions compared with warfarin
and no need for routine coagulation monitoring or dose
adjustment. The ﬁxed dosing together with fewer interactions
may simplify patient management, particularly with the
polypharmacy commonly seen in HF. These drugs have
a potential for an improved beneﬁt–risk proﬁle compared with
warfarin, which may increase their use in practice, especially in
those at increased bleeding risk. However, important adverse
effects have been noted with these new anticoagulants,
including gastrointestinal distress, which may limit compli-
ance. At present, there is no commercially available agent to
reverse the effect of these newer drugs. Trials comparing new
anticoagulants with warfarin have enrolled >10,000 patients
with HF. As more detailed evaluations of the comparative
beneﬁts and risks of these newer agents in patients with HF are
still pending, the writing committee considered their use in
patients with HF and nonvalvular AF as an alternative to
warfarin to be reasonable.
The beneﬁt afforded by low-dose aspirin in patients with
systolic HF but no previous MI or known CAD (or speciﬁ-
cally in patients proven free of CAD) remains unknown. A
Cochrane review failed to ﬁnd sufﬁcient evidence to support its
use (532). Retrospective and observational studies again had
conﬂicting results and used very different criteria to identify
patients as nonischemic, with some demonstrating protection
from aspirin overall (532) or only in patients with more severe
depression of systolic function (518), whereas others found no
beneﬁt from aspirin (530). The high incidence of diabetes
mellitus and hypertension in most HF studies, combined with
a failure to use objective methods to exclude CAD in enrolled
patients, may leave this question unanswered. Currently, dataare insufﬁcient to recommend aspirin for empiric primary
prevention in HF patients known to be free of atherosclerotic
disease and without additional risk factors.
See Online Data Supplement 21 for additional data on
anticoagulants.
7.3.2.8.2. Statins: Recommendation
CLASS III: No Beneﬁt
1. Statins are not beneﬁcial as adjunctive therapy when
prescribed solely for the diagnosis of HF in the absence of
other indications for theiruse (533–538). (Level of Evidence: A)
Statin therapy has been broadly implicated in prevention of
adverse cardiovascular events, including new-onset HF.
Originally designed to lower cholesterol in patients with
cardiovascular disease, statins are increasingly recognized for
their favorable effects on inﬂammation, oxidative stress, and
vascular performance. Several observational and post hoc
analyses from large clinical trials have implied that statin
therapy may provide clinical beneﬁt to patients with HF
(533–536). However, 2 large RCTs have demonstrated that
rosuvastatin has neutral effects on long-term outcomes in
patients with chronic HFrEF when added to standard GDMT
(537,538). At present, statin therapy should not be prescribed
primarily for the treatment of HF to improve clinical outcomes.
See Online Data Supplement 22 for additional data on
statin therapy.
7.3.2.8.3. Omega-3 Fatty Acids: Recommendation
CLASS IIa
1. Omega-3 polyunsaturated fatty acid (PUFA) supplementa-
tion is reasonable to use as adjunctive therapy in patients
with NYHA class II–IV symptoms and HFrEF or HFpEF,
unless contraindicated, to reduce mortality and cardiovas-
cular hospitalizations (539,540). (Level of Evidence: B)
Supplementation with omega-3 PUFA has been evaluated
as an adjunctive therapy for cardiovascular disease and HF
(541). Trials in primary and secondary prevention of coronary
heart disease showed that omega-3 PUFA supplementation
results in a 10% to 20% risk reduction in fatal and nonfatal
cardiovascular events. The GISSI (Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto miocardico) Pre-
venzione trial demonstrated a 21% reduction in death among
post-MI patients taking 1 g of omega-3 PUFA (850 mg to 882
mg of eicosapentaenoic acid [EPA] and docosahexaenoic acid
[DHA] as ethyl esters in the ratio of 1:1.2) (542). Post hoc
subgroup analysis revealed that this reduction in mortality and
SCD was concentrated in the approximately 2000 patients
with reduced LVEF (539). The GISSI-HF investigators
randomized 6,975 patients in NYHA class II–IV chronic HF
to 1 g daily of omega-3 PUFA (850 mg to 882 mg EPA/DHA)
or matching placebo. Death from any cause was reduced from
29% with placebo to 27% in those treated with omega-3 PUFA
(540). The outcome of death or admission to hospital for
a cardiovascular event was also signiﬁcantly reduced. In re-
ported studies, this therapy has been safe and very well toler-
ated (540–543). Further investigations are needed to better
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supplements. The use of omega-3 PUFA supplementation is
reasonable as adjunctive therapy in patients with chronic HF.
See Online Data Supplement 23 for additional data on
omega-3 fatty acids.
7.3.2.9. DRUGS OF UNPROVEN VALUE OR THAT MAY
WORSEN HF: RECOMMENDATIONS
CLASS III: No Beneﬁt
1. Nutritional supplements as treatment for HF are not rec-
ommended in patients with current or prior symptoms of
HFrEF (544,545). (Level of Evidence: B)
2. Hormonal therapies other than to correct deﬁciencies are
not recommended for patients with current or prior symp-
toms of HFrEF. (Level of Evidence: C)
CLASS III: Harm
1. Drugs known to adversely affect the clinical status of
patients with current or prior symptoms of HFrEF are poten-
tially harmful and should be avoided or withdrawn whenever
possible (e.g., most antiarrhythmic drugs, most calcium
channel–blocking drugs [except amlodipine], NSAIDs, or
thiazolidinediones) (546–557). (Level of Evidence: B)
2. Long-term use of infused positive inotropic drugs is poten-
tially harmful for patients with HFrEF, except as palliation for
patients with end-stage disease who cannot be stabilized
with standard medical treatment (see recommendations for
stage D). (Level of Evidence: C)
7.3.2.9.1. Nutritional Supplements and Hormonal
Therapies. Patients with HF, particularly those treated with
diuretics, may become deﬁcient in vitamins and micro-
nutrients. Several nutritional supplements (e.g., coenzyme
Q10, carnitine, taurine, and antioxidants) and hormonal
therapies (e.g., growth hormone or thyroid hormone) have
been proposed for the treatment of HF (558–563). Testos-
terone has also been evaluated for its beneﬁcial effect in HF
with modest albeit preliminary effects (564). Aside from
replenishment of documented deﬁciencies, published data
have failed to demonstrate beneﬁt for routine vitamin, nutri-
tional, or hormonal supplementation (565). In most data or
other literature regarding nutraceuticals, there are issues,
including outcomes analyses, adverse effects, and drug-
nutraceutical interactions, that remain unresolved.
No clinical trials have demonstrated improved survival
rates with use of nutritional or hormonal therapy, with the
exception of omega-3 fatty acid supplementation as previ-
ously noted. Some studies have suggested a possible effect for
coenzyme Q10 in reduced hospitalization rates, dyspnea, and
edema in patients with HF, but these beneﬁts have not been
seen uniformly (566–569). Because of possible adverse
effects and drug interactions of nutritional supplements and
their widespread use, clinicians caring for patients with HF
should routinely inquire about their use. Until more data are
available, nutritional supplements or hormonal therapies are
not recommended for the treatment of HF.
7.3.2.9.2. Antiarrhythmic Agents. With atrial and ven-
tricular arrhythmias contributing to the morbidity andmortalityof HF, various classes of antiarrhythmic agents have been
repeatedly studied in large RCTs. Instead of conferring
survival beneﬁt, however, nearly all antiarrhythmic agents
increase mortality in the HF population (548–550). Most
antiarrhythmics have some negative inotropic effect and some,
particularly the class I and class III antiarrhythmic drugs, have
proarrhythmic effects. Hence, class I sodium channel antago-
nists and the class III potassium channel blockers d-sotalol and
dronedarone should be avoided in patients with HF. Amio-
darone and dofetilide are the only antiarrhythmic agents to
have neutral effects on mortality in clinical trials of patients
with HF and thus are the preferred drugs for treating arrhyth-
mias in this patient group (570–573).
See Online Data Supplement 24 for additional data on
antiarrhythmic agents.
7.3.2.9.3. CalciumChannelBlockers: Recommendation
CLASS III: No Beneﬁt
1. Calcium channel–blocking drugs are not recommended as
routine treatment for patients with HFrEF (551,574,575).
(Level of Evidence: A)
By reducing peripheral vasoconstriction and LV afterload,
calcium channel blockers were thought to have a potential
role in the management of chronic HF. However, ﬁrst-
generation dihydropyridine and nondihydropyridine calcium
channel blockers also have myocardial depressant activity.
Several clinical trials have demonstrated either no clinical
beneﬁt or even worse outcomes in patients with HF treated
with these drugs (546,547,551–553). Despite their greater
selectivity for calcium channels in vascular smooth muscle
cells, second-generation calcium channel blockers, dihy-
dropyridine derivatives such as amlodipine and felodipine,
have failed to demonstrate any functional or survival beneﬁt
in patients with HF (575–579). Amlodipine, however, may be
considered in the management of hypertension or ischemic
heart disease in patients with HF because it is generally well
tolerated and had neutral effects on morbidity and mortality in
large RCTs. In general, calcium channel blockers should be
avoided in patients with HFrEF.
See Online Data Supplement 25 for additional data on
calcium channel blockers.
7.3.2.9.4. NonsteroidalAnti-InﬂammatoryDrugs. NSAIDs
inhibit the synthesis of renal prostaglandins, which mediate
vasodilation in the kidneys and directly inhibit sodium
resorption in the thick ascending loop of Henle and collecting
tubule. Hence, NSAIDs can cause sodium and water retention
and blunt the effects of diuretics. Several observational cohort
studies have revealed increased morbidity and mortality in
patients with HF using either nonselective or selective
NSAIDs (554–556,580–582).
See Online Data Supplement 26 for additional data on
NSAIDs.
7.3.2.9.5. Thiazolidinediones. Thiazolidinediones increase
insulin sensitivity by activating nuclear peroxisome proliferator-
activated receptor gamma. Expressed in virtually all tissues,
yCounseling should be speciﬁc to each individual patient and should include
documentation of a discussion about the potential for sudden death and nonsudden
death from HF or noncardiac conditions. Information should be provided about the
efﬁcacy, safety, and potential complications of an ICD and the potential for deﬁ-
brillation to be inactivated if desired in the future, notably when a patient is
approaching end of life. This will facilitate shared decision making between
patients, families, and the medical care team about ICDs (30).
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sodium reabsorption in the collecting ducts of the kidney. In
clinical trials, thiazolidinediones have been associated with
increased incidence of HF events, even in those without any prior
history of clinical HF (557,583–588).
See Table 19 for a summary of recommendations from this
section and Table 20 for strategies for achieving optimal
GDMT; see Online Data Supplement 27 for additional data
on thiazolidinediones.
7.3.3. Pharmacological Treatment for Stage C HFpEF:
Recommendations
See Table 21 for a summary of recommendations from this
section.
CLASS I
1. Systolic and diastolic blood pressure should be controlled in
patients with HFpEF in accordance with published clinical
practice guidelines to prevent morbidity (27,91). (Level of
Evidence: B)
2. Diuretics should be used for relief of symptoms due to volume
overload in patients with HFpEF. (Level of Evidence: C)
CLASS IIa
1. Coronary revascularization is reasonable in patients with
CAD in whom symptoms (angina) or demonstrable myocar-
dial ischemia is judged to be having an adverse effect on
symptomatic HFpEF despite GDMT. (Level of Evidence: C)
2. Management of AF according to published clinical practice
guidelines in patients with HFpEF is reasonable to improve
symptomatic HF (Section 9.1). (Level of Evidence: C)
3. The use of beta-blocking agents, ACE inhibitors, and ARBs
in patients with hypertension is reasonable to control blood
pressure in patients with HFpEF. (Level of Evidence: C)
CLASS IIb
1. The use of ARBs might be considered to decrease hospitali-
zations for patients with HFpEF (589). (Level of Evidence: B)
CLASS III: No Beneﬁt
1. Routine use of nutritional supplements is not recommended
for patients with HFpEF. (Level of Evidence: C)
Trials using comparable and efﬁcacious agents for HFrEF
have generally been disappointing when used in patients with
HFpEF (590). Thus, most of the recommended therapies for
HFpEF are directed at symptoms, especially comorbidities,
and risk factors that may worsen cardiovascular disease.
Blood pressure control concordant with existing hyper-
tension guidelines remains the most important recommenda-
tion in patients with HFpEF. Evidence from an RCT has
shown that improved blood pressure control reduces hospi-
talization for HF (591), decreases cardiovascular events, and
reduces HF mortality in patients without prevalent HF (311).
In hypertensive patients with HFpEF, aggressive treatment
(often with several drugs with complementary mechanisms of
action) is recommended. ACE inhibitors and/or ARBs are
often considered as ﬁrst-line agents. Speciﬁc blood pressure
targets in HFpEF have not been ﬁrmly established; thus, the
recommended targets are those used for general hypertensive
populations.CAD is common in patients with HFpE (592); however,
there are no studies to determine the impact of revasculari-
zation on symptoms or outcomes speciﬁcally in patients with
HFpEF. In general, contemporary revascularization guidelines
(10,12), should be used in the care of patients with HFpEF
and concomitant CAD. Speciﬁc to this population, it might be
reasonable to consider revascularization in patients for whom
ischemia appears to contribute to HF symptoms, although this
determination can be difﬁcult.
Theoretical mechanisms for the worsening of HF symp-
toms by AF among patients with HFpEF include shortened
diastolic ﬁlling time with tachycardia and the loss of atrial
contribution to LV diastolic ﬁlling. Conversely, chronotropic
incompetence is also a concern. Slowing the heart rate is
useful in tachycardia but not in normal resting heart rate;
a slow heart rate prolongs diastasis and worsens chronotropic
incompetence. Currently, there are no speciﬁc trials of rate
versus rhythm control in HFpEF.
7.3.4. Device Therapy for Stage C HFrEF:
Recommendations
See Table 22 for a summary of recommendations from this
section.
CLASS I
1. ICD therapy is recommended for primary prevention of SCD
to reduce total mortality in selected patients with non-
ischemic DCM or ischemic heart disease at least 40 days
post-MI with LVEF of 35% or less and NYHA class II or III
symptoms on chronic GDMT, who have reasonable expec-
tation of meaningful survival for more than 1 yeary
(355,593). (Level of Evidence: A)
2. CRT is indicated for patients who have LVEF of 35% or less,
sinus rhythm, left bundle-branch block (LBBB) with a QRS
duration of 150 ms or greater, and NYHA class II, III, or
ambulatory IV symptoms on GDMT. (Level of Evidence: A for
NYHA class III/IV (38,78,116,594); Level of Evidence: B for
NYHA class II (595,596)).
3. ICD therapy is recommended for primary prevention of SCD
to reduce total mortality in selected patients at least 40
days post-MI with LVEF of 30% or less, and NYHA class I
symptoms while receiving GDMT, who have reasonable
expectation of meaningful survival for more than 1 yeary
(362,597,598). (Level of Evidence: B)
CLASS IIa
1. CRT can be useful for patients who have LVEF of 35% or
less, sinus rhythm, a non-LBBB pattern with a QRS duration
of 150 ms or greater, and NYHA class III/ambulatory
class IV symptoms on GDMT (78,116,594,596). (Level of
Evidence: A)
Table 19. Recommendations for Pharmacological Therapy for Management of Stage C HFrEF
Recommendations COR LOE References
Diuretics
Diuretics are recommended in patients with HFrEF with fluid retention I C N/A
ACE inhibitors
ACE inhibitors are recommended for all patients with HFrEF I A 343,412–414
ARBs
ARBs are recommended in patients with HFrEF who are ACE inhibitor intolerant I A 108,345,415,450
ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in HFrEF IIa A 451–456
Addition of an ARB may be considered in persistently symptomatic patients with HFrEF
on GDMT
IIb A 420,457
Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially
harmful
III: Harm C N/A
Beta blockers
Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all
stable patients
I A 346,416–419,448
Aldosterone receptor antagonists
Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV
who have LVEF 35%
I A 425,426,478
Aldosterone receptor antagonists are recommended in patients following an acute MI
who have LVEF 40% with symptoms of HF or DM
I B 446
Inappropriate use of aldosterone receptor antagonists may be harmful III: Harm B 479,480
Hydralazine and isosorbide dinitrate
The combination of hydralazine and isosorbide dinitrate is recommended for African
Americans with NYHA class III–IV HFrEF on GDMT
I A 423,424
A combination of hydralazine and isosorbide dinitrate can be useful in patients
with HFrEF who cannot be given ACE inhibitors or ARBs
IIa B 449
Digoxin
Digoxin can be beneficial in patients with HFrEF IIa B 484–491
Anticoagulation
Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional
risk factor for cardioembolic stroke should receive chronic anticoagulant therapy*
I A 508–514
The selection of an anticoagulant agent should be individualized I C N/A
Chronic anticoagulation is reasonable for patients with chronic HF who have permanent/
persistent/paroxysmal AF but are without an additional risk factor for cardioembolic stroke*
IIa B 509–511,515–517
Anticoagulation is not recommended in patients with chronic HFrEF without AF, a prior
thromboembolic event, or a cardioembolic source
III: No Benefit B 518–520
Statins
Statins are not beneficial as adjunctive therapy when prescribed solely for HF III: No Benefit A 533–538
Omega-3 fatty acids
Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in HFrEF
or HFpEF patients
IIa B 539,540
Other drugs
Nutritional supplements as treatment for HF are not recommended in HFrEF III: No Benefit B 544,545
Hormonal therapies other than to correct deficiencies are not recommended in HFrEF III: No Benefit C N/A
Drugs known to adversely affect the clinical status of patients with HFrEF are potentially
harmful and should be avoided or withdrawn
III: Harm B 546–557
Long-term use of an infusion of a positive inotropic drug is not recommended and may be
harmful except as palliation
III: Harm C N/A
Calcium channel blockers
Calcium channel–blocking drugs are not recommended as routine treatment in HFrEF III: No Benefit A 551,574,575
*In the absence of contraindications to anticoagulation.
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; COR, Class of Recommendation; DM, diabetes mellitus;
GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not available; NYHA, New York Heart Association; and PUFA, poly-
unsaturated fatty acids.
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Table 20. Strategies for Achieving Optimal GDMT
1. Uptitrate in small increments to the recommended target dose or the highest tolerated dose for those medications listed in Table 15 with an appreciation that
some patients cannot tolerate the full recommended doses of all medications, particularly patients with low baseline heart rate or blood pressure or with
a tendency to postural symptoms.
2. Certain patients (e.g., the elderly, patients with chronic kidney disease) may require more frequent visits and laboratory monitoring during dose titration and more
gradual dose changes. However, such vulnerable patients may accrue considerable benefits from GDMT. Inability to tolerate optimal doses of GDMT may change
after disease-modifying interventions such as CRT.
3. Monitor vital signs closely before and during uptitration, including postural changes in blood pressure or heart rate, particularly in patients with orthostatic
symptoms, bradycardia, and/or “low” systolic blood pressure (e.g., 80 to 100 mmHg).
4. Alternate adjustments of different medication classes (especially ACE inhibitors/ARBs and beta blockers) listed in Table 15. Patients with elevated or normal blood
pressure and heart rate may tolerate faster incremental increases in dosages.
5. Monitor renal function and electrolytes for rising creatinine and hyperkalemia, recognizing that an initial rise in creatinine may be expected and does not
necessarily require discontinuation of therapy; discuss tolerable levels of creatinine above baseline with a nephrologist if necessary.
6. Patients may complain of symptoms of fatigue and weakness with dosage increases; in the absence of instability in vital signs, reassure them that these
symptoms are often transient and usually resolve within a few days of these changes in therapy.
7. Discourage sudden spontaneous discontinuation of GDMT medications by the patient and/or other clinicians without discussion with managing clinicians.
8. Carefully review doses of other medications for HF symptom control (e.g., diuretics, nitrates) during uptitration.
9. Consider temporary adjustments in dosages of GDMT during acute episodes of noncardiac illnesses (e.g., respiratory infections, risk of dehydration, etc).
10. Educate patients, family members, and other clinicians about the expected benefits of achieving GDMT, including an understanding of the potential benefits of
myocardial reverse remodeling, increased survival, and improved functional status and HRQOL.
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical
therapy; HF, heart failure; and HRQOL, health-related quality of life.
Table 21. Recommendations for Treatment of HFpEF
Recommendations COR LOE
Systolic and diastolic blood pressure should be controlled according to
published clinical practice guidelines
I B (27,91)
Diuretics should be used for relief of symptoms due to volume overload. I C
Coronary revascularization for patients with CAD in whom angina or
demonstrable myocardial ischemia is present despite GDMT
IIa C
Management of AF according to published clinical practice guidelines
for HFpEF to improve symptomatic HF
IIa C
Use of beta-blocking agents, ACE inhibitors, and ARBs for hypertension in HFpEF IIa C
ARBs might be considered to decrease hospitalizations in HFpEF IIb B (589)
Nutritional supplementation is not recommended in HFpEF III: No Benefit C
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARBs, angiotensin-receptor blockers; CAD, coronary artery disease; COR,
Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction;
LOE, and Level of Evidence.
yCounseling should be speciﬁc to each individual patient and should include
documentation of a discussion about the potential for sudden death and nonsudden
death from HF or noncardiac conditions. Information should be provided about the
efﬁcacy, safety, and potential complications of an ICD and the potential for deﬁ-
brillation to be inactivated if desired in the future, notably when a patient is
approaching end of life. This will facilitate shared decision making between
patients, families, and the medical care team about ICDs (30).
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less, sinus rhythm, LBBB with a QRS duration of 120 to 149
ms, and NYHA class II, III, or ambulatory IV symptoms on
GDMT (78,116,594–596,599). (Level of Evidence: B)
3. CRT can be useful in patients with AF and LVEF of 35% or
less on GDMT if a) the patient requires ventricular pacing or
otherwise meets CRT criteria and b) atrioventricular nodal
ablation or pharmacological rate control will allow near
100% ventricular pacing with CRT (600–605). (Level of
Evidence: B)
4. CRT can be useful for patients on GDMT who have LVEF
of 35% or less and are undergoing placement of a new
or replacement device implantation with anticipated
requirement for signiﬁcant (>40%) ventricular pacing
(155,602,606,607). (Level of Evidence: C)CLASS IIb
1. The usefulness of implantation of an ICD is of uncertain
beneﬁt to prolong meaningful survival in patients with a high
risk of nonsudden death as predicted by frequent hospitali-
zations, advanced frailty, or comorbidities such as systemic
malignancy or severe renal dysfunctiony (608–611). (Level
of Evidence: B)
Table 22. Recommendations for Device Therapy for Management of Stage C HF
Recommendations COR LOE References
ICD therapy is recommended for primary prevention of SCD in selected patients with
HFrEF at least 40 d post-MI with LVEF 35% and NYHA class II or III symptoms on
chronic GDMT, who are expected to live >1 y*
I A 355,593
CRT is indicated for patients who have LVEF 35%, sinus rhythm, LBBB with
a QRS 150 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT
I A (NYHA class III/IV) 38,78,116,594
B (NYHA class II) 595,596
ICD therapy is recommended for primary prevention of SCD in selected patients with
HFrEF at least 40 d post-MI with LVEF 30% and NYHA class I symptoms while
receiving GDMT, who are expected to live >1 y*
I B 362,597,598
CRT can be useful for patients who have LVEF 35%, sinus rhythm, a non-LBBB
pattern with QRS 150 ms, and NYHA class III/ambulatory class IV symptoms
on GDMT
IIa A 78,116,594,596
CRT can be useful for patients who have LVEF 35%, sinus rhythm, LBBB with a QRS
120 to 149 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT
IIa B 78,116,594–596,599
CRT can be useful in patients with AF and LVEF 35% on GDMT if a) the patient
requires ventricular pacing or otherwise meets CRT criteria and b) AV nodal ablation
or rate control allows near 100% ventricular pacing with CRT
IIa B 600–605
CRT can be useful for patients on GDMT who have LVEF 35% and are undergoing new
or replacement device implantation with anticipated ventricular pacing (>40%)
IIa C 155,602,606,607
An ICD is of uncertain benefit to prolong meaningful survival in patients with a high risk
of nonsudden death such as frequent hospitalizations, frailty, or severe
comorbidities*
IIb B 608–611
CRT may be considered for patients who have LVEF 35%, sinus rhythm, a non-LBBB
pattern with a QRS duration of 120 to 149 ms, and NYHA class III/ambulatory class IV
on GDMT
IIb B 596,612
CRT may be considered for patients who have LVEF 35%, sinus rhythm, a non-LBBB
pattern with QRS 150 ms, and NYHA class II symptoms on GDMT
IIb B 595,596
CRT may be considered for patients who have LVEF 30%, ischemic etiology of HF,
sinus rhythm, LBBB with QRS 150 ms, and NYHA class I symptoms on GDMT
IIb C 595,596
CRT is not recommended for patients with NYHA class I or II symptoms and non-LBBB
pattern with QRS <150 ms
III: No Benefit B 595,596,612
CRT is not indicated for patients whose comorbidities and/or frailty limit survival to <1 y III: No Benefit C 38
*Counseling should be specific to each individual patient and should include documentation of a discussion about the potential for sudden death and nonsudden
death from HF or noncardiac conditions. Information should be provided about the efficacy, safety, and potential complications of an ICD and the potential for
defibrillation to be inactivated if desired in the future, notably when a patient is approaching end of life. This will facilitate shared decision making between patients,
families, and the medical care team about ICDs (30).
AF indicates atrial fibrillation; AV, atrioventricular; COR, Class of Recommendation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical
therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LBBB, left bundle-branch block; LOE, Level of
Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; and SCD, sudden cardiac death.
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or less, sinus rhythm, a non-LBBB pattern with QRS duration
of 120 to 149 ms, and NYHA class III/ambulatory class IV
on GDMT (596,612). (Level of Evidence: B)
3. CRT may be considered for patients who have LVEF of 35%
or less, sinus rhythm, a non-LBBB pattern with a QRS
duration of 150 ms or greater, and NYHA class II symptoms
on GDMT (595,596). (Level of Evidence: B)
4. CRT may be considered for patients who have LVEF of 30%
or less, ischemic etiology of HF, sinus rhythm, LBBB with
a QRS duration of 150 ms or greater, and NYHA class I
symptoms on GDMT (595,596). (Level of Evidence: C)
CLASS III: No Beneﬁt
1. CRT is not recommended for patients with NYHA class I or II
symptoms and non-LBBB pattern with QRS duration less
than 150 ms (595,596,612). (Level of Evidence: B)
2. CRT is not indicated for patients whose comorbidities and/
or frailty limit survival with good functional capacity to less
than 1 year (38). (Level of Evidence: C)See Figure 2, indications for CRT therapy algorithm.
7.3.4.1. IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
Patients with reduced LVEF are at increased risk for
ventricular tachyarrhythmias leading to SCD. Sudden death in
HFrEF has been substantially decreased by neurohormonal
antagonists that alter disease progression and also protect
against arrhythmias. Nonetheless, patients with systolic
dysfunction remain at increased risk for SCD due to
ventricular tachyarrhythmias. Patients who have had sustained
ventricular tachycardia, ventricular ﬁbrillation, unexplained
syncope, or cardiac arrest are at highest risk for recurrence.
Indications for ICD therapy as secondary prevention of SCD
in these patients are also discussed in the ACCF/AHA/HRS
device-based therapy guideline (4).
The use of ICDs for primary prevention of SCD in patients
with HFrEF without prior history of arrhythmias or syncope
has been evaluated in multiple RCTs. ICD therapy for primary
Figure 2. Indications for CRT therapy algorithm. CRT indicates cardiac resynchronization therapy; CRT-D, cardiac resynchronization
therapy-deﬁbrillator; GDMT, guideline-directed medical therapy; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; LBBB,
left bundle-branch block; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and NYHA, New York Heart Association.
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For patients with LVEF 30% after remote MI, use of ICD
therapy led to a 31% decrease in mortality over 20 months, for
an absolute decrease of 5.6% (362). For patients with mild to
moderate symptoms of HF with LVEF 35% due either to
ischemic or nonischemic etiology, there was a 23% decrease
in mortality over a 5-year period, for an absolute decrease of
7.2% (593). For both these trials, the survival beneﬁt appeared
after the ﬁrst year. Other smaller trials were consistent with
this degree of beneﬁt, except for patients within the ﬁrst 40
days after acute MI, in whom SCD was decreased but there
was an increase in other events such that there was no net
beneﬁt for survival (598,614). Both SCD and total mortality
are highest in patients with HFrEF with class IV symptoms, in
whom ICDs are not expected to prolong meaningful survival
and are not indicated except in those for whom heart trans-
plantation or MCS is anticipated.
The use of ICDs for primary prevention in patients with
HFrEF should be considered only in the setting of optimal
GDMT and with a minimum of 3 to 6 months of appropriate
medical therapy. A repeat assessment of ventricular function
is appropriate to assess any recovery of ventricular function
on GDMT that would be above the threshold where an ICD is
indicated. This therapy will often improve ventricularfunction to a range for which the risk of sudden death is too
low to warrant placement of an ICD. In addition, the trials of
ICDs for primary prevention of SCD studied patients who
were already on GDMT.
ICDs are highly effective in preventing death from
ventricular arrhythmias, but frequent shocks can decrease
HRQOL and lead to posttraumatic stress syndrome (615).
Therapy with antiarrhythmic drugs and catheter ablation for
ventricular tachycardia can decrease the number of ICD
shocks given and can sometimes improve ventricular function
in cases of very frequent ventricular tachyarrhythmias.
Reﬁned device programming can optimize pacing therapies
to avert the need for shocks, minimize inappropriate shocks,
and avoid aggravation of HF by frequent ventricular pacing.
Although there have been occasional recalls of device
generators, these are exceedingly rare in comparison to
complications related to intracardiac device leads, such as
fracture and infection.
ICDs are indicated only in patients with a reasonable
expectation of survival with good functional status beyond
a year, but the range of uncertainty remains wide. The
complex decision about the relative risks and beneﬁts of ICDs
for primary prevention of SCD must be individualized for
each patient. Unlike other therapies that can prolong life with
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tion with CRT. Patients with multiple comorbidities have
a higher rate of implant complications and higher competing
risks of death from noncardiac causes (616). Older patients,
who are at a higher risk of nonsudden death, are often
underrepresented in the pivotal trials where the average
patient is <65 years of age (617). The major trials for
secondary prevention of SCD showed no beneﬁt in patients
>75 years of age (618), and a meta-analysis of primary
prevention of SCD also suggested lesser effectiveness of
ICDs (619). Populations of patients with multiple HF hospi-
talizations, particularly in the setting of chronic kidney
disease, have a median survival rate of <2 years, during
which the beneﬁt of the ICD may not be realized (608). There
is widespread recognition of the need for further research to
identify patients most and least likely to beneﬁt from ICDs for
primary prevention of SCD in HF. Similar considerations
apply to the decision to replace the device generator.
Consideration of ICD implantation is highly appropriate for
shared decision making (30). The risks and beneﬁts carry
different relative values depending on patient goals and pref-
erences. Discussion should include the potential for SCD and
nonsudden death from HF or noncardiac conditions. Infor-
mation should be provided in a format that patients can
understand about the estimated efﬁcacy, safety, and potential
complications of an ICD and the ease with which deﬁbrillation
can be inactivated if no longer desired (620). As the preva-
lence of implantable devices increases, it is essential that
clearly deﬁned processes be in place to support patients and
families when decisions about deactivation arise (621).
7.3.4.2. CARDIAC RESYNCHRONIZATION THERAPY
In approximately one third of patients, HF progression is
accompanied by substantial prolongation of the QRS
interval, which is associated with worse outcome (622).
Multisite ventricular pacing (termed CRT or biventricular
pacing) can improve ventricular contractile function, di-
minish secondary mitral regurgitation, reverse ventricular
remodeling, and sustain improvement in LVEF. Increased
blood pressure with CRT can allow increased titration of
neurohormonal antagonist medications that may further
contribute to improvement. Beneﬁts were proven initially in
trials of patients with NYHA class III or ambulatory class IV
HF symptoms and QRS duration of 120 to 130 ms. These
results have included a decrease of approximately 30% in
rehospitalization and reductions in all-cause mortality in the
range of 24% to 36%. Improvement in survival is evident as
early as the ﬁrst 3 months of therapy. Functional improve-
ments have been demonstrated on average as a 1 to 2 mL/kg/
min increase in peak oxygen consumption, 50- to 70-meter
increase in 6-minute walk distance, and a reduction of 10
points or more in the 0- to 105-point scale of the Minnesota
Living With Heart Failure Questionnaire, all considered
clinically signiﬁcant. These results include patients with a
wide range of QRS duration and, in most cases, sinus rhythm
(78,116,594,623).Although it is still not possible to predict with conﬁdence
which patients will improve with CRT, further experiences
have provided some clariﬁcation. Beneﬁt appears conﬁned
largely to patients with a QRS duration of at least 150 ms and
LBBB pattern (624–628). The weight of the evidence has
been accumulated from patients with sinus rhythm, with meta-
analyses indicating substantially less clinical beneﬁt in
patients with permanent AF (604,605). Because effective
CRT requires a high rate of ventricular pacing (629), the
beneﬁt for patients with AF is most evident in patients who
have undergone atrioventricular nodal ablation, which ensures
obligate ventricular pacing (601–603).
In general, most data derive from patients with class III
symptoms. Patients labeled as having class IV symptoms
account for a small minority of patients enrolled. Furthermore,
these patients, characterized as “ambulatory” NYHA class IV,
are not refractory due to ﬂuid retention, frequently hospitalized
for HF, or dependent on continuous intravenous inotropic
therapy. CRT should not be considered as “rescue” therapy for
stage D HF. In addition, patients with signiﬁcant noncardiac
limitations are unlikely to derive major beneﬁt from CRT.
Since publication of the 2009 HF guideline (38), new
evidence supports extension of CRT to patients with milder
symptoms. LV remodeling was consistently reversed or hal-
ted, with beneﬁt also in reduction of HF hospitalizations
(595,596,599). In this population with low 1-year mortality,
reduction of HF hospitalization dominated the composite
primary endpoints, but a mortality beneﬁt was subsequently
observed in a 2-year extended follow-up study (630) and in
a meta-analysis of 5 trials of CRT in mild HF that included
4213 patients with class II symptoms (631). Overall beneﬁts
in class II HF were noted only in patients with QRS 150 ms
and LBBB, with an adverse impact with shorter QRS duration
or non-LBBB.
The entry criterion for LVEF in CRT trials has ranged
from 30% to 40%. The trials with class III–IV symptoms
included patients with LVEF 35% (78,116,594). The 2
individual trials showing improvement in mortality with class
II HF included patients with LVEF 30% (632,633). Trials
demonstrating signiﬁcant improvement in LV size and EF
have included patients with LVEF 35% (115) and
LVEF 40% (599), which also showed reduction in the
secondary endpoint of time to hospitalization and a reduction
in the composite of clinical HF events comparable to that of
all of the CRT trials (624). The congruence of evidence from
the totality of CRT trials with regard to remodeling and HF
events supports a common threshold of 35% for beneﬁt from
CRT in patients with class II, III, and IV HF symptoms. For
patients with class II HF, all but 1 of the trials tested CRT in
combination with an ICD, whereas there is evidence for
beneﬁt with both CRT-deﬁbrillator and CRT alone in patients
with class III–IV symptoms (78,116).
Although the weight of evidence is substantial for patients
with class II symptoms, these CRT trials have included only
372 patients with class I symptoms, most with concomitant
ICD for the postinfarction indication (595,599). Considering
Table 23. ESC Definition of Advanced HF
1. Severe symptoms of HF with dyspnea and/or fatigue at rest or with minimal
exertion (NYHA class III or IV)
2. Episodes of fluid retention (pulmonary and/or systemic congestion,
peripheral edema) and/or reduced cardiac output at rest (peripheral
hypoperfusion)
3. Objective evidence of severe cardiac dysfunction shown by at least 1 of the
following:
a. LVEF <30%
b. Pseudonormal or restrictive mitral inflow pattern
c. Mean PCWP >16 mmHg and/or RAP >12 mmHg by PA catheterization
d. High BNP or NT-proBNP plasma levels in the absence of noncardiac
causes
4. Severe impairment of functional capacity shown by 1 of the following:
a. Inability to exercise
b. 6-Minute walk distance 300 m
c. Peak _Vo2 <12 to 14 mL/kg/min
5. History of 1 HF hospitalization in past 6 mo
6. Presence of all the previous features despite “attempts to optimize” therapy,
including diuretics and GDMT, unless these are poorly tolerated or
contraindicated, and CRT when indicated
BNP indicates B-type natriuretic peptide; CRT, cardiac resynchronization
therapy; ESC, European Society of Cardiology; GDMT, guideline-directed
medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart
Association; PA, pulmonary artery; PWCP, pulmonary capillary wedge pressure;
and RAP, right atrial pressure.
Adapted from Metra et al. (32).
Table 24. Clinical Events and Findings Useful for Identifying
Patients With Advanced HF
Repeated (2) hospitalizations or ED visits for HF in the past year
Progressive deterioration in renal function (e.g., rise in BUN and creatinine)
Weight loss without other cause (e.g., cardiac cachexia)
Intolerance to ACE inhibitors due to hypotension and/or worsening renal
function
Intolerance to beta blockers due to worsening HF or hypotension
Frequent systolic blood pressure <90 mmHg
Persistent dyspnea with dressing or bathing requiring rest
Inability to walk 1 block on the level ground due to dyspnea or fatigue
Recent need to escalate diuretics to maintain volume status, often reaching
daily furosemide equivalent dose >160 mg/d and/or use of supplemental
metolazone therapy
Progressive decline in serum sodium, usually to <133 mEq/L
Frequent ICD shocks
ACE indicates angiotensin-converting enzyme; BUN, blood urea nitrogen; ED,
emergency department; HF, heart failure; and ICD, implantable cardioverter-
defibrillator.
Adapted from Russell et al. (642).
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early adverse events, which in 1 trial occurred in 13% of
patients with CRT-ICD compared with 6.7% in patients
with ICD only (596). On the basis of limited data from
MADIT-CRT (Multicenter Automatic Deﬁbrillator Implanta-
tion Trial-Cardiac Resynchronization Therapy), CRT-ICD
may be considered for patients with class I symptoms >40
days after MI, LVEF 30%, sinus rhythm, LBBB, and
QRS 150 ms (595).
These indications for CRT all include expectation for
ongoing GDMT and diuretic therapy as needed for ﬂuid
retention. In addition, regular monitoring is required after
device implantation because adjustment of HF therapies and
reprogramming of device intervals may be required. The trials
establishing the beneﬁt of these interventions were conducted
in centers offering expertise in both implantation and follow-
up. Recommendations for CRT are made with the expectation
that they will be performed in centers with expertise and
outcome comparable to that of the trials that provide the bases of
evidence. The beneﬁt–risk ratio for this intervention would be
anticipated to be diminished for patients who do not have
access to these specialized care settings orwho are nonadherent.
See Online Data Supplements 28 and 29 for additional
data on device therapy and CRT.
7.4. Stage D
7.4.1. Deﬁnition of Advanced HF
A subset of patients with chronic HF will continue to progress
and develop persistently severe symptoms despite maximum
GDMT. Various terminologies have been used to describe
this group of patients who are classiﬁed with ACCF/AHA
stage D HF, including “advanced HF,” “end-stage HF,” and
“refractory HF.” In the 2009 ACCF/AHA HF guideline, stage
D was deﬁned as “patients with truly refractory HF who might
be eligible for specialized, advanced treatment strategies, such
as MCS, procedures to facilitate ﬂuid removal, continuous
inotropic infusions, or cardiac transplantation or other inno-
vative or experimental surgical procedures, or for end-of-life
care, such as hospice” (38). The European Society of Cardi-
ology has developed a deﬁnition of advanced HF with
objective criteria that can be useful (32) (Table 23). There are
clinical clues that may assist clinicians in identifying patients
who are progressing toward advanced HF (Table 24). The
Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) has developed 7 proﬁles that further
stratify patients with advanced HF (Table 25) (635).
7.4.2. Important Considerations in Determining If the
Patient Is Refractory
Patients considered to have stage D HF should be thoroughly
evaluated to ascertain that the diagnosis is correct and that
there are no remediable etiologies or alternative explanations
for advanced symptoms. For example, it is important to
determine that HF and not a concomitant pulmonary disorder
is the basis of dyspnea. Similarly, in those with presumed
cardiac cachexia, other causes of weight loss should be ruledout. Likewise, other reversible factors such as thyroid disor-
ders should be treated. Severely symptomatic patients pre-
senting with a new diagnosis of HF can often improve
substantially if they are initially stabilized. Patients should
also be evaluated for nonadherence to medications (636–639),
sodium restriction (640), and/or daily weight monitoring
(641). Finally, a careful review of prior medical management
Table 25. INTERMACS Profiles
Profile* Profile Description Features
1 Critical cardiogenic shock
(“Crash and burn”)
Life-threatening hypotension and rapidly escalating inotropic/pressor support, with critical organ hypoperfusion often
confirmed by worsening acidosis and lactate levels.
2 Progressive decline
(“Sliding fast” on
inotropes)
“Dependent” on inotropic support but nonetheless shows signs of continuing deterioration in nutrition, renal function, fluid
retention, or other major status indicator. Can also apply to a patient with refractory volume overload, perhaps with
evidence of impaired perfusion, in whom inotropic infusions cannot be maintained due to tachyarrhythmias, clinical
ischemia, or other intolerance.
3 Stable but inotrope
dependent
Clinically stable on mild-moderate doses of intravenous inotropes (or has a temporary circulatory support device) after
repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms, or progressive
organ dysfunction (usually renal).
4 Resting symptoms on
oral therapy at home
Patient who is at home on oral therapy but frequently has symptoms of congestion at rest or with activities of daily living
(dressing or bathing). He or she may have orthopnea, shortness of breath during dressing or bathing, gastrointestinal
symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites, or severe lower-extremity edema.
5 Exertion intolerant
(“housebound”)
Patient who is comfortable at rest but unable to engage in any activity, living predominantly within the house or
housebound.
6 Exertion limited
(“walking wounded”)
Patient who is comfortable at rest without evidence of fluid overload but who is able to do some mild activity. Activities of
daily living are comfortable and minor activities outside the home such as visiting friends or going to a restaurant can
be performed, but fatigue results within a few minutes or with any meaningful physical exertion.
7 Advanced NYHA class III Patient who is clinically stable with a reasonable level of comfortable activity, despite a history of previous
decompensation that is not recent. This patient is usually able to walk more than a block. Any decompensation
requiring intravenous diuretics or hospitalization within the previous month should make this person a Patient Profile 6
or lower.
*Modifier options: Profiles 3–6 can be modified with the designation frequent flyer for patients with recurrent decompensations leading to frequent (generally at least
2 in last 3 mo or 3 in last 6 mo) emergency department visits or hospitalizations for intravenous diuretics, ultrafiltration, or brief inotropic therapy. Profile 3 can be
modified in this fashion if the patient is usually at home. If a Profile 7 patient meets the definition of frequent flyer, the patient should be moved to Profile 6 or worse.
Other modifier options include arrhythmia, which should be used in the presence of recurrent ventricular tachyarrhythmias contributing to the overall clinical course
(e.g., frequent implantable cardioverter-defibrillator shocks or requirement of external defibrillation, usually more than twice weekly); or temporary circulatory support
for hospitalized patients profiles 1–3 (635).
INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support; and NYHA, New York Heart Association.
Adapted from Stevenson et al. (643).
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pies likely to improve clinical status have been considered.
See Online Data Supplements 30 and 31 for additional
data on therapiesdimportant considerations and sildenaﬁl.
7.4.3. Water Restriction: Recommendation
CLASS IIa
1. Fluid restriction (1.5 to 2 L/d) is reasonable in stage D,
especially in patients with hyponatremia, to reduce conges-
tive symptoms. (Level of Evidence: C)
Recommendations for ﬂuid restriction in HF are largely
driven by clinical experience. Sodium and ﬂuid balance
recommendations are best implemented in the context of
weight and symptom monitoring programs. Routine strict
ﬂuid restriction in all patients with HF regardless of symptoms
or other considerations does not appear to result in signiﬁcant
beneﬁt (644). Limiting ﬂuid intake to around 2 L/d is usually
adequate for most hospitalized patients who are not diuretic
resistant or signiﬁcantly hyponatremic. In 1 study, patients on
a similar sodium and diuretic regimen showed higher read-
mission rates with higher ﬂuid intake, suggesting that ﬂuid
intake affects HF outcomes (385). Strict ﬂuid restriction may
best be used in patients who are either refractory to diuretics
or have hyponatremia. Fluid restriction, especially in con-
junction with sodium restriction, enhances volume manage-
ment with diuretics. Fluid restriction is important to managehyponatremia, which is relatively common with advanced HF
and portends a poor prognosis (645,646). Fluid restriction may
improve serum sodium concentration; however, it is difﬁcult to
achieve and maintain. In hot or low-humidity climates,
excessive ﬂuid restriction predisposes patients with advanced
HF to the risk of heat stroke. Hyponatremia in HF is primarily
due to an inability to excrete free water. Norepinephrine and
angiotensin II activation result in decreased sodium delivery to
the distal tubule, whereas arginine vasopressin increases water
absorption from the distal tubule. In addition, angiotensin II
also promotes thirst. Thus, sodium and ﬂuid restriction in
advanced patients with HF is important.
7.4.4. Inotropic Support: Recommendations
CLASS I
1. Until deﬁnitive therapy (e.g., coronary revascularization,
MCS, heart transplantation) or resolution of the acute
precipitating problem, patients with cardiogenic shock
should receive temporary intravenous inotropic support to
maintain systemic perfusion and preserve end-organ perfor-
mance. (Level of Evidence: C)
CLASS IIa
1. Continuous intravenous inotropic support is reasonable as
“bridge therapy” in patients with stage D HF refractory to
GDMT and device therapy who are eligible for and awaiting
MCS or cardiac transplantation (647,648). (Level of
Evidence: B)
Table 26. Intravenous Inotropic Agents Used in Management of HF
Inotropic Agent
Dose (mcg/kg)
Drug Kinetics
and Metabolism
Effects
Adverse
Effects
Special
ConsiderationsBolus Infusion (/min) CO HR SVR PVR
Adrenergic agonists
Dopamine N/A 5 to 10 t1/2: 2 to 20 min [ [ 4 4 T, HA, N, tissue
necrosis
Caution: MAO-I
N/A 10 to 15 R,H,P [ [ [ 4
Dobutamine N/A 2.5 to 5 t1/2: 2 to 3 min
H
[ [ Y 4 [/YBP, HA, T, N,
F, hypersensitivity
Caution: MAO-I;
CI: sulfite allergyN/A 5 to 20 [ [ 4 4
PDE inhibitor
Milrinone N/R 0.125 to 0.75 t1/2: 2.5 h H [ [ Y Y T, YBP Renal dosing,
monitor LFTs
BP indicates blood pressure; CI, contraindication; CO, cardiac output; F, fever; H, hepatic; HA, headache; HF, heart failure; HR, heart rate; LFT, liver function test;
MAO-I, monoamine oxidase inhibitor; N, nausea; N/A, not applicable; N/R, not recommended; P, plasma; PDE, phosphodiesterase; PVR, pulmonary vascular resistance;
R, renal; SVR, systemic vascular resistance; and T, tachyarrhythmias; t1/2, elimination half-life.
zAlthough optimal patient selection for MCS remains an active area of investiga-
tion, general indications for referral for MCS therapy include patients with
LVEF <25% and NYHA class III–IV functional status despite GDMT, including,
when indicated, CRT, with either high predicted 1- to 2-year mortality (e.g., as
suggested by markedly reduced peak oxygen consumption and clinical prognostic
scores) or dependence on continuous parenteral inotropic support. Patient selection
requires a multidisciplinary team of experienced advanced HF and transplantation
cardiologists, cardiothoracic surgeons, nurses, and ideally, social workers and
palliative care clinicians.
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1. Short-term, continuous intravenous inotropic support may
be reasonable in those hospitalized patients presenting with
documented severe systolic dysfunction who present with
low blood pressure and signiﬁcantly depressed cardiac
output to maintain systemic perfusion and preserve end-
organ performance (592,649,650). (Level of Evidence: B)
2. Long-term, continuous intravenous inotropic support may be
considered as palliative therapy for symptom control in
select patients with stage D HF despite optimal GDMT and
device therapy who are not eligible for either MCS or cardiac
transplantation (651–653). (Level of Evidence: B)
CLASS III: Harm
1. Long-term use of either continuous or intermittent, intrave-
nous parenteral positive inotropic agents, in the absence of
speciﬁc indications or for reasons other than palliative care,
is potentially harmful in the patient with HF (416,654–659).
(Level of Evidence: B)
2. Use of parenteral inotropic agents in hospitalized patients
without documented severe systolic dysfunction, low blood
pressure, or impaired perfusion and evidence of signiﬁcantly
depressed cardiac output, with or without congestion, is
potentially harmful (592,649,650). (Level of Evidence: B)
Despite improving hemodynamic compromise, positive
inotropic agents have not demonstrated improved outcomes in
patients with HF in either the hospital or outpatient setting
(416,654–658). Regardless of their mechanism of action (e.g.,
inhibition of phosphodiesterase, stimulation of adrenergic or
dopaminergic receptors, calcium sensitization), chronic oral
inotrope treatment increased mortality, mostly related to
arrhythmic events. Parenteral inotropes, however, remain as
an option to help the subset of patients with HF who are
refractory to other therapies and are suffering consequences
from end-organ hypoperfusion. Inotropes should be consid-
ered only in such patients with systolic dysfunction who have
low cardiac index and evidence of systemic hypoperfusion
and/or congestion (Table 26). To minimize adverse effects,
lower doses are preferred. Similarly, the ongoing need for
inotropic support and the possibility of discontinuation should
be regularly assessed.See Online Data Supplements 32 and 33 for additional
data on inotropes.
7.4.5. Mechanical Circulatory Support:
Recommendations
CLASS IIa
1. MCS is beneﬁcial in carefully selectedz patients with stage
D HFrEF in whom deﬁnitive management (e.g., cardiac
transplantation) or cardiac recovery is anticipated or plan-
ned (660–667). (Level of Evidence: B)
2. Nondurable MCS, including the use of percutaneous and
extracorporeal ventricular assist devices (VADs), is
reasonable as a “bridge to recovery” or “bridge to decision”
for carefully selectedz patients with HFrEF with acute,
profound hemodynamic compromise (668–671). (Level of
Evidence: B)
3. Durable MCS is reasonable to prolong survival for carefully
selectedz patients with stage D HFrEF (672–675). (Level of
Evidence: B)
MCS has emerged as a viable therapeutic option for
patients with advanced stage D HFrEF refractory to optimal
GDMT and cardiac device intervention. Since its initial use 50
years ago for postcardiotomy shock (676), the implantable
VAD continues to evolve.
Designed to assist the native heart, VADs are differentiated
by the implant location (intracorporeal versus extracorporeal),
approach (percutaneous versus surgical), ﬂow characteristic
(pulsatile versus continuous), pump mechanism (volume
displacement, axial, centrifugal), and the ventricle(s) sup-
ported (left, right, biventricular). VADs are effective in both
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pensated, hemodynamically unstable HFrEF that is refractory
to inotropic support, and the long-term (months to years)
management of stage D chronic HFrEF. Nondurable or
temporary, MCS provides an opportunity for decisions about
the appropriateness of transition to deﬁnitive management
such as cardiac surgery or durable, that is, permanent, MCS
or, in the case of improvement and recovery, suitability for
device removal. Nondurable MCS thereby may be helpful as
either a bridge to decision or a bridge to recovery.
More common scenarios for MCS, however, are long-term
strategies, including 1) bridge to transplantation, 2) bridge to
candidacy, and 3) destination therapy. Bridge to transplant
and destination therapy have the strongest evidence base with
respect to survival, functional capacity, and HRQOL beneﬁts.
Data from INTERMACS provides valuable information on
risk factors and outcomes for patients undergoing MCS. The
greatest risk factors for death among patients undergoing
bridge to transplant include acuity and severity of clinical
condition and evidence of right ventricular failure (677). MCS
may also be used as a bridge to candidacy. Retrospective
studies have shown reduction in pulmonary pressures with
MCS therapy in patients with HF considered to have “ﬁxed”
pulmonary hypertension (661–663). Thus, patients who may
be transplant-ineligible due to irreversible severe pulmonaryTable 27. Recommendations for Inotropic Support, MCS, and
Recommendations
Inotropic support
Cardiogenic shock pending definitive therapy or resolution
BTT or MCS in stage D refractory to GDMT
Short-term support for threatened end-organ dysfunction in hospitalized p
stage D and severe HFrEF
Long-term support with continuous infusion palliative therapy in select s
Routine intravenous use, either continuous or intermittent, is potentially
stage D HF
Short-term intravenous use in hospitalized patients without evidence of
threatened end-organ performance is potentially harmful
MCS
MCS is beneficial in carefully selected* patients with stage D HF in whom
management (e.g., cardiac transplantation) is anticipated or planned
Nondurable MCS is reasonable as a “bridge to recovery” or “bridge to d
carefully selected* patients with HF and acute profound disease
Durable MCS is reasonable to prolong survival for carefully selected* pa
stage D HFrEF
Cardiac transplantation
Evaluation for cardiac transplantation is indicated for carefully selected p
stage D HF despite GDMT, device, and surgical management
*Although optimal patient selection for MCS remains an active area of in
patients with LVEF<25% and NYHA class III–IV functional status despite GDM
year mortality (e.g., as suggested by markedly reduced peak oxygen consu
parenteral inotropic support. Patient selection requires a multidisciplinary t
cardiothoracic surgeons, nurses, and ideally, social workers and palliative
BTT indicates bridge to transplant; COR, Class of Recommendation; CRT,
therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction
mechanical circulatory support; N/A, not applicable; and NYHA, New York Hhypertension may become eligible with MCS support over
time. Other bridge-to-candidacy indications may include
obesity and tobacco use in patients who are otherwise candi-
dates for cardiac transplantation. There is ongoing interest in
understanding how MCS facilitates LV reverse remodeling.
Current scientiﬁc and translational research in the area aims to
identify clinical, cellular, molecular, and genomic markers of
cardiac recovery in the patient with VAD (678,679).
See Online Data Supplements 34 and 35 for additional
data on MCS and left VADs.
7.4.6. Cardiac Transplantation: Recommendation
CLASS I
1. Evaluation for cardiac transplantation is indicated for
carefully selected patients with stage D HF despite
GDMT, device, and surgical management (680). (Level of
Evidence: C)
Cardiac transplantation is considered the gold standard for
the treatment of refractory end-stage HF. Since the ﬁrst
successful cardiac transplantation in 1967, advances in
immunosuppressive therapy have vastly improved the long-
term survival of transplant recipients with a 1-, 3-, and
5-year posttransplant survival rate of 87.8%, 78.5%, and
71.7% in adults, respectively (681). Similarly, cardiac trans-
plantation has been shown to improve functional status andCardiac Transplantation
COR LOE References
I C N/A
IIa B 647,648
atients with IIb B 592,649,650
tage D HF IIb B 651–653
harmful in III: Harm B 416,654–659
shock or III: Harm B 592,649,650
definitive IIa B 660–667
ecision” for IIa B 668–671
tients with IIa B 672–675
atients with I C 680
vestigation, general indications for referral for MCS therapy include
T, including, when indicated, CRT, with either high predicted 1- to 2-
mption and clinical prognostic scores) or dependence on continuous
eam of experienced advanced HF and transplantation cardiologists,
care clinicians.
cardiac resynchronization therapy; GDMT, guideline-directed medical
; LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MCS,
eart Association.
Figure 3. Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
AF, atrial ﬁbrillation; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; DM, diabetes
mellitus; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; HRQOL, health-related quality of life; HTN, hypertension; ICD, implantable
cardioverter-deﬁbrillator; LV, left ventricular; LVH, left ventricular hypertrophy; MCS, mechanical circulatory support; and MI, myocardial
infarction. Adapted from Hunt et al. (38).
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those patients who are at highest risk of death from advanced
HF (689). Cardiopulmonary exercise testing helps reﬁne
candidate selection (690–696). Data suggest acceptable
posttransplant outcomes in patients with reversible pulmonary
hypertension (697), hypertrophic cardiomyopathy (698),
peripartum cardiomyopathy (699), restrictive cardiomyopathy
(700,701), and muscular dystrophy (702). Selected patients
with stage D HF and poor prognosis should be referred to
a cardiac transplantation center for evaluation and transplant
consideration. Determination of HF prognosis is addressed in
Sections 6.1.2 and 7.4.2. The listing criteria and evaluation
and management of patients undergoing cardiac trans-
plantation are described in detail by the International Society
for Heart and Lung Transplantation (680).
See Table 27 for a summary of recommendations from this
section, Figure 3 for the stages of HF development; and
Online Data Supplement 36 for additional data on
transplantation.8. The Hospitalized Patient
8.1. Classiﬁcation of Acute Decompensated HF
Hospitalization for HF is a growing and major public health
issue (703). Presently, HF is the leading cause of hospitali-
zation among patients >65 years of age (51); the largest
percentage of expenditures related to HF are directly attrib-
utable to hospital costs. Moreover, in addition to costs,
hospitalization for acutely decompensated HF represents
a sentinel prognostic event in the course of many patients with
HF, with a high risk for recurrent hospitalization (e.g., 50% at
6 months) and a 1-year mortality rate of approximately 30%
(211,704). The AHA has published a scientiﬁc statement
about this condition (705).
There is nowidely accepted nomenclature for HF syndromes
requiring hospitalization. Patients are described as having
“acute HF,” “acute HF syndromes,” or “acute(ly) decom-
pensated HF”; while the third has gained greatest acceptance,
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distinction between those with a de novo presentation of HF
from those with worsening of previously chronic stable HF.
Data from HF registries have clariﬁed the proﬁle of
patients with HF requiring hospitalization (107,704,706,707).
Characteristically, such patients are elderly or near elderly,
equally male or female, and typically have a history of
hypertension, as well as other medical comorbidities,
including chronic kidney disease, hyponatremia, hematologic
abnormalities, and chronic obstructive pulmonary disease
(107,706,708–713). A relatively equal percentage of patients
with acutely decompensated HF have impaired versus
preserved LV systolic function (707,714,715); clinically,
patients with preserved systolic function are older, more
likely to be female, to have signiﬁcant hypertension, and to
have less CAD. The overall morbidity and mortality for both
groups is high.
Hospitalized patients with HF can be classiﬁed into
important subgroups. These include patients with acute
coronary ischemia, accelerated hypertension and acutely
decompensated HF, shock, and acutely worsening right HF.
Patients who develop HF decompensation after surgical
procedures also bear mention. Each of these various cate-
gories of HF has speciﬁc etiologic factors leading to decom-
pensation, presentation, management, and outcomes.
Noninvasive modalities can be used to classify the patient
with hospitalized HF. The history and physical examination
allows estimation of a patient’s hemodynamic status, that is,
the degree of congestion (“dry” versus “wet”), as well as the
adequacy of their peripheral perfusion (“warm” versus “cold”)
(716) (Figure 4). Chest x-ray is variably sensitive for the
presence of interstitial or alveolar edema, even in the presence
of elevated ﬁlling pressures. Thus, a normal chest x-ray does
not exclude acutely decompensated HF (717). The utility
of natriuretic peptides in patients with acutely decom-
pensated HF has been described in detail in Section 6.3.1.
Both BNP and NT-proBNP are useful for the identiﬁcation
or exclusion of acutely decompensated HF in dyspneicNo
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Figure 4. Classiﬁcation of patients presenting with acutely
decompensated heart failure. Adapted with permission from
Nohria et al. (716).patients (247,249,250,718,719), particularly in the context of
uncertain diagnosis (720–722). Other options for diagnostic
evaluation of patients with suspected acutely decompensated
HF, such as acoustic cardiography (723), bioimpedance
vector monitoring (724), or noninvasive cardiac output
monitoring (725) are not yet validated.8.2. Precipitating Causes of
Decompensated HF: Recommendations
CLASS I
1. ACS precipitating acute HF decompensation should be
promptly identiﬁed by ECG and serum biomarkers, including
cardiac troponin testing, and treated optimally as appro-
priate to the overall condition and prognosis of the patient.
(Level of Evidence: C)
2. Common precipitating factors for acute HF should be
considered during initial evaluation, as recognition of these
conditions is critical to guide appropriate therapy. (Level of
Evidence: C)
ACS is an important cause of worsening or new-onset HF
(726). Although acute ST-segment elevation myocardial
infarction can be readily apparent on an ECG, other ACS cases
may be more challenging to diagnose. Complicating the clini-
cal scenario is that many patients with acute HF, with or without
CAD, have serum troponin levels that are elevated (727).
However, many other patients may have low levels of
detectable troponins not meeting criteria for an acute ischemic
event (278,728). Registry data have suggested that the use of
coronary angiography is low for patients hospitalized with
decompensated HF, and opportunities to diagnose important
CAD may be missed (729). For the patient with newly
discovered HF, clinicians should always consider the possi-
bility that CAD is an underlying cause of HF (726).
Besides ACS, several other precipitating causes of acute
HF decompensation must be carefully assessed to inform
appropriate treatment, optimize outcomes, and prevent future
acute events in patients with HF (730). See list below.
Common Factors That Precipitate Acute
Decompensated HF
 Nonadherence with medication regimen, sodium and/or
ﬂuid restriction
 Acute myocardial ischemia
 Uncorrected high blood pressure
 AF and other arrhythmias
 Recent addition of negative inotropic drugs (e.g.,
verapamil, nifedipine, diltiazem, beta blockers)
 Pulmonary embolus
 Initiation of drugs that increase salt retention (e.g.,
steroids, thiazolidinediones, NSAIDs)
 Excessive alcohol or illicit drug use
 Endocrine abnormalities (e.g., diabetes mellitus,
hyperthyroidism, hypothyroidism)
 Concurrent infections (e.g., pneumonia, viral illnesses)
 Additional acute cardiovascular disorders (e.g., valve
disease endocarditis, myopericarditis, aortic dissection)
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ticularly among blacks, women, and those with HFpEF (731).
In the ADHERE registry, almost 50% of patients admitted
with HF had blood pressure >140/90 mmHg (107). Abrupt
discontinuation of antihypertensive therapy may precipitate
worsening HF. The prevalence of AF in patients with acute HF
is >30% (731). Infection increases metabolic demands in
general. Pulmonary infections, which are common in patients
with HF, may add hypoxia to the increased metabolic demands
and are associated with worse outcomes (730). The sepsis
syndrome is associated with reversible myocardial depression
that is likely mediated by cytokine release (732). Patients with
HF are hypercoagulable, and the possibility of pulmonary
embolus as an etiology of acute decompensation should be
considered. Deterioration of renal function can be both
a consequence and contributor to decompensated HF. Resto-
ration of normal thyroid function in those with hypothyroidism
or hyperthyroidism may reverse abnormal cardiovascular
function (733). In patients treated with amiodarone, thyroid
disturbances should be suspected.
Excessive sodium and ﬂuid intake may precipitate acute
HF (379,384). Medication nonadherence for ﬁnancial or other
reasons is a major cause of hospital admission (734). Several
drugs may precipitate acute HF (e.g., calcium channel
blockers, antiarrhythmic agents, glucocorticoids, NSAIDs and
cyclooxygenase-2 inhibitors, thiazolidinediones, and over-
the-counter agents like pseudoephedrine). Finally, excessive
alcohol intake and use of illicit drugs, such as cocaine and
methamphetamine, also need to be investigated as potential
causes of HF decompensation.
See Online Data Supplement 37 for additional data on
comorbidities in the hospitalized patient.8.3. Maintenance of GDMT During
Hospitalization: Recommendations
CLASS I
1. In patients with HFrEF experiencing a symptomatic exac-
erbation of HF requiring hospitalization during chronic
maintenance treatment with GDMT, it is recommended
that GDMT be continued in the absence of hemodynamic
instability or contraindications (195,735,736). (Level of
Evidence: B)
2. Initiation of beta-blocker therapy is recommended after
optimization of volume status and successful discontinua-
tion of intravenous diuretics, vasodilators, and inotropic
agents. Beta-blocker therapy should be initiated at a low
dose and only in stable patients. Caution should be used
when initiating beta blockers in patients who have required
inotropes during their hospital course (195,735,736). (Level
of Evidence: B)
The patient’s maintenance HF medications should be
carefully reviewed on admission, and it should be decided
whether adjustments should be made as a result of the
hospitalization. In the majority of patients with HFrEF who
are admitted to the hospital, oral HF therapy should be
continued, or even uptitrated, during hospitalization. It hasbeen demonstrated that continuation of ACE inhibitors or
ARBs and beta blockers for most patients is well tolerated and
results in better outcomes (195,735,736). Withholding of, or
reduction in, beta-blocker therapy should be considered only
in patients hospitalized after recent initiation or increase in
beta-blocker therapy or with marked volume overload or
marginal/low cardiac output. Patients admitted with signiﬁcant
worsening of renal function should be considered for a reduc-
tion in, or temporary discontinuation of ACE inhibitors, ARBs,
and/or aldosterone antagonists until renal function improves.
Although it is important to ensure that evidence-based medi-
cations are instituted before hospital discharge, it is equally
critical to reassess medications on admission and adjust their
administration in light of the worsening HF.
8.4. Diuretics in Hospitalized Patients:
Recommendations
CLASS I
1. Patients with HF admitted with evidence of signiﬁcant
ﬂuid overload should be promptly treated with intravenous
loop diuretics to reduce morbidity (737,738). (Level of
Evidence: B)
2. If patients are already receiving loop diuretic therapy, the
initial intravenous dose should equal or exceed their chronic
oral daily dose and should be given as either intermittent
boluses or continuous infusion. Urine output and signs and
symptoms of congestion should be serially assessed, and
the diuretic dose should be adjusted accordingly to relieve
symptoms, reduce volume excess, and avoid hypotension
(739). (Level of Evidence: B)
3. The effect of HF treatment should be monitored with careful
measurement of ﬂuid intake and output, vital signs, body
weight that is determined at the same time each day,
and clinical signs and symptoms of systemic perfusion and
congestion. Daily serum electrolytes, urea nitrogen, and
creatinine concentrations should be measured during the
use of intravenous diuretics or active titration of HF medi-
cations. (Level of Evidence: C)
CLASS IIa
1. When diuresis is inadequate to relieve symptoms, it is
reasonable to intensify the diuretic regimen using either:a. higher doses of intravenous loop diuretics (38,739)
(Level of Evidence: B); or
b. addition of a second (e.g., thiazide) diuretic (740–743).
(Level of Evidence: B).CLASS IIb
1. Low-dose dopamine infusion may be considered in addition
to loop diuretic therapy to improve diuresis and better
preserve renal function and renal blood ﬂow (744,745).
(Level of Evidence: B)
Patients with signiﬁcant ﬂuid overload should be initially
treated with loop diuretics given intravenously during hospi-
talization. Therapy should begin in the emergency department
without delay, as early therapy has been associated with better
outcomes (37,738). Patients should be carefully monitored,
including serial evaluation of volume status and systemic
perfusion. Monitoring of daily weight, supine and standing
vital signs, and ﬂuid input and output is necessary for daily
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function should be performed while intravenous diuretics are
administered or HF medications are actively titrated. Intra-
venous loop diuretics have the potential to reduce glomerular
ﬁltration rate, further worsen neurohumoral activation, and
produce electrolyte disturbances. Thus, although the use of
diuretics may relieve symptoms, their impact on mortality has
not been well studied. Diuretics should be administered at
doses sufﬁcient to achieve optimal volume status and relieve
congestion without inducing an excessively rapid reduction in
intravascular volume, which could result in hypotension, renal
dysfunction, or both. Because loop diuretics have a relatively
short half-life, sodium reabsorption in the tubules will occur
once the tubular concentration of the diuretics declines.
Therefore, limiting sodium intake and dosing the diuretic
continuously or multiple times per day will enhance diuretic
effectiveness (434,737,746–748).
Some patients may present with moderate to severe renal
dysfunction such that the diuretic response may be blunted,
necessitating higher initial diuretic doses. In many cases,
reduction of ﬂuid overload may improve congestion and
improve renal function, particularly if signiﬁcant venous
congestion is reduced (749). Clinical experience suggests it is
difﬁcult to determine whether congestion has been adequately
treated in many patients, and registry data have conﬁrmed that
patients are frequently discharged after a net weight loss of only
a few pounds. Although patients may rapidly improve symp-
tomatically, they may remain congested or hemodynamically
compromised. Routine use of serial natriuretic peptide
measurement or Swan-Ganz catheter has not been conclusively
shown to improve outcomes among these patients. Neverthe-
less, careful evaluation of all physical ﬁndings, laboratory
parameters, weight change, and net ﬂuid change should be
considered before discharge.
When a patient does not respond to initial intravenous
diuretics, several options may be considered. Efforts should
be made to make certain that congestion persists and that
another hemodynamic proﬁle or alternate disease process is
not evident. If there is doubt about the ﬂuid status, consid-
eration should be given for assessment of ﬁlling pressures and
cardiac output using right-heart catheterization. If volume
overload is conﬁrmed, the dose of the loop diuretic should be
increased to ensure that adequate drug levels reach the kidney.
Adding a second diuretic, typically a thiazide, can improve
diuretic responsiveness (435,442,443). Theoretically, contin-
uous diuretic infusion may enhance diuresis because contin-
uous diuretic delivery to the nephron avoids rebound sodium
and ﬂuid reabsorption (440,441,750,751). However, the
DOSE (Diuretic Optimization Strategies Evaluation) trial did
not ﬁnd any signiﬁcant difference between continuous infu-
sion versus intermittent bolus strategies for symptoms,
diuresis, or outcomes (739). It is reasonable to try an alternate
approach of using either bolus or continuous infusion therapy
different from the initial strategy among patients who are
resistant to diuresis. Finally, some data suggest that low-dose
dopamine infusion in addition to loop diuretics may improvediuresis and better preserve renal function, although ongoing
trials will provide further data on this effect (744).
See Online Data Supplement 17 for additional data on
diuretics.
8.5. Renal Replacement Therapyd
Ultraﬁltration: Recommendations
CLASS IIb
1. Ultraﬁltration may be considered for patients with obvious
volume overload to alleviate congestive symptoms and ﬂuid
weight (752). (Level of Evidence: B)
2. Ultraﬁltration may be considered for patients with refractory
congestion not responding to medical therapy. (Level of
Evidence: C)
If all diuretic strategies are unsuccessful, ultraﬁltration may
be considered. Ultraﬁltration moves water and small- to
medium-weight solutes across a semipermeable membrane to
reduce volume overload. Because the electrolyte concentra-
tion is similar to plasma, relatively more sodium can be
removed than by diuretics (753–755). Initial studies sup-
porting use of ultraﬁltration in HF were small but provided
safety and efﬁcacy data in acute HF (755–757). Use of
ultraﬁltration in HF has been shown to reduce neurohormone
levels and increase diuretic responsiveness. In a larger trial of
200 unselected patients with acute HF, ultraﬁltration did
reduce weight compared with bolus or continuous diuretics at
48 hours, had similar effects on the dyspnea score compared
with diuretics, and improved readmission rate at 90 days
(752). A randomized acute HF trial in patients with car-
diorenal syndrome and persistent congestion has failed to
demonstrate a signiﬁcant advantage of ultraﬁltration over
bolus diuretic therapy (758,759). Cost, the need for veno-
venous access, provider experience, and nursing support
remain concerns about the routine use of ultraﬁltration.
Consultation with a nephrologist is appropriate before initi-
ating ultraﬁltration, especially in circumstances where the
non-nephrology provider does not have sufﬁcient experience
with ultraﬁltration.
See Online Data Supplements 17 and 38 for additional
data on diuretics versus ultraﬁltration in acute decom-
pensated HF and worsening renal function and mortality.
8.6. Parenteral Therapy in Hospitalized HF:
Recommendation
CLASS IIb
1. If symptomatic hypotension is absent, intravenous nitro-
glycerin, nitroprusside, or nesiritide may be considered an
adjuvant to diuretic therapy for relief of dyspnea in patients
admitted with acutely decompensated HF (760–763). (Level
of Evidence: A)
The different vasodilators include 1) intravenous nitro-
glycerin, 2) sodium nitroprusside, and 3) nesiritide.
Intravenous nitroglycerin acts primarily through venodila-
tion, lowers preload, andmay help to rapidly reduce pulmonary
congestion (764,765). Patients with HF and hypertension,
coronary ischemia, or signiﬁcant mitral regurgitation are often
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erin. However, tachyphylaxis to nitroglycerin may develop
within 24 hours, and up to 20% of those with HF may develop
resistance to even high doses (766–768).
Sodium nitroprusside is a balanced preload-reducing
venodilator and afterload-reducing arteriodilator that also
dilates the pulmonary vasculature (769). Data demonstrating
efﬁcacy are limited, and invasive hemodynamic blood pressure
monitoring (such as an arterial line) is typically required; in
such cases, blood pressure and volume status should be
monitored frequently. Nitroprusside has the potential for
producing marked hypotension and is usually used in the
intensive care setting as well; longer infusions of the drug have
been rarely associated with thiocyanate toxicity, particularly in
the setting of renal insufﬁciency. Nitroprusside is potentially of
value in severely congested patients with hypertension or
severe mitral valve regurgitation complicating LV dysfunction.
Nesiritide (human BNP) reduces LV ﬁlling pressure but
has variable effects on cardiac output, urinary output, and
sodium excretion. An initial study demonstrated that the
severity of dyspnea is reduced more rapidly compared with
diuretics alone (760). A large randomized trial in patients with
acute decompensated HF demonstrated nesiritide had no
impact on mortality, rehospitalization, or renal function,
a small but statistically signiﬁcant impact on dyspnea, and an
increased risk of hypotension (762). Because nesiritide has
a longer effective half-life than nitroglycerin or nitroprusside,
adverse effects such as hypotension may persist longer.
Overall, presently there are no data that suggest that intrave-
nous vasodilators improve outcomes in the patient hospitalized
with HF; as such, use of intravenous vasodilators is limited
to the relief of dyspnea in the hospitalized HF patient with
intact blood pressure. Administration of intravenous vasodi-
lators in patients with HFpEF should be done with caution
because these patients are typically more volume sensitive.
The use of inotropic support as indicated for hospitalized
HF with shock or impending shock and/or end-organ perfu-
sion limitations is addressed in Section 7.4.4. See Table 26 for
drug therapies and Online Data Supplements 32 and 33 for
additional information on inotropic support.
See Online Data Supplement 39 for additional data on
nesiritide.8.7. Venous Thromboembolism Prophylaxis
in Hospitalized Patients: Recommendation
CLASS I
1. A patient admitted to the hospital with decompensated HF
should receive venous thromboembolism prophylaxis with
an anticoagulant medication if the risk–beneﬁt ratio is
favorable (21,770). (Level of Evidence: B)
HF has long been recognized as affording additional risk
for venous thromboembolic disease, associated with a number
of pathophysiologic changes, including reduced cardiac
output, increased systemic venous pressure, and chemical
changes promoting blood clotting. When patients arehospitalized for decompensated HF or when patients with
chronic stable HF are hospitalized for other reasons, they are
at increased risk for venous thromboembolic disease, although
accurate numerical estimates are lacking in the literature.
Most early data on the effectiveness of different anticoag-
ulant regimens to reduce the incidence of venous thrombo-
embolic disease in hospitalized patients were either
observational, retrospective reports (776,777) or prospective
studies using a variety of drugs and differing deﬁnitions of
therapeutic effect and endpoints (774,778–780), making
summary conclusions difﬁcult. Early studies involved patients
with far longer hospital lengths of stay than occur pre-
sently and were performed well before present standard-
of-care treatments and diagnostic tests were available
(774,778–780). Newer trials using presently available antith-
rombotic drugs often were not limited to patients with HF but
included those with other acute illnesses, severe respiratory
diseases, or simply a broad spectrum of hospitalized medical
patients (771–774,781). In most studies, patients were cate-
gorized as having HF by admitting diagnosis, clinical signs, or
functional class, whereas only 1 study (782) provided LVEF
data on enrolled study patients. All included trials tried to
exclude patients perceived to have an elevated risk of
bleeding complications or with an elevated risk of toxicity
from the speciﬁc agent tested (e.g., enoxaparin in patients
with compromised renal function). Patients with HF typically
made up a minority of the study cohort, and signiﬁcance of
results were not always reported by the authors, making
ACCF/AHA class I recommendations difﬁcult to support
using this guideline methodology. In some trials, concurrent
aspirin was allowed but not controlled for as a confounding
variable (772,783).
For patients admitted speciﬁcally for decompensated HF
and with adequate renal function (serum creatinine <2.0 mg/
dL), randomized trials suggest that enoxaparin 40 mg
subcutaneously once daily (770,773,774,783) or unfractio-
nated heparin 5,000 units subcutaneously every 8 hours (771)
will reduce radiographically demonstrable venous thrombosis.
Effects on mortality or clinically signiﬁcant pulmonary
embolism rates are unclear. Lower doses of enoxaparin do not
appear superior to placebo (770,773), whereas continuing
weight-based enoxaparin therapy up to 3 months after
hospital discharge does not appear to provide additional
beneﬁt (782).
A single prospective study failed to demonstrate certoparin
to be noninferior to unfractionated heparin (783), whereas
retrospective analysis of a prospective trial of dalteparin was
underpowered to determine beneﬁt in its HF cohort (776).
Fondaparinux failed to show signiﬁcant difference from
placebo in an RCT that included a subgroup of 160 patients
with HF (781).
No adequate trials have evaluated anticoagulant beneﬁt in
patients with chronic but stable HF admitted to the hospital
for other reasons. However, the MEDENOX (Medical
Patients with Enoxaparin) trial suggested that the beneﬁt of
enoxaparin may extend to this population (770,773,774).
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lactic efﬁcacy of graded compression stockings in general
medical patients, but signiﬁcant cutaneous complications
were associated with their use. No studies were performed
exclusively on patients with HF. Two RCTs in patients with
stroke found no efﬁcacy of these devices (785,786).
See Online Data Supplement 20 for additional data on
anticoagulation.8.8. Arginine Vasopressin Antagonists:
Recommendation
CLASS IIb
1. In patients hospitalized with volume overload, including HF,
who have persistent severe hyponatremia and are at risk for
or having active cognitive symptoms despite water restric-
tion and maximization of GDMT, vasopressin antagonists
may be considered in the short term to improve serum
sodium concentration in hypervolemic, hyponatremic states
with either a V2 receptor selective or a nonselective vaso-
pressin antagonist (787,788). (Level of Evidence: B)
Even mild hyponatremia may be associated with neuro-
cognitive problems, including falls and attention deﬁcits
(789). Treatment of hypervolemic hyponatremia with a V2-
selective vasopressin antagonist (tolvaptan) was associated
with a signiﬁcant improvement in the mental component of
the Medical Outcomes Study Short Form General Health
Survey (788). Hyponatremia may be treated with water
restriction and maximization of GDMT that modulate angio-
tensin II, leading to improved renal perfusion and decreasedTable 28. Recommendations for Therapies in the Hospitalized H
Recommendations
HF patients hospitalized with fluid overload should be treated with intravenou
HF patients receiving loop diuretic therapy should receive an initial parentera
than or equal to their chronic oral daily dose; then dose should be serially
HFrEF patients requiring HF hospitalization on GDMT should continue GDMT ex
hemodynamic instability or where contraindicated
Initiation of beta-blocker therapy at a low dose is recommended after optimiz
status and discontinuation of intravenous agents
Thrombosis/thromboembolism prophylaxis is recommended for patients hosp
Serum electrolytes, urea nitrogen, and creatinine should be measured during
medications, including diuretics
When diuresis is inadequate, it is reasonable to
a. give higher doses of intravenous loop diuretics; or
b. add a second diuretic (e.g., thiazide)
Low-dose dopamine infusion may be considered with loop diuretics to impro
Ultrafiltration may be considered for patients with obvious volume overload
Ultrafiltration may be considered for patients with refractory congestion
Intravenous nitroglycerin, nitroprusside, or nesiritide may be considered an adj
therapy for stable patients with HF
In patients hospitalized with volume overload and severe hyponatremia, vaso
antagonists may be considered
COR indicates Class of Recommendation; GDMT, guideline-directed medic
fraction; LOE, Level of Evidence; and N/A, not available.thirst. Alternative causes of hyponatremia (e.g., syndrome of
inappropriate antidiuretic hormone, hypothyroidism, and
hypoaldosteronism) should be assessed. Vasopressin antago-
nists improve serum sodium in hypervolemic, hyponatremic
states (787,788); however, longer-term therapy with a V2-
selective vasopressin antagonist did not improve mortality in
patients with HF (790,791). Currently, 2 vasopressin antag-
onists are available for clinical use: conivaptan and tolvaptan.
It may be reasonable to use a nonselective vasopressin
antagonist to treat hyponatremia in patients with HF with
cognitive symptoms due to hyponatremia. However, the long-
term safety and beneﬁt of this approach remains unknown. A
summary of the recommendations for the hospitalized patient
appears in Table 28.8.9. Inpatient and Transitions of Care:
Recommendations
See Table 29 for a summary of recommendations from this
section.
CLASS I
1. The use of performance improvement systems and/or
evidence-based systems of care is recommended in the
hospital and early postdischarge outpatient setting to
identify appropriate HF patients for GDMT, provide clinicians
with useful reminders to advance GDMT, and assess
the clinical response (82,365,706,792–796). (Level of
Evidence: B)
2. Throughout the hospitalization as appropriate, before
hospital discharge, at the ﬁrst postdischarge visit, and inF Patient
COR LOE References
s diuretics I B 737,738
l dose greater
adjusted
I B 739
cept in cases of I B 195,735,736
ation of volume I B 195,735,736
italized with HF I B 21,770–774
titration of HF I C N/A
IIa B 38,739
B 740–743
ve diuresis IIb B 744,745
IIb B 752
IIb C N/A
uvant to diuretic IIb A 760–763
pressin IIb B 787,788
al therapy; HF, heart failure; HFrEF, heart failure with reduced ejection
Table 29. Recommendations for Hospital Discharge
Recommendations or Indications COR LOE References
Performance improvement systems in the hospital and early postdischarge
outpatient setting to identify HF for GDMT
I B 82,365,706,792–796
Before hospital discharge, at the first postdischarge visit, and in subsequent
follow-up visits, the following should be addressed:
a. initiation of GDMT if not done or contraindicated;
b. causes of HF, barriers to care, and limitations in support;
c. assessment of volume status and blood pressure with adjustment
of HF therapy;
d. optimization of chronic oral HF therapy;
e. renal function and electrolytes;
f. management of comorbid conditions;
g. HF education, self-care, emergency plans, and adherence; and
h. palliative or hospice care
I B 204,795,797–799
Multidisciplinary HF disease-management programs for patients at high
risk for hospital readmission are recommended
I B 82,800–802
A follow-up visit within 7 to 14 d and/or a telephone follow-up within 3 d
of hospital discharge are reasonable
IIa B 101,803
Use of clinical risk-prediction tools and/or biomarkers to identify
higher-risk patients are reasonable
IIa B 215
COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; and LOE, Level of Evidence.
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addressed (204,795,797–799). (Level of Evidence: B):
a. initiation of GDMT if not previously established and not
contraindicated;
b. precipitant causes of HF, barriers to optimal care tran-
sitions, and limitations in postdischarge support;
c. assessment of volume status and supine/upright hypo-
tension with adjustment of HF therapy as appropriate;
d. titration and optimization of chronic oral HF therapy;
e. assessment of renal function and electrolytes where
appropriate;
f. assessment and management of comorbid conditions;
g. reinforcement of HF education, self-care, emergency
plans, and need for adherence; and
h. consideration for palliative care or hospice care in
selected patients.
3. Multidisciplinary HF disease-management programs are
recommended for patients at high risk for hospital read-
mission, to facilitate the implementation of GDMT, to
address different barriers to behavioral change, and to
reduce the risk of subsequent rehospitalization for HF
(82,800–802). (Level of Evidence: B)
CLASS IIa
1. Scheduling an early follow-up visit (within 7 to 14 days) and
early telephone follow-up (within 3 days) of hospital
discharge are reasonable (101,803). (Level of Evidence: B)
2. Use of clinical risk-prediction tools and/or biomarkers to
identify patients at higher risk for postdischarge clinical
events are reasonable (215). (Level of Evidence: B)
Decisions about pharmacological therapies delivered
during hospitalization likely can impact postdischarge
outcome. Continuation or initiation of HF GDMT prior to
hospital discharge is associated with substantially improved
clinical outcomes for patients with HFrEF. However, caution
should be used when initiating beta blockers in patients whohave required inotropes during their hospital course or when
initiating ACE inhibitors, ARBs, or aldosterone antagonists in
those patients who have experienced marked azotemia or are
at risk for hyperkalemia. The patient should be transitioned to
oral diuretic therapy to verify its effectiveness. Similarly,
optimal volume status should be achieved. Blood pressure
should be adequately controlled, and, in patients with AF,
ventricular response should also be well controlled. The
hospitalization is a “teachable moment” to reinforce patient
and family education and develop a plan of care, which
should be communicated to the appropriate healthcare team.
Safety for patients hospitalized with HF is crucial. System
changes necessary to achieve safer care include the adoption
by all U.S. hospitals of a standardized set of 30 “Safe Prac-
tices” endorsed by the National Quality Forum (804) and
National Patient Safety Goals espoused by The Joint
Commission (805). Improved communication between clini-
cians and nurses, medication reconciliation, carefully planned
transitions between care settings, and consistent documenta-
tion are examples of patient safety standards that should be
ensured for patients with HF discharged from the hospital.
The prognosis of patients hospitalized with HF, and espe-
cially those with serial readmissions, is suboptimal. Hence,
appropriate levels of symptomatic relief, support, and pallia-
tive care for patients with chronic HF should be addressed as
an ongoing key component of the plan of care, especially
when patients are hospitalized with acute decompensation
(806). The appropriateness of discussion about advanced
therapy or end-of-life preferences is reviewed in Section 11.
For patients with HF, the transition from inpatient to
outpatient care can be an especially vulnerable period because
of the progressive nature of the disease state, complex medical
regimens, the large number of comorbid conditions, and the
Yancy et al. JACC Vol. 62, No. 16, 2013
2013 ACCF/AHA Heart Failure Guideline: Full Text October 15, 2013:e147–239
e200multiple clinicians who may be involved. Patient education
and written discharge instructions or educational material
given to the patient, family members, and/or caregiver during
the hospital stay or at discharge to home are essential
components of transition care. These should address all of
the following: activity level, diet, discharge medications,
follow-up appointment, weight monitoring, and what to do if
symptoms worsen (297). Thorough discharge planning that
includes special emphasis on ensuring adherence to an
evidence-based medication regimen (795) is associated with
improved patient outcomes (792,797,807). More intensive
delivery of discharge instructions, coupled tightly with
subsequent well-coordinated follow-up care for patients
hospitalized with HF, has produced positive results in several
studies (82,793,800). The addition of a 1-hour, nurse educator–
delivered teaching session at the time of hospital discharge,
using standardized instructions, resulted in improved clinical
outcomes, increased self-care and treatment adherence, and
reduced cost of care. Patients receiving the education inter-
vention also had a lower risk of rehospitalization or death and
lower costs of care (365). There are ongoing efforts to further
develop evidence-based interventions in this population.
Transitional care extends beyond patient education. Care
information, especially changes in orders and new diagnostic
information, must be transmitted in a timely and clearly
understandable form to all of the patient’s clinicians who will
be delivering follow-up care. Other important components of
transitional care include preparation of the patient and care-
giver for what to expect at the next site of care, reconciliation
of medications, follow-up plans for outstanding tests, and
discussions about monitoring signs and symptoms of wors-
ening conditions. Early outpatient follow-up, a central
element of transitional care, varies signiﬁcantly across U.S.
hospitals. Early postdischarge follow-up may help minimize
gaps in understanding of changes to the care plan or knowl-
edge of test results and has been associated with a lower risk
of subsequent rehospitalization (803). A follow-up visit
within 7 to 14 days and/or a telephone follow-up within 3
days of hospital discharge are reasonable goals of care.
See Online Data Supplement 40 for additional data on oral
medications for the hospitalized patient.9. Important Comorbidities in HF
9.1. Atrial Fibrillationx
Patients with HF are more likely than the general population
to develop AF (808). There is a direct relationship between
the NYHA class and prevalence of AF in patients with HF
progressing from 4% in those who are NYHA class I to 40%xThe “ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial
Fibrillation” and the 2 subsequent focused updates from 2011 (6–8) are considered
policy at the time of publication of the present HF Guideline; however, a fully
revised AF guideline, which will include updated recommendations on AF, is in
development, with publication expected in 2013 or 2014.in those who are NYHA class IV (809). AF is also a strong
independent risk factor for subsequent development of HF
(376,808). In addition to those with HFrEF, patients with
HFpEF are also at greater risk for AF than the general age-
matched population (811). HF and AF can interact to promote
their perpetuation and worsening through mechanisms such
as rate-dependent worsening of cardiac function, ﬁbrosis, and
activation of neurohumoral vasoconstrictors. AF can worsen
symptoms in patients with HF, and, conversely, worsened HF
can promote a rapid ventricular response in AF.
Similar to other patient populations, for those with AF and
HF, the main goals of therapy are prevention of thrombo-
embolism and symptom control. Most patients with AF and
HF would be expected to be candidates for systemic anti-
coagulation unless otherwise contraindicated. General prin-
ciples of management include correction of underlying causes
of AF and HF as well as optimization of HF management
(Table 30). As in other patient populations, the issue of rate
control versus rhythm control has been investigated. For
patients who develop HF as a result of AF, a rhythm control
strategy should be pursued. It is important to recognize that
AF with a rapid ventricular response is one of the few
potentially reversible causes of HF. Because of this, a patient
who presents with newly detected HF in the presence of AF
with a rapid ventricular response should be presumed to have
a rate-related cardiomyopathy until proved otherwise. In this
situation, 2 strategies can be considered. One is rate control of
the patient’s AF and see if HF and EF improve. The other is to
try to restore and maintain sinus rhythm. In this situation, it is
common practice to initiate amiodarone and then arrange for
cardioversion 1 month later. Amiodarone has the advantage of
being both an effective rate-control medication and the most
effective antiarrhythmic medication with a lower risk of
proarrhythmic effect.
In patients with HF who develop AF, a rhythm-control
strategy has not been shown to be superior to a rate-control
strategy (812). If rhythm control is chosen, limited data
suggest that AF catheter ablation in HF patients may lead to
improvement in LV function and quality of life but is less
likely to be effective than in patients with intact cardiac
function (813,814). Because of their favorable effect on
morbidity and mortality in patients with systolic HF, beta-
adrenergic blockers are the preferred agents for achieving
rate control unless otherwise contraindicated. Digoxin may be
an effective adjunct to a beta blocker. The nondihydropyridine
calcium antagonists, such as diltiazem, should be used with
caution in those with depressed EF because of their negative
inotropic effect. For those with HFpEF, nondihydropyridine
calcium antagonists can be effective for achieving rate control
but may be more effective when used in combination with
digoxin. For those for whom a rate-control strategy is chosen,
when rate control cannot be achieved either because of drug
inefﬁcacy or intolerance, atrioventricular node ablation and
CRT device placement can be useful (78,116,595,596). See
Figures 5 and 6 for AF treatment algorithms.
See Online Data Supplement 41 for additional data on AF.
Table 30. Clinical Evaluation in Patients With AF
Minimum evaluation
1. History and physical examination, to define  Presence and nature of symptoms associated with AF
 Clinical type of AF (paroxysmal, persistent, or permanent)
 Onset of first symptomatic attack or date of discovery of AF
 Frequency, duration, precipitating factors, and modes of termination of AF
 Response to any pharmacological agents that have been administered
 Presence of any underlying heart disease or other reversible conditions (e.g., hyperthyroidism
or alcohol consumption)
2. ECG, to identify  Rhythm (verify AF)
 LV hypertrophy
 P-wave duration and morphology or fibrillatory waves
 Preexcitation
 Bundle-branch block
 Prior MI
 Other atrial arrhythmias
 To measure and follow the R-R, QRS, and QT intervals in conjunction with antiarrhythmic
drug therapy
3. Transthoracic echocardiogram, to identify  Valvular heart disease
 LA and RA size
 LV and RV size and function
 Peak RV pressure (pulmonary hypertension)
 LV hypertrophy
 LA thrombus (low sensitivity)
 Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function  For a first episode of AF, when the ventricular rate is difficult to control
Additional testing (one or several tests may be necessary)
1. 6-Minute walk test  If the adequacy of rate control is in question
2. Exercise testing  If the adequacy of rate control is in question (permanent AF)
 To reproduce exercise-induced AF
 To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
3. Holter monitoring or event recording  If diagnosis of the type of arrhythmia is in question
 As a means of evaluating rate control
4. Transesophageal echocardiography  To identify LA thrombus (in the LA appendage)
 To guide cardioversion
5. Electrophysiological study  To clarify the mechanism of wide-QRS-complex tachycardia
 To identify a predisposing arrhythmia such as atrial flutter or paroxysmal
supraventricular tachycardia
 To seek sites for curative ablation or AV conduction block/modification
6. Chest x-ray to evaluate  Lung parenchyma, when clinical findings suggest an abnormality
 Pulmonary vasculature, when clinical findings suggest an abnormality
Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs.
AF indicates atrial fibrillation; AV, atrioventricular; ECG, electrocardiogram; LA, left atrial; LV, left ventricular; MI, myocardial infarction; RA, right atrial; and
RV, right ventricular.
Reproduced from Fuster et al. (6).
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Anemia is a common ﬁnding in patients with chronic HF.
Although variably reported, in part due to the lack of
consensus on the deﬁnition of anemia, the prevalence of
anemia among patients with HF increases with HF severity.
Anemia is also more common in women and is seen in both
patients with HFrEF and HFpEF (818–823). The World
Health Organization deﬁnes anemia as a hemoglobin level
of <12 g/dL in women and <13 g/dL in men. Registries have
reported anemia to be present in 25% to 40% of HF patients
(818–820). Anemia is associated with an increased mortality
risk in HF. In a large study of >150,000 patients, the mor-
tality risk was approximately doubled in anemic HF patientscompared with those without anemia, and this risk persisted
after controlling for other confounders, including renal
dysfunction and HF severity (818). Anemia is also associated
with reduced exercise capacity, impaired HRQOL, and
a higher risk for hospitalization (225,819,824,825). These
risks are inversely and linearly associated with hemoglobin
levels, although a U-shaped risk with the highest hemoglobin
levels has been reported (822,826).
Multiple etiological factors, many of which coexist within
individual patients, contribute to the development of anemia
in HF. Anemia in patients with HF is often normocytic and
accompanied by an abnormally low reticulocyte count
(825,827). Evaluation of anemia in HF requires careful
Figure 5. Pharmacological management of patients with newly discovered AF. AF indicates atrial ﬁbrillation; and HF, heart failure.
Reproduced from Fuster et al. (6).
Figure 6. Pharmacological management of patients with recurrent paroxysmal AF. AF indicates atrial ﬁbrillation. Reproduced from
Fuster et al. (6).
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e203consideration of other causes, the most common being
secondary causes of iron deﬁciency anemia.
In persons without identiﬁable causes of anemia,
erythropoiesis-stimulating agents have gained signiﬁcant
interest as potential adjunctive therapy in the patient with HF.
In a retrospective study of erythropoiesis-stimulating agents in
26 patients with HF and anemia, the hemoglobin level, LVEF,
and functional class improved (828). These patients required
lower diuretic doses and were hospitalized less often. Similar
ﬁndings were also observed in a randomized open-label study
of 32 patients (829). A single-blind RCT showed that eryth-
ropoietin increased hemoglobin, peak oxygen uptake, and
exercise duration in patients with severe HF and anemia
(830). Two further studies conﬁrmed these ﬁndings; however,
none of these were double blind (831,832).
These positive data led to 2 larger studies. A 165-patient
study showed that darbepoetin alfa was associated with
improvement in several HRQOL measures with a trend
toward improved exercise capacity (6-minute walking
distance þ347 m versus þ1110 m, P¼0.074) (833). In
STAMINA-HeFT (Study of Anemia in Heart Failure Trial),
319 patients were randomly assigned to darbepoetin alfa or
placebo for 12 months (834). Although darbepoetin alfa did
not improve exercise duration, it was well tolerated, and
a trend toward improvement in the composite endpoint of all-
cause mortality or ﬁrst hospitalization for HF was seen
(hazard ratio: 0.68; 95% conﬁdence interval: 0.43 to 1.08;
P¼0.10) (834). These favorable data led to the design and
initiation of the RED-HF (Phase III Reduction of Events With
Darbepoetin alfa in Heart Failure) trial (835).
Two trials in erythropoiesis-stimulating agents, however,
later raised concerns that patients treated with an
erythropoiesis-stimulating agent may have an increased risk
of cardiovascular events (836,837). Because the populationsTable 31. Ten Most Common Co-Occurring Chronic Conditions Among
Beneficiaries Age 65 y (N¼4,376,150)*
N %
Hypertension 3,685,373 84.2
Ischemic heart disease 3,145,718 71.9
Hyperlipidemia 2,623,601 60.0
Anemia 2,200,674 50.3
Diabetes 2,027,875 46.3
Arthritis 1,901,447 43.5
Chronic kidney disease 1,851,812 42.3
COPD 1,311,118 30.0
Atrial fibrillation 1,247,748 28.5
Alzheimer’s disease/dementia 1,207,704 27.6
*Mean No. of conditions is 6.1; median is 6.
yMean No. of conditions is 5.5; median is 5.
Data source: Centers for Medicare and Medicaid Services administrative claims d
(CCW), ccwdata.org (847).
COPD indicates chronic obstructive pulmonary disease; and HF, heart failure.in these trials differed, the RED-HF trial was continued.
Nevertheless, at the completion of the trial, the investigators
concluded that treatment with darbepoetin alfa did not
improve clinical outcomes in patients with systolic HF and
mild-to-moderate anemia (838). Finally, a trial using intra-
venous iron as a supplement in patients with HFrEF with iron
deﬁciency showed an improvement in functional status (840).
There were no untoward adverse effects of iron in this trial. In
the absence of a deﬁnitive evidence base, the writing
committee has deferred a speciﬁc treatment recommendation
regarding anemia.
9.3. Depression
Depression is common in patients with HF; those with
depressive symptoms have lower HRQOL, poorer self-care,
worse clinical outcomes, and more use of healthcare
services (841–843). Although it might be assumed that
depression occurs only among hospitalized patients (844),
a multicenter study demonstrated that even at least 3 months
after a hospitalization, 63% of patients with HF reported
symptoms of depression (845). Potential pathophysiologic
mechanisms proposed to explain the high prevalence of
depression in HF include autonomic nervous system
dysfunction, inﬂammation, cardiac arrhythmias, and altered
platelet function, but the mechanism remains unclear (846).
Although remission from depression may improve cardio-
vascular outcomes, the most effective intervention strategy is
not yet known (842).
9.4. Other Multiple Comorbidities
Although there are additional and important comorbidities
that afﬂict patients with HF as shown in Table 31, how best to
generate speciﬁc recommendations remains uncertain, given
the status of current evidence.Medicare Beneficiaries With HF (N[4,947,918), 2011
Beneficiaries Age <65 y (N¼571,768)y
N %
Hypertension 461,235 80.7
Ischemic heart disease 365,889 64.0
Diabetes 338,687 59.2
Hyperlipidemia 325,498 56.9
Anemia 284,102 49.7
Chronic kidney disease 257,015 45.0
Depression 207,082 36.2
Arthritis 201,964 35.3
COPD 191,016 33.4
Asthma 88,816 15.5
ata, January 2011December 2011, from the Chronic Condition Warehouse
Yancy et al. JACC Vol. 62, No. 16, 2013
2013 ACCF/AHA Heart Failure Guideline: Full Text October 15, 2013:e147–239
e20410. Surgical/Percutaneous/Transcatheter
Interventional Treatments of HF:
Recommendations
See Table 32 for a summary of recommendations from this
section.
CLASS I
1. Coronary artery revascularization via CABG or percutaneous
intervention is indicated for patients (HFpEF and HFrEF) on
GDMT with angina and suitable coronary anatomy, espe-
cially for a left main stenosis (>50%) or left main equivalent
disease (10,12,14,848). (Level of Evidence: C)
CLASS IIa
1. CABG to improve survival is reasonable in patients with mild
to moderate LV systolic dysfunction (EF 35% to 50%) and
signiﬁcant (‡70% diameter stenosis) multivessel CAD or
proximal left anterior descending coronary artery stenosis
when viable myocardium is present in the region of intended
revascularization (848–850). (Level of Evidence: B)
2. CABG or medical therapy is reasonable to improve morbidity
and cardiovascular mortality for patients with severe LV
dysfunction (EF <35%), HF, and signiﬁcant CAD (309,851).
(Level of Evidence: B)
3. Surgical aortic valve replacement is reasonable for patients
with critical aortic stenosis and a predicted surgical mortality
of no greater than 10% (852). (Level of Evidence: B)
4. Transcatheter aortic valve replacement after careful candi-
date consideration is reasonable for patients with critical
aortic stenosis who are deemed inoperable (853). (Level of
Evidence: B)
CLASS IIb
1. CABG may be considered with the intent of improving
survival in patients with ischemic heart disease with severeTable 32. Recommendations for Surgical/Percutaneous/Transc
Recommendations
CABG or percutaneous intervention is indicated for HF patients on GDMT w
and suitable coronary anatomy, especially significant left main stenosis o
equivalent
CABG to improve survival is reasonable in patients with mild to moderate L
dysfunction and significant multivessel CAD or proximal LAD stenosis wh
myocardium is present
CABG or medical therapy is reasonable to improve morbidity and mortality f
with severe LV dysfunction (EF <35%), HF, and significant CAD
Surgical aortic valve replacement is reasonable for patients with critical aor
and a predicted surgical mortality of no greater than 10%
Transcatheter aortic valve replacement is reasonable for patients with critic
stenosis who are deemed inoperable
CABG may be considered in patients with ischemic heart disease, severe L
dysfunction, and operable coronary anatomy whether or not viable myoc
present
Transcatheter mitral valve repair or mitral valve surgery for functional mitra
insufficiency is of uncertain benefit
Surgical reverse remodeling or LV aneurysmectomy may be considered in
specific indications, including intractable HF and ventricular arrhythmias
CABG indicates coronary artery bypass graft; CAD, coronary artery dise
guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure wi
of Evidence; and LV, left ventricular.LV systolic dysfunction (EF <35%) and operable coro-
nary anatomy whether or not viable myocardium is present
(307–309). (Level of Evidence: B)
2. Transcatheter mitral valve repair or mitral valve surgery for
functional mitral insufﬁciency is of uncertain beneﬁt and
should only be considered after careful candidate selection
and with a background of GDMT (854–857). (Level of
Evidence: B)
3. Surgical reverse remodeling or LV aneurysmectomy may be
considered in carefully selected patients with HFrEF for
speciﬁc indications, including intractable HF and ventricular
arrhythmias (858). (Level of Evidence: B)
Surgical therapies and percutaneous interventions that are
commonly integrated, or at least considered, in HF manage-
ment include coronary revascularization (e.g, CABG, angio-
plasty, stenting); aortic valve replacement; mitral valve
replacement or repair; septal myectomy or alcohol septal
ablation for hypertrophic cardiomyopathy; surgical ablation of
ventricular arrhythmia; MCS; and cardiac transplantation
(675,680,859,860). Surgical placement of ICDs or LV pacing
leads is of historical importance but may be considered in
situations where transvenous access is not feasible.
The most common reason for intervention is CAD.
Myocardial viability indicates the likelihood of improved
outcomes with either surgical or medical therapy but does not
identify patients with greater survival beneﬁt from revascu-
larization (304). The dictum of CABG for left main CAD and
reduced LV function was considered absolute and subse-
quently extrapolated to all severities of LV dysfunction
without a conﬁrmatory evidence base (848). Newer studies
have addressed patients with multivessel CAD, HF, and at
least moderately severe to severe LV systolic dysfunctionatheter Interventional Treatments of HF
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e205(861,862). Both surgical and medical therapies have similar
outcomes, and decisions about revascularization should be
made jointly by the HF team and cardiothoracic surgeon. The
most important considerations in the decision to proceed with
a surgical or interventional approach include coronary
anatomy that is amenable to revascularization and appropriate
concomitant GDMT. Valvular heart disease is not an infre-
quent cause of HF; however, when valvular disease is
managed correctly and pre-emptively, its adverse conse-
quences on ventricular mechanics can be ameliorated. The
advent of effective transcatheter approaches to both mitral and
aortic disease creates the need for greater considerations of
structural interventions for patients with LV systolic dys-
function and valvular heart disease. To date, the surgical or
transcatheter management of functional mitral insufﬁciency
has not been proven superior to medical therapy. A decision
to intervene in functional mitral regurgitation should be made
on a case-by-case basis, and consideration should be given to
participation in clinical trials and/or databases. The surgical or
transcatheter management of critical aortic stenosis is an
effective strategy with reasonable outcomes noted even in
patients with advanced age (>80 years). Indications for other
surgical or percutaneous interventions in the setting of HF are
driven by other relevant guidelines or other sections of this
guideline, including myomectomy for hypertrophic cardio-
myopathy, surgical or electrophysiological procedures for AF,
nondurable or durable MCS, and heart transplantation.
Several procedures under evaluation hold promise but are
not yet appropriate for a guideline-driven indication
(Table 33). This includes revascularization as a means toTable 33. Surgical/Percutaneous/Transcatheter Interventions
in Patients With HF
References
Appropriate Guideline-Directed Surgical/Percutaneous/
Transcatheter Interventions for HF
1. Surgical or percutaneous revascularization 10,12,14
2. Surgical or transcatheter aortic valve replacement 852,853
3. Surgical myomectomy or alcohol ablation for
hypertrophic cardiomyopathy
11
4. Nondurable MCS for cardiogenic shock 668–671
5. Durable MCS for advanced HF 672–675
6. Heart transplantation 680
7. Surgical/electrophysiological ablation of ventricular
tachycardia
866
Surgical/Percutaneous/Transcatheter Interventions Under
Evaluation in Patients With HF
1. Transcatheter intervention for functional mitral
insufficiency
854–857
2. Left atrial resection/left atrial appendage removal,
surgical or percutaneous, for AF
867
3. MCS for advanced HF as a bridge to recovery 868,869
AF indicates atrial fibrillation; HF, heart failure; and MCS, mechanical circulatory
support.support cellular regenerative therapies. For patients willing to
consider regenerative technologies, the ideal strategy is
referral to an enrolling clinical trial at a center experienced
in both high-risk revascularization and cell-based science
(863–865). Surgical reverse-ventricular remodeling (ventric-
ular reconstruction) does not appear to be of beneﬁt but may
be considered in carefully selected patients with HFrEF for
speciﬁed indications, including retractable HF and ventricular
arrhythmias (858).
11. Coordinating Care for Patients
With Chronic HF
11.1. Coordinating Care for Patients With
Chronic HF: Recommendations
CLASS I
1. Effective systems of care coordination with special atten-
tion to care transitions should be deployed for every patient
with chronic HF that facilitate and ensure effective care that
is designed to achieve GDMT and prevent hospitalization
(80,82,793,870–884). (Level of Evidence: B)
2. Every patient with HF should have a clear, detailed, and
evidence-based plan of care that ensures the achievement
of GDMT goals, effective management of comorbid condi-
tions, timely follow-up with the healthcare team, appropriate
dietary and physical activities, and compliance with
secondary prevention guidelines for cardiovascular disease.
This plan of care should be updated regularly and made
readily available to all members of each patient’s healthcare
team (13). (Level of Evidence: C)
3. Palliative and supportive care is effective for patients with
symptomatic advanced HF to improve quality of life
(30,885–888). (Level of Evidence: B)
Education, support, and involvement of patients with HF
and their families are critical and often complex, especially
during transitions of care. Failure to understand and follow
a detailed and often nuanced plan of care likely contributes to
the high rates of HF 30-day rehospitalization and mortality
seen across the United States (61,889). One critical inter-
vention to ensure effective care coordination and transition is
the provision of a comprehensive plan of care, with easily
understood, culturally sensitive, and evidence-based educa-
tional materials, to patients with HF and/or caregivers during
both hospital and ofﬁce-based encounters. A comprehensive
plan of care should promote successful patient self-care
(870,884,890). Hence, the plan of care for patients with HF
should continuously address in detail a number of complex
issues, including adherence to GDMT, timely follow-up with
the healthcare professionals who manage the patient’s HF and
associated comorbidities, appropriate dietary and physical
activities, including cardiac rehabilitation, and adherence to
an extensive list of secondary prevention recommendations
based on established guidelines for cardiovascular disease
(Table 34). Clinicians must maintain vigilance about
psychosocial, behavioral, and socioeconomic issues that
patients with HF and their caregivers face, including
Table 34. Plan of Care for Patients With Chronic HF
Plan of Care Relevant Guideline Section/Reference
Guideline-directed medical and device therapy
ACE inhibitor/ARB Sections 7.3.2.2 and 7.3.2.3
Beta blocker Section 7.3.2.4
Aldosterone receptor antagonist Section 7.3.2.5
Diuretic Sections 7.3.2.1 and 8.4
Hydralazine and isosorbide dinitrate Section 7.3.2.6
Digoxin Section 7.3.2.7
Discontinuation of drugs that may worsen HF Section 7.3.2.9
Biomarker-related therapeutic goals Section 6.3
HF-related devices (MCS, CRT, ICD) Sections 7.3.4 and 7.4.5
Management of comorbidities (examples)
Ischemic heart disease 2012 ACCF/AHA SIHD Guideline (14)
Antithrombotic therapies Section 7.3.2.8.1
Arrhythmia/arrhythmia risk Sections 7.3.2.9.2 and 9.1
Hypertension Section 7.1.1, JNC-VII (27)
Diabetes mellitus 2012 ADA Standards (90)
Chronic renal failure Section 8.5
Chronic obstructive pulmonary disease 2011 ACCP/ATS/ERS Guideline (908)
Secondary prevention interventions (e.g., lipids, smoking cessation,
influenza and pneumococcal vaccines)
2011 AHA/ACCF Secondary Prevention and Risk Reduction Guidelines and
Centers for Disease Control Adult Vaccinations (13,909,910)
Patient/family education
Diet and fluid restriction, weight monitoring Sections 7.3.1.1, 7.3.1.3, 7.3.1.5, and 7.4.3
Recognizing signs and symptoms of worsening HF Table 24
Risk assessment and prognosis Sections 3, 4.6, 6.1.2
QOL assessment 2012 AHA Scientific Statement on Advanced HF (30)
Advance care planning (e.g., palliative care and advance directives) Section 11.3 (30,888)
CPR training for family members AHA Family & Friends CPR (911)
Social support Section 7.3.1.2
Physical activity/cardiac rehabilitation
Exercise regimen Sections 7.3.1.5 and 7.3.1.6
Activities of daily living Section 7.3.1.6
Functional status assessment and classification Section 3
Psychosocial factors
Sex-specific issues 2011 AHA Guidelines for the Prevention of Cardiovascular Disease in Women (912)
Sexual activity 2012 AHA Scientific Statement on Sexual Activity (913)
Depression screening U.S. Preventive Services Task Force Guidelines (914)
Clinician follow-up and care coordination
Cardiologists and other relevant specialists 2000 AHA Scientific Statement for Team Management of Patients With HF (900)
Primary care physician NQF Preferred Practices for Care Coordination (898)
Advanced practice nurse Section 11.1–11.3, Joint Commission 2013 National Patient Safety Goals (915)
Other healthcare providers (e.g., home care)
Medication reconciliation Establishment of electronic personal health records HHS Meaningful Use Criteria
Socioeconomic and cultural factors Culturally sensitive issues NQF: A Comprehensive Framework and Preferred Practices for Measuring and
Reporting Cultural Competency (916)
Education and health literacy Section 7.3.1.1
Social support Section 7.3.1.2
ACCF indicates American College of Cardiology Foundation; ACCP, American College of Chest Physicians; ACE, angiotensin-converting enzyme; ADA, American
Diabetes Association; AHA, American Heart Association; ARB, angiotensin-receptor blocker; ATS, American Thoracic Society; CPR, cardiopulmonary resuscitation; CRT,
cardiac resynchronization therapy; ERS, European Respiratory Society; HF, heart failure; HHS, Health and Human Services; ICD, implantable cardioverter-defibrillator;
JNC, Joint National Committee; MCS, mechanical circulatory support; NQF, National Quality Forum; QOL, quality of life; and SIHD, stable ischemic heart disease.
Yancy et al. JACC Vol. 62, No. 16, 2013
2013 ACCF/AHA Heart Failure Guideline: Full Text October 15, 2013:e147–239
e206
JACC Vol. 62, No. 16, 2013 Yancy et al.
October 15, 2013:e147–239 2013 ACCF/AHA Heart Failure Guideline: Full Text
e207access to care, risk of depression, and healthcare disparities
(639,891–895). For example, patients with HF who live in
skilled nursing facilities are at higher risk for adverse events,
with a 1-year mortality rate >50% (896). Furthermore,
community-dwelling patients with HF are often unable to
afford the large number of medications prescribed, thereby
leading to suboptimal medication adherence (897).
11.2. Systems of Care to Promote Care
Coordination for Patients With Chronic HF
Improved communication between clinicians and nurses,
medication reconciliation, carefully planned transitions
between care settings, and consistent documentation are
examples of patient safety standards that should be ensured
for all patients with HF. The National Quality Forum has also
endorsed a set of patient-centered “Preferred Practices for
Care Coordination,” (898) which detail comprehensive spe-
ciﬁcations for successful care coordination for patients and
their families.
Systems of care designed to support patients with HF and
other cardiac diseases can produce a signiﬁcant improvement
in outcomes. Furthermore, the Centers for Medicare and
Medicaid Services is now ﬁnancially penalizing hospitals for
avoidable hospitalizations and readmissions, thereby empha-
sizing the importance of such systems-based care coordination
of patients with HF (899). However, the quality of evidence is
mixed for speciﬁc components of HF clinical management
interventions, such as home-based care (871,872), disease
management (873,874,880), and remote telemonitoring
programs (80,875,876,878). Unfortunately, numerous and
nonstandardized deﬁnitions of disease management
(873,879,880), including the speciﬁc elements that compose
disease management, impede efforts to improve the care of
patients with HF. Hence, more generic multidisciplinary
strategies for improving the quality and cost-effectiveness of
systems-based HF care should be evaluated with equal weight
to those interventions focused on improving adherence to
GDMT. For example, multidisciplinary approaches can
reduce rates of hospitalization for HF. Programs involving
specialized follow-up by a multidisciplinary team decrease
all-cause hospitalizations and mortality; however, this has not
been shown for “disease management programs” that focus
only on self-care activities (82,793,881,882,900). Further-
more, patient characteristics may be important predictors of
HF and other cardiac disease–related survival and hospitali-
zation. Overall, very few speciﬁc interventions have been
consistently identiﬁed and successfully applied in clinical
practice (204,214,901–903).
See Online Data Supplements 42 and 43 for additional
data on disease management and telemonitoring.
11.3. Palliative Care for Patients With HF
The core elements of comprehensive palliative care for HF
delivered by clinicians include expert symptom assessment
and management. Ongoing care should address symptom
control, psychosocial distress, HRQOL, preferences aboutend-of-life care, caregiver support, and assurance of access to
evidence-based disease-modifying interventions. The HF
team can help patients and their families explore treatment
options and prognosis. The HF and palliative care teams are
best suited to help patients and families decide when end-of-
life care (including hospice) is appropriate (30,885–888,904).
Assessment for frailty and dementia is part of this decision
care process offered to the patient and family.
Data suggest that advance directives specifying limitations
in end-of-life care are associated with signiﬁcantly lower
levels of Medicare spending, lower likelihood of in-hospital
death, and higher use of hospice care in regions character-
ized by higher levels of end-of-life spending (905). In newly
diagnosed cancer patients, palliative care interventions deliv-
ered early have had a positive impact on survival and HRQOL.
This approach may also be relevant for HF (906). Access to
formally trained palliative care specialists may be limited in
ambulatory settings. Therefore, cardiologists, primary care
physicians, physician assistants, advanced practice nurses, and
other members of the HF healthcare team should be familiar
with these local treatment options. Evaluation for cardiac
transplantation or MCS in experienced centers should include
formal palliative care consultation, which can improve
advanced care planning and enhance the overall quality of
decision making and integrated care for these patients,
regardless of the advanced HF therapy selected (907).
12. Quality Metrics/Performance Measures:
Recommendations
CLASS I
1. Performance measures based on professionally developed
clinical practice guidelines should be used with the goal of
improving quality of care for HF (706,801,917). (Level of
Evidence: B)
CLASS IIa
1. Participation in quality improvement programs and patient
registries based on nationally endorsed, clinical practice
guideline–based quality and performance measures can be
beneﬁcial in improving the quality of HF care (706,801).
(Level of Evidence: B)
Quality measurement and accountability have become
integral parts of medical practice over the past 2 decades. HF
has been a speciﬁc target of quality measurement, improve-
ment, and reporting because of its substantial impact on
population morbidity and mortality. Commonly used perfor-
mance measures for HF can be considered in 2 distinct
categories: process measures and outcomes measures.
Process performance measures focus on the aspects of care
that are delivered to a patient (e.g., the prescription of
a particular drug such as an ACE inhibitor in patients with LV
systolic dysfunction and without contraindications). Process
measures derive from the most deﬁnitive guideline recom-
mendations (i.e., class I and class III recommendations). A
small group of process measures for hospitalized patients with
HF have been reported to the public by the Centers for
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Compare program (918).
Measures used to characterize the care of patients with HF
should be those developed in a multiorganizational consensus
process using an explicit methodology focusing on measur-
ability, validity, reliability, feasibility, and ideally, correlation
with patient outcomes (919,920), and with transparent
disclosure and management of possible conﬂicts of interest. In
the case of HF, several national outcome measures are
currently in use (Table 35), and the ACCF/AHA/American
Medical Association–Physician Consortium for Performance
Improvement recently published revised performance
measures document includes several process measures for both
inpatient and outpatient HF care (Table 36) (921). Of note, the
ACCF/AHA distinguish between processes of care that can be
considered “Performance Measures” (i.e., suitable for use for
accountability purposes) and “Quality Metrics” (i.e., suitable
for use for quality improvement but not accountability) (922).
Measures are appealing for several reasons; by deﬁnition,
they reﬂect the strongest guideline recommendations. When
appropriately speciﬁed, they are relatively easy to calculate
and they provide a clear target for improvement. However,
they do not capture the broader range of care; they apply only
to those patients without contraindications to therapy.
Evidence of the relation between better performance with
respect to process measures and patient outcomes is con-
ﬂicting, and performance rates for those measures that have
been used as part of public reporting programs are generally
high for all institutions, limiting the ability of these measures
to identify high- and low-performing centers.
These limitations of process measures have generated
interest in the use of outcomes measures as a complementary
approach to characterize quality. With respect to HF, 30-day
mortality and 30-day readmission are reported by the
Centers for Medicare and Medicaid Services as part of the
Hospital Compare program (Table 35) and are incorporated in
the Centers for Medicare and Medicaid Services value-based
purchasing program (918). Outcomes measures are appealing
because they apply universally to almost all patients, and they
provide a perspective on the performance of health systems
(923). On the other hand, they are limited by the questionable
adequacy of risk adjustment and by the challenges ofTable 35. Outcome Measures for HF
Measure Developer
Congestive HF mortality rate
(NQF endorsed)
Agency for Health Research and Quality
HF 30-day mortality rate
(NQF endorsed)
Centers for Medicare and Medicaid Services
Congestive HF admission rate
(NQF endorsed)
Agency for Health Research and Quality
HF 30-day risk-standardized
HF readmission rate
(NQF endorsed)
Centers for Medicare and Medicaid Services
HF indicates heart failure; and NQF, National Quality Forum.improvement. The ACCF and AHA have published criteria
that characterize the necessary attributes of robust outcomes
measures (924).
See Online Data Supplement 44 for additional data on
quality metrics and performance measures.13. Evidence Gaps and
Future Research Directions
Despite the objective evidence compiled by the writing
committee on the basis of hundreds of clinical trials, there are
huge gaps in our knowledge base about many fundamental
aspects of HF care. Some key examples include an effective
management strategy for patients with HFpEF beyond blood
pressure control; a convincing method to use biomarkers in
the optimization of medical therapy; the recognition and
treatment of cardiorenal syndrome; and the critical need for
improving patient adherence to therapeutic regimens. Even
the widely embraced dictum of sodium restriction in HF is not
well supported by current evidence. Moreover, the majority of
the clinical trials that inform GDMT were designed around the
primary endpoint of mortality, so that there is less certainty
about the impact of therapies on the HRQOL of patients. It is
also of major concern that the majority of RCTs failed to
randomize a sufﬁcient number of the elderly, women, and
underrepresented minorities, thus, limiting insight into these
important patient cohorts. A growing body of studies on
patient-centered outcomes research is likely to address some
of these deﬁciencies, but time will be required.
HF is a syndrome with a high prevalence of comorbidities
and multiple chronic conditions, but most guidelines are
developed for patients with a single disease. Nevertheless, the
coexistence of additional diseases such as arthritis, renal
insufﬁciency, diabetes mellitus, or chronic lung disease with
the HF syndrome should logically require a modiﬁcation of
treatment, outcome assessment, or follow-up care. About 25%
of Americans have multiple chronic conditions; this ﬁgure
rises to 75% in those >65 years of age, including the diseases
referred to above, as well as asthma, hypertension, cognitive
disorders, or depression (847). Most RCTs in HF speciﬁcally
excluded patients with signiﬁcant other comorbidities from
enrollment, thus limiting our ability to generalize our recom-
mendations to many real-world patients. Therefore, the clini-
cian must, as always, practice the art of using the best of the
guideline recommendations as they apply to a speciﬁc patient.
Future research will need to focus on novel pharmacolog-
ical therapies, especially for hospitalized HF; regenerative
cell-based therapies to restore myocardium; and new device
platforms that will either improve existing technologies (e.g.,
CRT, ICD, left VAD) or introduce simpler, less morbid
devices that are capable of changing the natural history of HF.
What is critically needed is an evidence base that clearly
identiﬁes best processes of care, especially in the transition
from hospital to home. Finally, preventing the burden of
this disease through more successful risk modiﬁcation,
Table 36. ACCF/AHA/AMA-PCPI 2011 HF Measurement Set
Measure Description* Care Setting Level of Measurement
1. LVEF assessment Percentage of patients aged 18 y with a diagnosis of HF for whom the
quantitative or qualitative results of a recent or prior (any time in the past)
LVEF assessment is documented within a 12-mo period
Outpatient Individual practitioner
2. LVEF assessment Percentage of patients aged 18 y with a principal discharge diagnosis of HF
with documentation in the hospital record of the results of an LVEF
assessment performed either before arrival or during hospitalization, OR
documentation in the hospital record that LVEF assessment is planned for
after discharge
Inpatient  Individual practitioner
 Facility
3. Symptom and activity
assessment
Percentage of patient visits for those patients aged18 y with a diagnosis of
HF with quantitative results of an evaluation of both current level of
activity and clinical symptoms documented
Outpatient Individual practitioner
4. Symptom managementy Percentage of patient visits for those patients aged18 y with a diagnosis of
HF and with quantitative results of an evaluation of both level of activity
AND clinical symptoms documented in which patient symptoms have
improved or remained consistent with treatment goals since last
assessment OR patient symptoms have demonstrated clinically important
deterioration since last assessment with a documented plan of care
Outpatient Individual practitioner
5. Patient self-care educationyz Percentage of patients aged 18 y with a diagnosis of HF who were provided
with self-care education on 3 elements of education during 1 visits
within a 12-mo period
Outpatient Individual practitioner
6. Beta-blocker therapy for LVSD
(outpatient and inpatient
setting)
Percentage of patients aged 18 y with a diagnosis of HF with a current or
prior LVEF <40% who were prescribed beta-blocker therapy with
bisoprolol, carvedilol, or sustained-release metoprolol succinate either
within a 12-mo period when seen in the outpatient setting or at hospital
discharge
Inpatient and
outpatient
 Individual practitioner
 Facility
7. ACE inhibitor or ARB therapy
for LVSD (outpatient and
inpatient setting)
Percentage of patients aged 18 y with a diagnosis of HF with a current or
prior LVEF <40% who were prescribed ACE inhibitor or ARB therapy either
within a 12-mo period when seen in the outpatient setting or at hospital
discharge
Inpatient and
outpatient
 Individual practitioner
 Facility
8. Counseling about ICD
implantation for patients
with LVSD on combination
medical therapyyz
Percentage of patients aged 18 y with a diagnosis of HF with current
LVEF 35% despite ACE inhibitor/ARB and beta-blocker therapy for at
least 3 mo who were counseled about ICD implantation as a treatment
option for the prophylaxis of sudden death
Outpatient Individual practitioner
9. Postdischarge appointment
for HF patients
Percentage of patients, regardless of age, discharged from an inpatient
facility to ambulatory care or home health care with a principal discharge
diagnosis of HF for whom a follow-up appointment was scheduled and
documented, including location, date, and time for a follow-up office visit
or home health visit (as specified)
Inpatient Facility
NB, Regarding test measure no. 8, implantation of ICD must be consistent with published guidelines. This measure is intended to promote counseling only.
*Refer to the complete measures for comprehensive information, including measure exception.
yTest measure designated for use in internal quality improvement programs only. These measures are not appropriate for any other purpose (e.g., pay for
performance, physician ranking, or public reporting programs).
zNew measure.
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-converting enzyme; AHA, American Heart Association; AMA-PCPI, American Medical
AssociationPhysician Consortium for Performance Improvement; ARB, angiotensin-receptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator;
LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction.
Adapted from Bonow et al. (921).
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ogies (i.e., systems biology) or effective treatment interventions
that reduce the progression from stage A to stage B is an urgent
need.
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Appendix 2. Continued
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Appendix 3. Abbreviations
ACE ¼ angiotensin-converting enzyme
ACS ¼ acute coronary syndrome
AF ¼ atrial fibrillation
ARB ¼ angiotensin-receptor blocker
BMI ¼ body mass index
BNP ¼ B-type natriuretic peptide
CABG ¼ coronary artery bypass graft
CAD ¼ coronary artery disease
CRT ¼ cardiac resynchronization therapy
DCM ¼ dilated cardiomyopathy
ECG ¼ electrocardiogram
EF ¼ ejection fraction
GDMT ¼ guideline-directed medical therapy
HbA1c ¼ hemoglobin A1c
HF ¼ heart failure
HFpEF ¼ heart failure with preserved ejection fraction
HFrEF ¼ heart failure with reduced ejection fraction
HRQOL ¼ health-related quality of life
ICD ¼ implantable cardioverter-defibrillator
LBBB ¼ left bundle-branch block
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
MCS ¼ mechanical circulatory support
MI ¼ myocardial infarction
NSAIDs ¼ nonsteroidal anti-inflammatory drugs
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide
NYHA ¼ New York Heart Association
PUFA ¼ polyunsaturated fatty acids
RCT ¼ randomized controlled trial
SCD ¼ sudden cardiac death
VAD ¼ ventricular assist device
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